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ABSTRACT
The technique of in vivo microdialysis was used to monitor the
efflux of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC),
homovanillic acid (HVA), 5-hydroxy-indoleaceticacid (5-HIAA) and
3-methoxytyramine (3-MT) from the striatum of halothane
anaesthetised rats. Dialysis probes were acutely implanted and
perfused with artificial cerebrospinal fluid. The concentrations
of amines and metabolites in the perfusate were assayed with
reverse-phase high performance liauid chromatography and
electrochemical detection.
The actions of various DA releasing agents were studied.
Pharmacological or biochemical intervention affecting the releasing
actions of these agents allowed an evaluation of their mechanisms of
action in vivo. Furthermore, information was obtained concerning
the heterogeneous location of intraterminal pools of DA.
The effects of Ca^+ depletion and of the DA uptake inhibitor
nomifensine on the action of releasing agents were compared. The
results suggest that two mechanisms of release can be separated.
Amphetamine (AMPH), tyramine (TYR) and to some extent ouabain
(OUAB), were blocked by nomifensine and so were deduced to be
dependent on the DA uptake carrier. Their action was independent
of changes in extracel1ular Ca2+.
In contrast, high [K+] (KC1) and veratrine (VER)-induced
release were sensitive to changes in extracellular Ca^"1" and
independent of the action of nomifensine on the carrier. Release
was blocked by preventing Na+ influx with tetrodotoxin (TTX).
The action of OUAB was also partly inhibited by these agents.
Attempts to define the source of the released DA were less
clear. The suggestion was made that release from a vesicular
storage pool should be reserpine sensitive whilst release from a
pool of newly synthesised DA should be differentially sensitive to
a-methyl-p-tyrosine (AMT). The results show that all releasing
agents are at least partly sensitive to both manipulations although
to differing degrees suggesting that both pools are accessible to
all the releasers. Thus, the order of degree of inhibition by
reserpine (TYR > KC1 > VER = OUAB = AMPH is in contrast to that for
short term AMT (AMPH > OUAB > KC1 > VER > TYR).
DOPAC efflux levels were altered by agents that preferentially
released newly synthesised DA. The increased efflux of 3-MT does
not happen unless reuptake and/or monoamine oxidase has been
inhibited suggesting an extraneuronal source of this metabolite.
CHAPTER 1
GENERAL INTRODUCTION
1.1 Dopamine: a neurotransmitter in the CNS
1.1.1 Hi story
The neurotransmitter dopamine, is now recognised as one of the
major transmitters in the vertebrate CNS and the anatomy, physiology
and pharmacology of dopaminergic neurotransmission have been studied
extensively.
For any compound to be defined as a neurotransmitter, it must
satisfy certain criteria. Controversy surrounds the relative
importance of the individual criteria but the schemes proposed by
Herman (1966) and Orrego (1979) are considered to satisfy the
definition of a neurotransmitter. These put forward six criteria:
(1) the transmitter must be present intraneuronally (2) there
must be a transmitter syntnesising system (3) there should be an
intraneuronal storage system (4) the transmitter should oe
2+
released by a physiological or pharmacological stimulus in a Ca
dependent fashion (5) there must be an inactivation mechanism to
terminate the action of the transmitter and (6) the transmitter
should have an identifiable postsynaptic action.
Dopamine satisfies these criteria but it was to be five decades
from the first reports of dopamine to its recognition as a
neurotransmitter. The dopamine molecule was first synthesised in
1910 by Barger & Ewins and by Mannich & Jacobsohn and classified at
the time as a weak sympathomimetic due to its weak vasodepressor
action (see Hornykiewicz, 1984 for a review). Blaschko, in 1939,
recognised DA as an intermediate in the synthesis of noradrenaline
(NA) and proposed the now familiar route of the biosynthesis of NA
and adrenaline (AD). The increasing freauency of reported
measurements of DA in mammalian tissues and fluids awoke researchers
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to the possibility of a separate physiological role for DA (see
Anden, 1964). Attention was switched to the CNS when DA was
reported to occur in eaual concentrations to NA (Montagu, 1957;
Carlsson et al., 1958). Carlsson also showed that, as well as
depleting NA and 5-hydroxytryptamine (5-HT), reserpine also depleted
DA in the CNS. Moreover, the precursor of DA, L-DOPA, increased
the DA concentration in brain tissue after reserpine treatment.
This helped to explain some of the CNS side effects of reserpine
that could not be attributed to depletion of NA and 5-HT such as
catalepsy and an extrapyramidal motor syndrome similar to
Parkinson's disease.
Until this time, DA had only been described in the whole brain
and not localised to specific areas. However, Bertler & Rosengren
(1959) reported the occurrence of DA in high concentration in the
absence of NA in the corpus striatum of the dog brain. This area
was known to be a major part of the basal ganglia and a major
constituent of the brain extrapyramidal motor system. This led
them to conclude that DA is concerned with the function of the
corpus striatum and so with central motor function thereby
explaining the postulated DA depleting effects of reserpine upon the
extrapyramidal motor system.
By the early 1960's, a considerable body of evidence existed for
DA as a central neurotransmitter. A biosynthetic pathway had been
proposed as well as the specific localisation of DA to certain areas
of the brain. Moreover, the first evidence existed for a possible
role of DA in the control of motor function.
-3-
1.1.2 The anatomy of dopaminergic systems
The advent of the Falck-Hi1larp fluorescence techniaue in the
early 1960's facilitated the specific location and visualisation of
dopaminergic neurones. Prior to this, there was no method
available that was specific for DA. The method relies on the
conversion of DA to a highly fluorescent 5,6-dihydroxyindole which
emits light over a specific spectrum. This was easily measured in
the spectrophotof1uorimeter. This method was used by Carlsson &
Hillarp (1962), Dahlstrom & Fuxe (1964) and Fuxe (1965) to identify
DA in nerve cell bodies and terminals. This resulted in the
identification of three major dopaminergic pathways. Anden et al.
(1966) and Ungerstedt (1971a) divided these into: (a) A major
ascending nigrostriatal pathway from the DA neurones of substantia
nigra pars compacta (cell group A9) to the larger part of the
striatum, (b) a mesolimbic system from the medial mesencephalon
(cell group A10) to the nucleus accumbens, olfactory tubercle, and
several cortical areas within the entorhinal cortex and the frontal
lobe. In later autoradiographic studies (Fallon & Moore, 1978;
Beckstead et al., 1979), the major projection from cell group A10
was found to involve not only the nucleus accumbens and olfactory
tubercle, but also the ventral auarter of the entire length of the
striatum and (c) the final major dopaminergic pathway is the
tuberoinfundibular pathway which is involved in the hypothalamic
control of secretion of hormones from the anterior pituitary gland.
1.1.3 Synthesis of catecholamines
The synthetic pathway for catecholamines begins with the
-4-
essential amino acids phenylalanine and tyrosine. Generally, the
dietary intake of tyrosine is adeauate for catecholamine synthesis,
but phenylalanine can be converted to tyrosine by phenylalanine
hydroxylase (see Bowman & Rand, 1982). The first step is the
addition of a hydroxyl group to tyrosine converting it from a phenol
to the corresponding catechol amino acid, dihydroxyphenylalanine
(DOPA) (Levitt et al., 1967). This is catalysed by the enzyme
tyrosine hydroxylase, which requires Fe and reduced pteridine as
cofactors (Roth, 1979). Molecular oxygen is also reauired since
during the oxidation process catalysed by the enzyme, one atom of
oxygen is required for incorporation into tyrosine while the other
is reduced to water. The two different fates of the oxygen atoms
have led to the classification of tyrosine hydroxylase as a mixed
function oxygenase.
The final stage in DA biosynthesis is the decarboxylation of
DOPA to DA (Blaschko, 1950) (See Sourkes, 1979). This is carried
out by the ubiquitous enzyme aromatic-L-amino acid decarboxylase,
also referred to as DOPA decarboxylase. This is a non-selective
enzyme and will decarboxylate many aromatic amino acids including
5-hydroxytryptophan to form 5-hydroxytryptamine (5-HT) (Sourkes,
1979). Noradrenaline (NA) is formed from DA by 8-hydroxylation
mediated by the enzyme dopamine B-hydroxylase. This is a copper
requiring enzyme that also utilises molecular oxygen as a
co-substrate and ascorbate as a co-factor.
Control of dopamine synthesis in the brain
The rate limiting step in the synthesis of DA and consequently
NA is the conversion of tyrosine to DOPA by tyrosine hydroxylase
(TH) (Nagatsu et al., 1964). Three levels of control are proposed
-5-
to exist for the modulation of DA synthesis and release, (1) end
product inhibition (2) presynaptic DA autoreceptors and (3) the
striatonigral negative feedback loop.
End product inhibition
This is an intracellular control mechanism whereby the products
of the biosynthetic pathway (DA in dopaminergic neurones, NA in
noradrenergic neurones), inhibit the action of TH so inhibiting
further production of that transmitter. The mechanism that
achieves this is thought to be competition between the product and
the pteridine cofactor reauired by TH (Fernstrom, 1983). Anything
that reduces the pool of transmitter mediating the inhibition such
as nerve stimulation, reduces the inhibition and conseauently
stimulates production of the transmitter.
Activation of catechol aminergic cells induces the secretion of
catecholamines and also induces the de novo synthesis of
catecholamines to replenish the stores. This has been demonstrated
in chromaffin cells, PC12 cells, superior cervical ganglia and in
rat striatal synaptosomes (see Haycock, 1987). The increase in
catalytic activity of TH is associated with a calcium dependent
phosphorylation of TH at several sites upon the N-terminal region of
the enzyme. This is likely to form part of the regulatory
mechanism that determines the activity of TH.
DA autoreceptors
Dopamine autoreceptors are situated on the dopaminergic nerve
terminals and on the cell body and dendrites (Roth et al., 1984).
When stimulated by released DA they act to inhibit tyrosine
hydroxylase activity so reducing DA synthesis. This has been
demonstrated by the agonist induced reduction in the hydroxylation
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of tyrosine using apomorphine (Walters & Roth, 1976). Accordingly,
DA synthesis is also blocked. The effect is reversed by prior
administration of DA receptor antagonists (Roth et al., 1984). An
alternative techniaue is to drive the dopamine neurones by
stimulating their axons and to measure the impulse induced increase
in tyrosine hydroxylation. Using this model, the agonist induced
reduction of this tyrosine hydroxylation has been used as an
indication of the presence of synthesis modulating autoreceptors
(see Roth et al., 1984). Electrophysiological techniaues have been
used to study cell body/dendritic DA autoreceptors (Aghajanian &
Bunney, 1977; Skirboll et al., 1979). Using single unit recording
techniaues, the effects of DA and DA agonists upon the physiological
activity of identified dopaminergic neurones has been used to
demonstrate the presence and effects of DA autoreceptors. In
addition, release modulating autoreceptors act to decrease DA
release. DA autoreceptors have been classified as D^ receptors,
mainly due to the affinity of D^ antagonists such as sulpiride for
these receptors (see Woodruff, 1986). The role of DA autoreceptors
was first postulated by Carlsson et al. (1972). They showed that
transection of DA fibres acutely increased the rate of tyrosine
hydroxylation and increased DA levels. The suggestion was that by
removing the nerve impulse stimulated release of DA, the inhibitory
autoreceptors are no longer occupied which removes this route of
inhibition. Other workers using y-butyrolactone (GBL) to diminish
the firing rate of nigrostriatal DA neurones, also reported an
increase in the rate of tyrosine hydroxylation and in DA levels (see
Walters et al., 1976). This effect was blocked by the DA agonist
apomorphine and by the DA releasing drug amphetamine. Accordingly,
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the actions of these drugs were blocked by the DA antagonists
haloperidol and chlorpromazine (Walters et al., 1976). A variety
of DA autoreceptor selective agonists have been reported. These
include N-0437 (Van der Weide et al., 1986), auinpirole (LY 17155)
(Walters et al., 1984), 3-PPP (Hjorth et al., 1983) and B-HT 920
(Anden et al., 1983). Of these, B-HT 920 has been reported to be
the most selective for autoreceptors and has been shown to inhibit
DA release and synthesis (Jennewein et al., 1986; Pifl &
Hornykiewicz, 1988).
Interestingly, there is evidence that synthesis modulating DA
autoreceptors are absent on terminals of certain mesocortical DA
neurones (Roth et al., 1984). It was noticed that mesocortical
systems showed a different responsiveness to acutely and chronically
administered antipsychotics as well as to mild stress and
conditioned fear when compared to nigrostriatal and mesolimbic
systems (see Roth et al., 1984). Using biochemical and
electrophysiological methodology, Roth and co-workers demonstrated a
lack of synthesis modulating DA autoreceptors in the prefrontal
cortex, cingulate cortex and entorhinal cortex. The significance
of this is not clear, but it endows certain properties upon these DA
systems such as a higher rate of physiological activity (firing)
with a different pattern of activity (more bursting), a higher
turnover rate of transmitter, diminished biochemical and
electrophysiological responsiveness to DA agonists and antagonists
and a transmitter synthesis that is more readily influenced by the
availability of tyrosine (see Roth et al., 1984 for review).
The striatonigral pathway
Due to the fact that DA receptor antagonists were seen to
-8-
increase the synthesis and metabolism of DA, several groups proposed
that in addition to end product inhibition, DA receptor mediated
control of dopaminergic neurotransmission occurs (Carlsson &
Lindavist, 1963; Kehr et al., 1972; Anden, 1972). An inhibitory
striatonigral pathway was proposed as a return loop reciprocating
the nigrostriatal pathway. This return pathway is via
non-dopaminergic neurones that synapse directly onto dopaminergic
nigrostriatal neurones (see Nauta & Domesick, 1984). In this way,
it is suggested that postsynaptic DA receptors feed information
backwards via this pathway to control the activity of the
nigrostriatal neurones (Carlsson & Lindavist, 1963; Bunney &
Aghajanian, 1975). This mechanism is often known as the
striatonigral negative feedback theory and persists even after the
discovery of DA autoreceptors which appear to achieve a similar
result.
The existence of such a negative feedback pathway has been
questioned by Garcia-Munoz et al. (1977) on the basis of lesion
experiments. It was found that lesioning the striatonigral pathway
caused no change in DA turnover on the lesioned side. Moreover,
agonist and antagonist effects upon DA metabolites were the same for
the control and lesioned sides. The authors proposed that this was
evidence for the lack of a striatonigral negative feedback pathway
and further proposed that this pathway may be the striatal motor
output pathway.
In addition to these three mechanisms, it has also been
suggested that tyrosine availability may also be a controlling
factor for DA synthesis (Wurtman et al., 1974). This was not a
popular concept at the time because it was believed that TH is
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saturated at the normal tyrosine concentration found in brain
(100-200pM). The for TH was reported to be 50-90yM. So
tyrosine levels exceed the Km but not remarkably so. Wurtman
injected tyrosine and caused a small but significant increase in
DOPA accumulation. Later studies showed an increase in NA but not
in DA (Ulus et al., 1977). Ulus reported that dopaminergic
neurones had to fire rapidly to be sensitive to tyrosine levels.
So the possibility exists that tyrosine availability may play a role
in the modulation of DA and NA synthesis albeit a minor one.
1.1.4 Dopamine storage
Dopamine is stored in the presynaptic terminal within vesicular
storage pools. The accumulation of DA within these pools is
achieved by a vesicular uptake mechanism (Philippu St Beyer, 1973;
Philippu et al., 1975). This uptake carrier is distinctly
different to the plasma membrane uptake carrier. The vesicular
2+
uptake carrier is highly dependent upon ATP and Mg tnat
stimulates an ATPase to produce an electrochemical H+ gradient
across the membrane (Taugner, 1971; Johnson & Scarpa, 1979). This
is used to transport DA across the vesicular membrane (Philippu et
al., 1975). Vesicular uptake is also temperature dependent and has
a Km for DA uptake of 1.52 x lCT^M (Philippu St Beyer, 1973).
DA uptake across the plasma membrane in contrast, is independent
of Mg^ and ATP (Holz St Coyle, 1974). The Km for DA uptake is
1.3 x 10 7M (Holz & Coyle, 1974). Reserpine and amphetamine are
both competitive inhibitors of vesicular uptake (Carlsson et al.,
1962; Kirshner, 1962; Lentzen St Philippu, 1977) whereas the
process is not sensitive to inhibition by ouabain (Philippu St Beyer,
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1973; Philippu et al., 1975) unlike the plasma membrane carrier
(Holz & Coyle, 1974).
1.1.5 Dopamine release
Calcium entry into the nerve terminal is the trigger for
neurotransmitter release. The dependence of the release process
upon calcium was first proposed in the 'calcium hypothesis' of Katz
& Miledi (1967), for the neuromuscular junction. Calcium entry is
triggered by depolarisation of the nerve cell which opens voltage
dependent calcium channels (see Raiteri et al., 1978). The
resultant increase in the intracellular concentration of calcium
facilitates the release of neurotransmitter substances.
The calcium dependency of DA release has been demonstrated by
numerous groups (e.g. Baldessarini & Kopin, 1967; Blaustein, 1975;
Holz, 1975; Lane & Aprison 1977; Drapeau & Blaustein, 1983;
Nachshen & Sanchez-Armass, 1987). Several of these groups have
2+
reported that Ca entry is the rate limiting step for DA release
during the first few seconds of depolarisation, a timescale which
they considered to represent the physiological situation (Drapeau &
Blaustein, 1983; Nachshen & Sanchez-Armass, 1987). These groups
have demonstrated that dopamine release is directly dependent on the
extracellular calcium concentration during the depolarisation of
nerve terminals. Moreover, the change in the free cytosolic
concentration of calcium induced by nerve stimulation is a linear
function of the inward calcium current. However, they have also
2
shown that the relationship between the external Ca
concentration and dopamine release is highly non-linear. This
-11-
non-1inearity, they propose, can only be due to the exocytotic
process.
The calcium dependence of the release process has been
demonostrated pharmacologically. Thus, depolarising stimuli and
the calcium ionophore A23187 increase the release of DA (Raiteri et
al., 1979). The calcium channel agonist BAY K 8644 has also oeen
demonstrated to increase DA release by increasing the voltage
dependent entry of calcium into rat striatal symptosomes (Woodward &
Leslie, 1986).
The recent development of j_n vivo voltammetric techniaues has
provided a techniaue with great spatial and temporal resolution for
studying in vivo DA release. Electrical stimulation of the medial
forebrain bundle has been shown to release DA in the rat caudate
nucleus (Miller et al., 1985; Kuhr & Wightman, 1986).
Pharmacologically evoked release using high potassium concentrations
or neuroleptics, for example, have also been shown to increase DA
release using voltam metric techniques (Blaha & Lane, 1983;
Gerhardt et al., 1986, 1987; Lane & Blaha, 1987).
A second calcium independent release mechanism has been
reported. This is thought to occur by a reversal of the membrane
uptake carrier and has been demonstrated for NA in heart slices
(Paton, 1973) and in hypothalamic synaptosomes (Raiteri et al.,
1977). The possibility of the NA or DA passively diffusing across
the membrane of the nerve terminal can be excluded since these
molecules are largely ionised at physiological pH. The uptake
carrier is responsible for the reuptake of released transmitter
amines and will be described in the following section. Under
certain pharmacologically induced conditions, it has been proposed
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that the uptake carrier operates in the reverse direction to
transport amines from inside the nerve terminal to the outside
(Raiteri et al., 1979; Fischer & Cho, 1979). The involvement of
the uptake carrier in this process is demonstrated by the fact that
nomifensine, a potent inhibitor of the DA uptake carrier (Horn et
al., 1971; Hunt et al., 1974), inhibits this elicited DA release.
Similarly, desipramine, a NA uptake inhibitor, reduced NA release
elicited by a Na -free medium, from heart slices (Paton, 1973) and
from hypothalamic synaptosomes (Raiteri et al., 1977).
1.1.6 Transmitter inactivation
Termination of the extracellular action of monoaminergic
neurotransmitters in the CNS is probably achieved by compartmental
sequestration by specific reuptake into the nerve endings from which
they were released. This was proposed for NA during the 1960's
(see Coyle & Snyder, 1969) and was later shown to account for 70-80%
of released NA in the periphery (Iversen, 1975). The existence of
a similar mechanism for DA was also proposed during the 1960's when
3
the accumulation of [ H]-DA was observed in specific brain areas
(Fuxe & Ungerstedt, 1968). Coyle & Snyder (1969) then reported
that reuptake of released DA from synaptosomes accounts for the
physiological inactivation of the transmitter. Since these early
studies, it has been shown that specific uptake carriers exist for
the reuptake of catecholamine neurotransmitters in the periphery
and the CNS (Horn et al., 1971; Hunt et al., 1974; Kannengiesser
et al., 1976; Hunt et al., 1979; Horn, 1979) and that this is the
primary method for the inactivation of these released
-13-
transmitters. However, in addition to presynaptic reuptake, it is
becoming clear that uptake of released neurotransmitters may involve
postsynaptic sites and glial cells.
Glial uptake has been reported for amino acids (Fonnum, 1984;
Mize et al., 1981) as well as monoamines (Henn & Hamberger, 1971;
Hoffman & Vernadakis, 1979). In astrocyte cultures, high affinity
3 3
uptake of [ H]—NA and [ H]-DA has been demonstrated with a Km
of 0.3pM, a dependence upon Na+ and sensitivity to inhibition by
tricyclic antidepressants (Semenoff & Kimmelberg, 1985). The
functional significance of this type of uptake is unclear and in the
absence of an in vivo technique for determination of the
contribution made by glial cells in transmitter inactivation, only
speculations have been made.
Non-dopaminergic cells have been reported to accumulate released
DA in the substantia nigra (Kelly et al., 1985). This was
demonstrated in vivo in nigral slices and is evidence of a possible
non-dopaminergic postsynaptic uptake of DA. Once again, the
significance of such an uptake process is not clear and may not be
relevant under physiological conditions. However, the possibility
exists that both glial and postsynaptic uptake sites are operative
and may serve to inactivate released neurotransmitter that is not
captured by presynaptic uptake.
Characteristics of neuronal dopamine uptake
The DA reuptake mechanism is temperature-sensitive and is linear
for the initial two minutes in striatal synaptosomes (Holz & Coyle,
1974). Holz & Coyle also reported a concentration gradient of
1000:1 to be achieved in striatal synaptosomes. The system
displays Michaelis-Menten kinetics with a K for DA = 1.3 xv J
m
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10—. The uptake process is sodium dependent, less dependent
upon potassium and does not reauire calcium (Horn, 1978).
Various e-phenylethyl amine analogues of dopamine are also good
substrates for the uptake carrier. The structure activity
relationship is similar to that for the NA uptake carrier (Iversen,
1971).
1. Phenolic hydroxyl groups in the para or meta position enhance
the affinity for uptake.
2. a-methylation enhances uptake affinity.
3. B-hydroxylation decreases uptake affinity.
4. Mono or di N-methylation decreases uptake affinity.
5. 0-methylation of the phenolic hydroxyl group decreases uptake
affinity.
The uptake process is susceptible to metabolic inhibition by
drugs or by artificial conditions that interfere with the Na+
gradient of the plasma membrane. Thus, a lowering of the
extracellular Na concentration causes an increased release of
[ H]-DA from striatal synaptosomes that is thought to occur by a
reversal of the DA uptake carrier (see Raiteri et a 1., 1978). An
increase in the intracellular concentration of Na+ caused by the
+ + +
Na—K ATPase inhibitor ouabain or by the Na channel opener
3
veratridine also stimulates [ H]—DA release from striatal
synaptosomes (Raiteri et al., 1978).
Dopamine uptake inhibition
The therapeutic action of tricyclic antidepressants such as
imipramine and desimipramine was suggested to be achieved by the
inhibition of NA uptake (Fuxe & Ungerstedt, 1968; Coyle & Snyder,
1969; Samanin et al., 1975). This class of uptake inhibitors has
very little activity against DA uptake which is suggestive of a
specific uptake carrier for DA distinct from that for NA (see
Samanin et al., 1975). Further evidence for this was obtained with
the discovery of a potent DA uptake inhibitor, nomifensine (see Hunt
et al., 1974). This has an IC^q for inhibition of DA uptake of
1.45 x 10 7M which is better than previously proposed DA uptake
inhibitors such as benztropine, IC^g = 3.1 x 10-7M and
—6
amphetamine, IC^g = 1.2 x 10 M. However, whilst nomifensine
is a potent inhibitor of DA uptake, it is not specific for DA since
it has been demonstrated to be more potent for the inhibition of NA
uptake with an IC^g = 1.2 x 10-8M (Heikkila & Manzino, 1984).
Since the discovery of nomifensine as a potent DA uptake inhibitor,
another range of compounds have emerged with a greater potency than
nomifensine and a much better specificity for DA uptake (Heikkila &
Manzino, 1984). These are GBR 13059, GBR 13098 and GBR 12909.
—8
Their IC^q values for inhibition of DA uptake are 4 x 10 M, 4.3
—8 —8
x 10 M and 5.1 x 10 M respectively. Their specificity is
apparent from their IC^g values for inhibition of NA uptake (8 x
10 7M, 5.6 x 10 7M and 2.5 x 10_8M, respectively). These are
the most specific compounds presently known for the inhibition of DA
uptake. Nomifensine was used for the inhibition of DA uptake in
experiments presented in this thesis. The experiments were
performed in the striatum of the rat which receives very little
noradrenergic innervation. Consequently, nomifensine was
considered suitable as a DA uptake inhibitor in this region.
It has now been shown that the action of amphetamine is
primarily as a releasing agent of DA and not as an uptake inhibitor
(Heikkila et al., 1975; Hunt et al., 1979). Prior to this, the
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situation was confusing since it had been proposed that an uptake
inhibitor could be confused as a releasing agent. Thus, by
inhibiting the reuptake of released transmitter, the extraneuronal
concentration of transmitter will increase so resembling transmitter
release. The situation was resolved somewhat by Hunt et al. (1979)
who reported that it was possible to distinguish drugs acting purely
as DA uptake inhibitors from those that mainly enhance DA release.
In their experiments, they compared nomifensine with amphetamine.
3
They used striatal synaptosomes preloaded with [ H]-DA and found
_5
that even at a high concentration of 10 M, nomifensine only
caused a small increase in the amount of radioactivity in the
medium. Amphetamine on the other hand caused a much greater
3
increase of [ H]-DA in the medium. This effect was diminished
when the two drugs were incubated simultaneously and not enhanced as
it would be if both were acting as DA releasers. An alternative
approach was adopted by Raiteri and co-workers (1975) who devised a
superfusion techniaue to discriminate between an uptake inhibitor
and a releaser. The rationale of their techniaue was that the
released substrate is removed by the stream of superfusion fluid as
soon as it is released, so preventing re-uptake. Conseauently, a
drug which does not exhibit any releasing activity in these
conditions, can be considered as a pure uptake inhibitor. Using
these criteria, Raiteri et al. (1978) classified nomifensine as a
pure uptake inhibitor. They have also suggested that amphetamine
has a mixed action in that it both releases and inhibits the uptake
3
of [ H]-DA in synaptosomes from rat striatum (Raiteri et al.,
1975).
The identity of nomifensine as a DA uptake inhibitor has
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provided an important method for the study and exploitation of the
DA carrier and the consequences upon dopaminergic neurotransmission.
Dopamine metabolism
Dopamine is metabolised by the action of two enzymes, monoamine
oxidase (MAO) and catechol-o-methyl transferase (COMT). MAO
cleaves the amine group from the DA molecule to form the
corresponding acid metabolite, namely 3-4-dihydroxyphenylacetic acid
(DOPAC) (see Tipton, 1979). COMT transfers an 0-methoxy group to
the 3-position of the phenyl ring of DOPAC to form
3-methoxy-4-hydroxyphenylacetic acid, usually know as homovanillic
acid (HVA) (see Guldberg, 1979). COMT also acts upon DA to form
3-methoxy-4-hydroxyphenylethyl amine or 3-methoxytyramine (3-MT).
3-MT can subseauently be metabolised to HVA by the action of MAO.
The K values of MAO for the two substrates DA and 3-MT are 405
m
and 475yM respectively (Houslay & Tipton, 1976), although more
recently, a much lower Km for DA has been reported of 3pM
(Schoemaker & Nickolson, 1983). The Km value of COMT for DA was
reported to be 160pM (Guldberg, 1979). DOPAC and HVA are also
further metabolised to some extent to their corresponding sulphate
conjugates which aids their removal from the brain (Dedek et al.,
1979). 3-MT is not metabolised to a sulphate conjugate.
In vertebrate brain, as well as other tissues, MAO is present in
two forms, MAO A and MAO B. This was first proposed by Johnston
(1968) when he noticed a biphasic decline in MAO activity in the
presence of increasing concentrations of the MAO inhibitor
clorgyline. He associated this with two forms of MAO with
different sensitivites to inhibition. Since this early report,
many investigators have reported the presence of two forms of MAO
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and attempted to localise these to different cell types within tne
CNS (Yang & Neff, 1974; Braestrup et al., 1975; Agid et al.,
1973; Houslay & Tipton, 1976; Demarest et al., 1980; Schoepp &
Azzaro, 1983; Francis et al., 1985; Kato et al., 1986; Kitahama
et al., 1987; Ross, 1987; Liccione & Azzaro, 1988). Several
groups have demonstrated that MAO A is located predominantly
presynaptically (Agid et al., 1973; Demarest et al., 1980; Francis
et al., 1985). These determinations were made by
immunohistochemical and selective lesioning techniaues. This led
Francis and co-workers (1985) to propose that striatal MAO A was
located 60% presynaptically and no more than 30% postsynaptically.
MAO B,on the other hand, has been reported to be located
predominantly postsynaptically and extraneuronally (Levitt et al.,
1982; Francis et al., 1985). Levitt & Co-workers used kainic acid
to selectively lesion striatal afferents and interneurones and
demonstrated MAO B in postsynaptic and glial cells with only a small
proportion located presynaptically.
MAO A and MAO B have different substrate specificities and
different inhibitor sensitivities (see Houslay & Tipton, 1976 for
review). This allows the use of selective inhibitors to achieve
selective pharmacological effects. NA and 5-HT are MAO A
preferring substrates whilst benzylamine and phenylethylamine are
MAO B preferring substrates. DA and 3-MT are mixed substrates for
both enzymes (Houslay & Tipton, 1974). Clorgyline is a relatively
selective inhibitor of Type A MAO (Johnston, 1968) whilst selegeline
is a relatively selective inhibitor of type B MAO (Knoll & Magyar,
1972).
The existence of two forms of MAO suggests a functional duality
of the enzymes. However, it is still not clear whether or not MAO
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B plays a role in striatal DA metabolism.
1.1.7 Classification of DA receptors in the CNS
During the mid-1970's, several groups identified binding sites
for DA based upon the binding of tritiated DA agonists or
antagonists to brain membranes and their subsequent displacement by
cold ligand (Creese et al., 1976; Burt et al., 1976; Seeman et
al., 1976; Creese et al., 1977). It was realised that a subclass
of DA receptors were linked to the enzyme adenylate cyclase which
was thought to be the second messenger system mediating dopaminergic
transmission. On the basis of this biochemical evidence, Seeman
(1977) and Kebabian & Calne (1979) proposed the existence of two
classes of DA receptor, the D^ receptor, associated with adenylate
cyclase and the increased formation of cAMP, and the D£ receptor,
which they proposed was not linked to adenylate cyclase.
Since this original classification of DA receptors, other groups
have proposed the existence of as few as one or as many as four
distinct DA receptor subtypes. These conclusions were largely
based on binding studies and different affinities of receptors for
ligands. It eventually became accepted that these multiple forms
were different affinity states of just two DA receptors and the
consensus now is that there are only two distinct types of DA
receptor (see Kebabian et al., 1986).
The original proposal made by Kebabian & Calne has since been
modified to state that D£ receptors inhibit the activity of
adenylate cyclase (Stoof & Kebabian, 1984). Moreover, peripheral
subtypes of DA receptors have also been identified and are known as
DA^ and receptors (see Woodruff, 1986).
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Progress has also been made in terms of selective DA receptor
agonists and antagonists (see Stoof & Kebabian, 1984; Woodruff,
1986). Selective agonists for the receptor include SKF 38393
which is more potent than DA for stimulating the production of cAMP
by adenylate cyclase (Stoof & Kebabian, 1984). Also included is
SKF 82526 which is less potent than SKF 38393 and has slightly more
D^ agonistic activity. The development of a selective D^
receptor antagonist SCH 23390 was an important development since it
has contributed to our scant knowledge of the function of D^
receptors. SCH 23390 has little effect on D2 receptors, being at
least 950 times more effective on D^ receptors than
Selective D£ agonists include RU 24926, RU 24213 and LY 141865,
wnilst D2 antagonists include domperidone and sulpiride (see Stoof
& Kebabian, 1984).
Physiological and biochemical roles have been attributed to the
two types of DA receptor. D^ stimulation has been shown to
enhance hormone release from bovine parathyroid gland and to enhance
the firing of neurosecretory cells in the CNS of Lymnaea stagnalis
(Stoof & Kebabian, 1984). D^ receptors have also been implicated
in the behaviour of rodents, in particular in its role in passive
avoidance behaviour in rats (Woodruff, 1986).
D£ receptors have been implicated in the inhibition of
prolactin and a-MSH release from the pituitary, the inhibition of
acetylcholine ACh and 8-endorphin release, and the autoinhibition of
DA release and turnover in the striatum.
1.1.8 Postsynaptic effects and functions of dopamine in the CNS
Since there is a widespread distribution of dopaminergic
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terminals within the striatum, nucleus accumbens, hypothalamus and
cortical areas, there is likely to be a multiplicity of DA
functions. Consequently, factors affecting dopaminergic
neurotransmission as a whole are likely to affect many functions
subserved by the areas where DA neurones terminate. This point
should be borne in mind when determining experimental data,
especially in behavioural studies.
DA has been implicated in many functions such as motility,
exploration, sensory and motor control, feeding, sexual arousal,
aggression, drive, sleep, stress and learning and attention
(Ungerstedt, 1979, 1984). Thus, apomorphine (a DA agonist) and
amphetamine (a DA releaser) result in behavioural excitation such as
increased motor activity and also in various stereotyped behaviours
including repetitive head and forelimb movements, sniffing,
grooming, chewing and gnawing (Moore, 1978; Costal 1 & Naylor,
1979). The depletion of DA with reserpine or DA receptor blockade
by antagonists results in hypokinesia and catalepsia. Lesion of
the nigro-striatal pathway with 6-hydroxydopamine results in
akinesia, adipsia and aphagia (Ungerstedt, 1971b). These are some
of the examples of the effects of excess or decreased levels of DA
in the CNS.
As mentioned previously, the nigrostriatal pathway is a major
dopaminergic pathway. The degeneration of this pathway has long
been recognised as a causal factor of Parkinson's disease (Ehringer
& Hornykiewicz, i960) (see Anden, 1979). Thus, the DA content of
human post-mortem brains of Parkinsons disease patients is virtually
abolished. The symptoms of the disease are temporarily relieved by
the DA precursor L-DOPA (Birkmayer & Hornykiewicz, 1961) (see Anden,
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1979), so implicating DA in the control of extrapyramidal motor
function. However, despite the recognised importance of the
nigrostriatal pathway in the mediation of this disease, the precise
function of the pathway is not understood. A role in the control
of motor behaviour is clear, but it is not known whether the
nigrostriatal pathway is excitatory or inhibitory or both.
Electrophysiological, pharmacological and morphological methods have
been used to try and establish this (see Freund et al., 1984).
Electrophysiological work has described both inhibition and
excitation in the striatum after stimulation of the substantia nigra
(see Walters et al., 1984). Stimulation of Dg autoreceptors in
the substantia nigra has been shown to have an inhibitory response
+
upon cell firing which has been associated with an increase in K
conductance. This causes a hyperpolarisation of tnese cells
(Bunney et al., 1973; Lacey et al., 1987). A similar phenomenon
has been reported in striatal neurones (Freedman & Weight, 1988).
Freedman used whole cell current clamp and voltage clamp upon
dissociated striatal neurones, and demonstrated that DA and the D^
+
agonist quinpirole opened K channels in the neuronal membrane.
This action was antagonised more potently by the antagnoist
spiperone than by the D^ antagonist SCH 23390. Freedman suggests
that such a D^ mediated effect upon K+ conductance in striatal
neurones may mediate inhibitory responses associated with D£
receptors in the striatum. However, he does not rule out the
involvement of other ion channels since D£ receptors also mediate
excitatory responses in the striatum. Pharmacological studies are
not clear because of the lack of discrimination between direct
actions of the nigrostriatal pathway or indirect actions involving
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other striatal neurones. Morphological methods have been used in
attempts to identify the neurones receiving input from nigrostriatal
fibres. It was long held that cholinergic neurones received a
large input but the methods used have since been shown to be
non-specific (see Freund et al., 1984). So there is still no
consensus with any of the methods.
Freund and co-workers (1984) have suggested a more subtle effect
of dopamine in the striatum based upon their morphological work that
studies synaptic contacts upon striatonigral neurones. They
propose that DA released from nigrostriatal terminals can directly
influence the functioning of striatonigral neurones by means of
different synaptic specialisations located on anatomically distinct
parts of striatonigral neurones. Through these specialisations
they propose that D-^ receptors might mediate hyperpolarisation so
leading to the attenuation of cell firing and that D^ receptors
mediate an increase of membrane conductance to certain ionic species
that slightly depolarises the neurone. This may selectively cut
off the input from a particular group of afferent neurones.
Consequently, the overall effect of DA upon striatonigral neurones
may not simply be one of excitation or inhibition, but rather a
selective control of the pattern of firing. In this fashiion, the
striatum may convert a highly diverse input into a specific pattern
of motor output.
1.2.1 Neurotransmitter compartmentalisation
There was, and still is, considerable research effort devoted to
the subject of vesicular storage of ACh in nerve terminals. The
same is true for two of the monoamine transmitters, NA and DA, to
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which the research expanded and encompassed.
Compartmentalisation of a transmitter concerns the heterogeneous
location of a transmitter within the nerve terminal. The concept
has been applied to ACh (see Zimmermann, 1979), NA (see Bavisch &
Trendelenburg, 1987; Eisenhofer, 1988) and DA (see de Belleroche &
Bradford, 1978).
Zimmermann (1979) in a commentary summarises the early evidence
for not only a heterogeneity of ACh storage, but specifically a
vesicular heterogeneity. The current controversy at the time was
whether or not ACh was located solely in the cytoplasm or was
heterogeneously distributed between the cytoplasm and a vesicular
store. Using radiolabelled ACh in the electric organ of Torpedo,
Zimmermann showed that not only was ACh taken up and stored in
vesicles, but that there was also a heterogeneity of vesicular
pools. He reported the appearance of smaller vesicles in the nerve
terminal following electrical stimulation. These vesicles had a
higher density than the larger group and contained newly synthesised
ACh. This was apparent from the high specific activity of the
radiolabelled ACh that rapidly appeared in those vesicles as opposed
to the low levels in the larger vesicles. Thus Zimmermann proposed
that ACh is preferentially released from and taken back up into the
smaller vesicles. This does not deny the existence of a
cytoplasmic pool of ACh as argued by Dunant & Israel (1979).
However, the evidence was that the rapidly turning over pool of
vesicular ACh represented the functional pool of transmitter.
This has also been demonstrated in sympathetic ganglia, the
cerebral cortex and Torpedo electric organ (see de Belleroche &
Bradford, 1978) where the most recently synthesised ACh was released
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in response to stimulation.
Parallels are thought to exist for monoamine transmitter storage
and release. Thus, Eisenhofer et al. (1988) report the
distribution of [ H]—NA in rat vas deferens into two pools, one
containing a high specific activity and the other a low specific
activity of radiolabel. Eisenhofer studied the effects of
tyramine, electrical stimulation and elevated K+ concentration
upon [^H]-NA and [^H]-DHPG (the deaminated metabolite of NA)
release from isolated rat vas deferens. He proposed the existence
of two intraneuronal pools of NA, a fast release labile pool that
preferentially contains newly synthesised NA and NA from reuptake,
and a slow release pool that contains most of the tissue NA and
which serves mainly as a storage pool.
Other workers using rat vas deferens demonstrated the release of
NA from two intraterminal pools, a vesicular pool and a cytoplasmic
pool (Langeloh et al., 1987; Langeloh & Trendelenburg, 1987).
Burn (1932) was the first to suggest that catecholamines might
be taken up into storage sites in tissue. However, it was not
until radiolabelled catecholamines became available that Axelrod et
al. (1959) and Whitby et al. (1961) injected [^H]-NA i.v. which
was seen to be taken up into peripheral tissues. The first direct
evidence for the accumulation of DA in brain tissue was obtained by
3
Glowinski & Iversen (1966). They injected [ H]-DA
intraventricular^ and observed accumulation in the following areas
in order of decreasing concentration: striatum > hypothalamus >
hippocampus > midbrain > medulla oblongata > cortex and
cerebellum. This early work initiated numerous studies of DA
storage and metabolism in nerve cells. This rapidly became a
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controversial issue relating to catecholamine neurotransmission, the
major controversy centering around the state of the transmitter
stores in the neurone. There were two views on this problem. The
first proposed that catecholamines are stored in a single open
compartment or pool from which they are released by action
potentials or drugs. The second proposed the existence of more
than one compartment, a functional pool where transmitter is
synthesised at a fast rate and from where it is preferentially
released, and a second storage pool.
Both possibilities were studied during the late 1960's into the
1970's. The most direct method at the time for the in vivo
determination of the disposition of an endogenous compound was to
inject a tracer dose of the radioactive precursor of that compound
and to follow the kinetic changes of the specific activity of the
compound as a function of the specific activity of the precursor.
Using this method, Neff et al. (1971) demonstrated that the curves
expressing the time changes of the specific activities of brain DA
and the precursor tyrosine were interrelated according to the model
describing a direct product-precursor relationship in a single open
compartment. Also, in earlier work, Costa & Neff (1966) followed
the decline in tissue DA concentration after AMT was given. They
obtained half lifes for DA utilisation of 2 hours in whole rat brain
and 2.1 hours in rabbit caudate nucleus. DA levels were observed
to decline in a monophasic fashion and on the basis of these results
they assumed a single storage pool of DA. However, both sets of
results were later disputed by other workers. Groppetti et al.
(1977) highlighted the drawbacks associated with the use of [ H]
tyrosine as a marker for DA synthesis. Firstly, tyrosine is
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involved in other metabolic pathways and so it has to be assumed
that the various tyrosine compartments reach identical specific
activities. The results presented by Neff neglected this fact.
Secondly, the labelled precursor method only allows the measurement
of overall changes and will not detect the existence of
heterogeneous compartments unless each is large enough to form a
significant portion of the pool of transmitter. The significance
of this is that a functionally important pool which may be small in
size with a high transmitter turnover rate may be overlooked when
using the labelled precursor tecnniaue.
This fact was pointed out by Javoy & Glowinski (1971). They
injected AMT and observed a biphasic decline in tissue DA levels.
A similar phenomenon was reported by Iversen & Glowinski (1966) when
3
they injected [ H]-DA intraventricularly and observed a biphasic
disappearance of this tracer. Within five minutes of injecting
AMT, Javoy & Glowinski observed a rapid decline of DA levels in rat
striatum with a tl/2 of 9 min. This was followed by a slower
decline from 30 min onwards with a tl/2 of 124 min. The authors
suggested that this multi exponential decline is indicative of the
heterogeneous location of DA in the striatum. They proposed a two
compartment model, compartments A and B. AMT caused the rapid
depletion of DA in compartment A. This contains at least 23£ of
the DA and is regarded as the functional compartment from which DA
is preferentially released. Compartment B is the main storage
compartment from which DA is utilised at a much slower rate. The
authors suggest it is this compartment that Costa & Neff measured in
their experiments on whole rat brain and rabbit caudate with DA half
lifes of 2 hours and 2.1 hours respectively. From the rate of DA
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decline, Costa & Neff calculated the rate of synthesis of DA in
rabbit caudate nucleus to be 2.85ug/g/h. This was estimated on the
basis of a single compartment. Javoy & Glowinski estimated a DA
turnover rate of 13.2yg/g/h whilst Javoy et al. (1970) estimated the
in vivo synthesis rate of DA in striatum on the basis of the initial
rise in DA after MAO inhibition to be 24yg/g/h. These two values
suggest a rate of synthesis at least four times that of Costa &
Neffs value. Javoy & Glowinski suggested that this large
discrepancy demonstrated that the hypothesis for a distribution of
DA in a single compartment could not be retained.
Further credence was given for the existence of more than one DA
storage compartment by the results of Groppetti et al. (1977).
They adopted an alternative approach by looking at the levels of
DOPAC and 3MT. If the single compartment model is valid, they
hypothesised that they would see the same product-precursor
relationship postulated by Neff et al. (1971). So by injecting
labelled tyrosine intravenously and intraventricularly, they
3 3
measured the specific activities of [ H]-DA, [ Hj-DOPAC and
3
[ H]-3MT. If only one compartment exists, then the
product-precursor relationship should be valid and this being the
case, the specific activity of DA should never be lower than that of
3 3
the metabolites DOPAC or 3MT. But [ H]-D0PAC and [ HJ-3MT had
3
much higher specific activities than [ H]-DA suggesting DA is
stored in more than one compartment.
Post-mortem studies in rats also suggested a heterogeneity of
pools. Carlsson (1974) reported a rapid increase in 3MT levels due
to post-mortem metabolism of DA. This increase was more evident
for endogenous DA than for labelled DA since labelled 3MT increased
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by only 50% over 20 min whereas endogenous 3MT increased 35-fold
over the same time. So this 3MT was converted from a pool of DA
that was poorly labelled by the radioactive precursor.
The results obtained by Javoy & Glowinski (1971) describing a
biphasic decline of DA following administration of AMT were later
disputed by Costa and co-workers (Doteuchi et al., 1974). Costa
did not dispute the likelihood of multiple pools of DA as he had
earlier, but rather the incorrect results drawn from the methodology
used by Javoy & Glowinski. This is probably worth mentioning since
it highlights the problems associated with using DA synthesis
inhibitors as a tool for determination of DA levels.
Costa argues that the biphasic decline in DA levels is due to
(1) an early incomplete inhibition of tyrosine hydroxylase and
(2) an increased release of DA during the first 20 min of AMT
stimulated by the metabolites of AMT, para-hydroxyamphetamine and
para-hydroxynorephedrine. Costa states that both of these factors
served to confuse the results and mislead the authors. The early
rapid decline in tissue DA was due to the DA releasing actions of
the metabolites. The levels of these decline after the first few
minutes and by 40 min AMT inhibition of tyrosine hydroxylase is
almost complete. When applying the principle of steady state
kinetics to the decline of neurotransmitter after synthesis
inhibition, the inhibition must be complete and instantaneous.
These requirements are not fulfilled by AMT which negates the
figures proposed by Javoy & Glowinski but not the principle of
multicompartments in the DA neurone.
The fact that DA seemed to be heterogeneously distributed, led
to the speculation that the different pools of DA were functionally
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distinguishable. Javoy & Glowinski (1971) and Glowinski (1975)
reported that newly synthesised DA was preferentially released from
striatal synaptosomes. The authors used [ H] tyrosine to label
[ H]-DA pools within the synaptosomes. They found that the
3
rapidly turning over pool of DA became labelled with [ H]-DA and
that this [ H]-DA was preferentially released. Other groups
reported similar findings. Thus, de Belleroche & Bradford (1978)
used [ H] tyrosine to differentially label pools of synaptosomal
DA. They found that stimulation released newly synthesised
[3H]-DA as did other groups (Raiteri et al., 1978, 1979; Katz et
al., 1976; Kapatos & Zigmond, 1977). So in synaptosomes at least,
DA is heterogeneously located in two or more compartments and is
preferentially released from one of them.
The newly synthesised releasable pool of DA was proposed to be a
vesicular pool (de Belleroche & Bradford, 1978; Raiteri et al.,
1978; 1979). This was based upon the sensitivity of this pool to
reserpine. A second, cytosolic pool of DA was reported to be the
pool where DA is accumulated in the presence of a MAO inhibitor
(Raiteri et al., 1978) and from where the carrier mediated release
of DA occurs (Raiteri et al., 1978, 1979; Fischer & Cho, 1979).
This cytosolic compartment is not reserpine sensitive (Schoemaker &
Nickolson, 1983). The transport of DA to the reserpine sensitive
pool was reported to follow Michaelis-Menten kinetics (Schoemaker &
Nickolson, 1983) which is in agreement with the transport kinetics
found for DA uptake by isolated rat striatal synaptic vesicles
(Philippu & Beyer, 1973). This is further evidence for the
vesicular location of the releasable pool of DA.
Finally, the j_n vitro work of Schoemaker & Nickolson (1983)
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using striatal synaptosome preparations yielded further results in
support of a multi compartmental DA storage mechanism. They
studied the kinetics of DA transport into and out of striatal
synaptosomes. They reported that under steady state condition, the
transport rates of DA are independent of time and follow first order
kinetics. The data obtained fitted significantly better to a three
compartment model (two intrasynaptosomal and one extrasynaptosomal)
than to a two compartment model (one intrasynaptosomal, one
extrasynaptosomal). They then considered the distribution of these
compartments and the nature of the DA uptake into them. The
possibilities are a parallel uptake from the medium into each
compartment or an in series uptake where DA is first taken into one
compartment from where it can then pass to the second compartment.
If the parallel uptake process occurred, then DA uptake would be
biphasic due to the differing kinetic parameters for uptake. This
process would fit a biphasic Hofstee plot of the initial DA uptake
velocity. But DA uptake by rat striatal synaptosomes can be
described by a single Michaelis-Menten process (Snyder S Coyle,
1968; Schoemaker S Nickolson, 1983). So they report that it is
most plausible that the in series configuration represents the
actual configuration of the kinetic compartments.
Since some of the early work auoted here, the auestion of
multiple intraterminal compartments or pools of DA has been studied
by several groups (e.g., Fischer & Cho, 1979; Kamal et al., 1981;
Liang S Rutledge, 1982; Langer & Arbilla, 1984; Niddam et al.,
1985; Herdon et al., 1985). The existence of two intraterminal
pools of DA in the striatum was recently proposed by Levi el &
Guibert (1987). By taking advantage of the reported differences in
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the renewal speed or turnover of DA for the different pools, they
reported the ability to preferentially label the functional pool of
DA j_n vivo by perfusing with [ H]-tyrosine. Thus, the functional
pool which has a renewal time of 9 min contains a high specific
activity of [ H]-DA whereas the storage pool is relatively poorly
labelled within the first few minutes since it has a renewal time of
3
about two hours. They worked on the premise that [ H]-DA release
largely reflected release from the functional pool whereas total DA
release including unlabel led endogenous DA reflected release from
the storage pool of DA. AMT was given and a rapid decline in
3
[ H]-DA levels observed. Total DA levels decreased much more
slowly. Their conclusion was that this was an indication of the
differential involvement of the two intraterminal pools in DA
release. Similar results were reported for AMPH stimulated release
of [^H]-DA (Miller & Shore, 1982; Niddam et al., 1985), where
3
AMPH preferentially released [ H]-DA.
It now seems to be generally accepted that DA, as well as other
transmitters, exists within more than one intraterminal
compartment. However, much speculation still exists in relation to
the size and physiological significance of multiple pools of
transmitter (see Paden, 1979). A discussion of these points will
be presented in Chapter 4. In addition, another model has been
proposed and tested by Justice et al. (1988)in which three
intraterminal pools of DA exist. A free cytosolic pool, a
releasable bound pool and an inactive bound pool. The implications
of this will also be discussed later.
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1.2.2 Compartmentalisation and organisation of DA metabolism
The precise locations of the DA metabolising enzymes is still a
matter of controversy. MAO is thought to be predominantly located
intraneuronally. Consequently, the major proportion of DOPAC is
derived from the intraneuronal metabolism of DA. COMT is proposed
to be located predominantly postsynaptically so implying a
compartmentalisation of DA metabolism. This would explain why
reserpine, which disrupts the storage of intraneuronal DA, gives
rise to increased DOPAC levels before those of HVA indicating an
intraneuronal formation of DOPAC (Guldberg & Broch, 1971;
Roffler-Tarlov et al., 1971). This is achieved by the action of
MAO which has been localised to presynaptic nerve terminals (Agid et
al., 1973; Demarest et al., 1980; Francis et al., 1985). It was
then considered that DOPAC could be used as an index of DA
metabolism (Roffler-Tarlov et al., 1971). However, since these
proposals, there has been an indication of an intraneuronal as well
as an extraneuronal location of COMT (Guldberg & Marsden, 1975).
This was also proposed by Korf et al. (1976) who observed an early
rise of DOPAC followed by a secondary rise of HVA after reserpine
and also after neuroleptic or cholinomimetic treatment and
electrical stimulation, all of which increase DA release or
metabolism. It now seems likely that DOPAC is the primary
metabolite of intraneuronal DA metabolism whilst HVA is the
secondary. HVA may be formed intraneuronally from DOPAC or
postsynaptically from DOPAC. The possible locations of COMT
outside the dopaminergic terminal are in postsynaptic cells, in
glial cells or in endothelial cells of blood capillaries (see
Kaakkola et al., 1987). HVA is also formed by the metabolism of DA
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first to 3MT and then to HVA. The functional significance of this
route of metabolism and indeed whether or not a significant
proportion of DA is routinely metabolised to 3MT is still a matter
of great speculation.
Following release, a fraction of the monoamine transmitter is
metabolised during reuptake (see Westerink, 1979). The metabolic
products do not re-enter the transmitter synthetic pathway.
Neuroscientists have attempted to utilise this characteristic in
attempts to determine changes in dopaminergic neurotransmission.
Since during neuronal activity, a proportion of the released
transmitter is not recovered, it is probable that steady state
levels of the transmitter are maintained by new molecules of the
precursor tyrosine entering the synthetic pathway. Conseauently,
the activity of tyrosine hydroxylase has been used as an assessment
of the activity of dopaminergic neurones. As a further
conseauence, changes in dopamine metabolite levels have come to be
eauated with changes in dopaminergic neuronal activity. Thus, a
neurochemical measure has been correlated with a neurophysiological
response (e.g., Roth et al., 1976; Umezo & Moore, 1979; Waldmeier
et al., 1981; Westerink & Spaan, 1982; Wood et al., 1987). The
resulting literature is littered with controversy, speculation and
contrary results. Before considering some of these results, it is
important to elucidate the connections between monoamine synthesis,
release and metabolism.
Firstly, what information is conveyed by monoamine
metabolites? Korf et al. (1973) stated that in the normal
untreated animal, monoamine metabolites are an indication of the
metabolic intactness of the monoaminergic neurones. Under
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experimental conditions, DOPAC and HVA reflect the metabolic
functioning of dopaminergic neurones. It may be speculative to
conclude any more than this. But, if DA metabolism is connected to
DA release, then surely it may be used as an indication of
release? However, studies of noradrenergic neurones in the spinal
cord have suggested that NA is stored at a concentration of about
50% of the holding capacity of the nerves. If synthesis is
stimulated by the addition of tyrosine or L-DOPA, the increased
level of newly synthesised transmitter results in the immediate
metabolism of this transmitter to maintain constant levels. No
definitive evidence exists that this transmitter is released before
it is metabolised (Commissiong, 1985). Commissiong also states
that this seems to be the case for DA and 5-HT as well as NA in the
spinal cord. This may hold for the brain as well.
A further problem in taking DA metabolites as indices of
dopaminergic neurotransmission or release is that it has been shown
that DA is synthesised and metabolised to DOPAC and HVA in
non-monoaminergic cells, possibly in other neuronal cells, capillary
endothelium or glial cells. This was surmised by Commissiong et
al. (1984) and by Hefti et al. (1981) when DA synthesis and
metabolism persisted even after the destruction of dopaminergic
neurones.
It has already been suggested that increased levels of DA
metabolites are not necessarily indicative of increased release of
DA. Digiulio et al. (1978) reported increased levels of DOPAC but
not HVA, which is indicative of increased intraneuronal metabolism,
as a response to chloral hydrate. Here we have a situation again
where there appears to be increased DA metabolism in the absence of
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increased DA release. Certainly, when increased release is
directly measured, there is also increased metabolism. The mistake
would appear to be in assuming the opposite, that increased
metabolism is indicative of increased release.
From the preceding discussion, it might appear that DA
metabolites can convey very little information about the state of
dopaminergic transmission. This is probably not the case. For
example, an increase in DOPAC levels is indicative of the increased
neuronal metabolism of DA but not of the increased release of DA for
the reasons outlined above. Taking this further, several authors
(e.g. Groppetti et al., 1977; Cubeddu et al., 1979) have proposed
tnat DOPAC is formed intraneuronally from newly synthesised DA and
not from vesicularly stored DA since vesicular DA is protected from
metaoolism by MAO. Thus, DA antagonist treatment, which increases
DA synthesis and may result in increased metabolism of this newly
synthesised DA, does not increase DA release (Zetterstrom et al.,
1984). Conversely, drugs that release vesicularly stored DA should
have no effect upon DOPAC levels. Thus methylphenidate and
tyramine, which both release vesicular DA, had no effect upon DOPAC
levels, whereas amphetamine and potassium chloride both decreased
DOPAC levels suggesting that they released non-vesicular newly
synthesised DA (Zetterstrom et al., 1988). These results suggest
that DOPAC may be a useful indicator of intraneuronal DA metabolism
and also may be useful as a determinant of the intracellular source
of pharmacologically released DA.
Information conveyed by pharmacologically induced changes in
levels of HVA is probably more limited than that for DOPAC. HVA is
considered to be a secondary metabolite of DA and, as such, is a
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less suitable indicator of changes in DA metabolism.
Much controversy surrounds the use of 3MT as an indicator of DA
release. 3MT is a metabolite of DA but the physiological
significance of this, and indeed, whether or not it represents a
normal and significantly used route of metabolism for DA remains
Questionable. However, it has been proposed to be a good indicator
of DA release (Wood et al., 1987; Westerink & Spaan, 1982). Other
groups disagree with this (Waldmeier et al., 1981; Vulto et al.,
1986).
The rationale for 3MT accumulation indicating DA release is that
COMT is located predominantly outside the dopaminergic terminal.
Therefore, 3MT is formed from extracel1ular DA that must first be
released (Wood et al., 1987). These authors also report that 30%
of extracel 1 ul ar DA is metabolised to 3MT. It is important to
remember that in the normal situation in the absence of any
pharamcological manipulation, most released DA is taken back up into
the presynaptic terminal. Indeed, it may be necessary to
artificially raise extracellular DA levels before seeing any rise in
3MT levels. Wood and co-workers also state that the turnover of
3MT is very rapid, being rapidly transformed to HVA by MAO.
However, this is contrary to the results of Westerink & Spaan
(1982). They report a turnover rate for DA of 20-30nmol g-"*"
-1 -1 -1
h and for 3MT of 2-3nmol g h in control rats suggesting
a maximum of 10% of the metabolism of DA is via 3MT. Moreover,
after neuroleptic treatment, DA formation was shown to increase 3-4
fold without a correlating increase in 3MT turnover (Westerink &
Spaan, 1982). Westerink suggests that since the deamination of DA
by MAO is much more efficient than the O-methylation by COMT, as
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shown by the more rapid disappearance of 3-MT after COMT inhibition
than the disappearance of DOPAC after MAO inhibition, this precludes
an important functional route of DA metabolism via 3MT. He further
suggests that since the reuptake of released DA is so efficient,
very little DA will be present extracellularly to diffuse to sites
where COMT is localised. This is supported by the observation that
3MT increases if DA release is stimulated in the presence of a MAO
inhibitor which facilitates the metabolism of DA by COMT (Kehr,
1976). On the other hand, Westerink and co-workers propose that
decreased DA release is followed by decreased 3MT levels (Westernik
& Spaan, 1982).
Whatever the reality of the situation, it is important to
consider several points when using DA metabolites as indices of
dopaminergic neurotransmission or release. Firstly, it has been
shown that the increased synthesis and metabolism of dopamine can be
a purely pharmacological response and may bear little or no
relationship to the state of dopaminergic neurotransmission.
Secondly, care must be taken when applying experimental or
pharmacologically induced conditions to the normal situation. It
is easy to lose sight of the normal physiological state of
neurotransmission. After all, any pharmacological intervention
immediately departs from the physiological state and the risk exists
that pharmacologically induced DA synthesis and metabolism
completely by-passes the functionally important pool of DA i.e.,
that DA released by nerve cell depolarisation. However, by
studying the metabolic fate of DA during physiological conditions
and pharmacological intervention, the contribution of different
pools of DA and different release processes may be further
elucidated.
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1.3 In vivo sampling techniques: an historical perspective
The extracellular space of the brain is a complex
microenvironment serving roles both as a communication channel
between neurones and in neuronal-glial interactions. The events
taking place in this environment are a direct conseauence of
intracellular activities within cells of the CNS. Conseauently,
any techniaue that facilitates a direct or indirect assessment of
these events may prove valuable as a research tool for the
investigation of neuronal interactions. Several techniaues have
been developed for just this purpose and will, no doubt, continue to
develop as technology provides researchers with progressively more
accurate and sensitive techniaues. A description of the major
techniaues is presented below, followed by a comparative criticism
of these techniques.
1.3.1 The cortical cup
This is one of the earliest methodologies used to determine the
release of a neurotransmitter in vivo. The techniaue was first
applied by Macintosh & Oborin (1953) (see Moroni & Pepeu, 1984).
These authors showed that ACh release was related to electrical
activity of the cortex. Their work was extended by Mitchell
(1961a,b and 1963) who demonstrated the electrically stimulated
release of ACh from the cortical surface of sheep and cats. In the
latter two papers, Mitchell also reported evoked cortical release of
ACh by peripheral stimulation. The observed release was confirmed
as neuronal release by removal of the cortex and by local cooling of
the cortex both of which abolished release.
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Principles of the technique
The cortical cup consists of a cylinder that is held in tight
contact with the surface of the cortex. The cylinder is usually
made of perspex, but silver and aluminium have also been used. The
2
size of the cup has varied from as large as 3.0cm (Mitchell,
2
1961) to as small as 0.2cm (see Moroni & Pepeu, 1984). The cup
formed by the cylinder and cortical surface is filled with a small
volume of collecting fluid such as Ringer solution. The
neurotransmitter is able to diffuse into this solution hopefully
from neurones close to the surface of the cortex. In this fashion,
the spontaneous and evoked release of transmitters in the cortex has
been studied. It may be necessary to include an inhibitor in the
collecting fluid to prevent the breakdown of the transmitter. This
is particularly necessary for ACh which is rapidly hydrolysed in the
absence of a cholinesterase inhibitor. The collecting fluid is
removed and substituted periodically. An appropriate assay is then
used for the transmitter collected in the fluid.
The size of the cylinder used will obviously affect the size of
the area sampled. The smaller the cylinder is then the more
discrete this area is. Constraints upon size are usually imposed
by the sensitivity of the detection method available for the
transmitter.
Applications of the cortical cup
Since the time of its inception up to the present day, the
cortical cup has been used for the study of neurotransmitter release
and interactions occurring within the cerebral cortex. The early
work by Mitchell successfully demonstrated both spontaneous and
stimulated neuronal release of ACh from the cerebral cortex of sheep
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and cats. Rasmusson & Szerb (1976) correlated the cortical release
of ACh with the behaviour of awake rabbits. Their results
suggested the existence of two cholinergic systems projecting to or
present within the cortex. Beani et al. (1978) demonstrated an
effect of NA upon ACh release. The injection of NA into the
cerebral ventricles decreased ACh outflow from the guinea pig
parietal cortex. The adrenergic effect was confirmed when
a-blocking agents were shown to counteract the effect of NA. More
recently, Moroni et al. (1981) reported the release of endogenous
GABA and glutamate using a cortical cup in rats. Their results
highlighted one particular problem associated with the use of this
techniaue in unanaesthetised animals. To avoid cortical damage, it
is usually necessary to leave the dura intact when placing the
cortical cup. This was found to have no effect upon spontaneous
GABA release. However, the authors report differences in
stimulated release. If 50mM KC1 was placed into the cup on an
intact dura, glutamate release increased and GABA release
decreased. With the dura removed, the opposite was true, KC1
decreased glutamate release and increased GABA release. However,
KC1 applied directly on the cortex will cause "spreading
depression". This electrical silence may be associated with GABA
release. Thus, it may be incorrect to conclude that it was the
dura that caused this effect. However, the authors concluded that
caution should be exercised when applying the techniaue to some
neurotransmitters. This phenomenon was first noticed for ACh
release (Beani et al., 1968). The ACh output from rabbits with an
intact dura was approximately 701 of that measured after removing
the dura. This was probably due to ACh leakage in the arachnoid
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space and the diffusional barrier presented by the dura (see Moroni
& Pepeu, 1984). However, despite this, the dura does not affect
the stimulated increase or decrease of Ach or the size of drug
induced changes. It would appear that the impairment caused by the
dura depends upon properties of the transmitter and this should be
borne in mind for each different transmitter.
Chronic superfusion of the cerebral cortex in unanaesthetised
animals has also been performed by Bradford & Co-workers (see
Abdul-Ghani et al., 1981). This group was able to follow the
patterns of amino acid release from both visual cortex and
sensorimotor cortex over periods of several days.
1.3.2 Ventricular Perfusion
Intraventricular perfusion involves the perfusion or sampling of the
cerebrospinal fluid contained within the ventricles which is in
contact with deep brain structures. Early applications of the
techniaue were reported during the 19601s (Portig & Vogt, 1966,
1967; Portig et al., 19M). Portig & Vogt (1966) perfused
artificial CSF through the anterior horn of one lateral ventricle of
the cat. When the caudate nucleus was stimulated by noise,
electrical stimulation of the sciatic nerves or by electrical
stimulation of the substantia nigra, they were occasionally able to
measure the release of DA and more consistently the release of ACh
into the CSF. In a later paper, the same group reported that
D-tubocuranine released DA from the caudate nucleus more reliably
(Portig & Vogt, 1967). Later still, Portig et al. (1968)
demonstrated that D-tubocurarine released DA and HVA from the
caudate nucleus into the lateral ventricle of the cat.
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Since these early experiments, intraventricular perfusion has
been used to monitor stimulus-induced release of endogenous GABA and
also neurotransmitter release from the cerebral cortex (see
Abdul-Ghani et al., 1981).
More recently, CSF sampling rather than ventricular perfusion
has been used to monitor levels of neurotransmitters and metabolites
in cisternal CSF (Curzon et al., 1985; Hutson et al., 1985).
Curzon and co-workers developed a technique whereby it was possible
to make repeated withdrawals of CSF samples from the cisterna magna
of conscious freely moving rats via an indwelling catheter. In
this way, they determined the turnover rates of DA and 5-HT by
measuring the accumulation of the metabolites DOPAC, HVA and 5-HIAA
(Curzon et al., 1985). Similarly, using the same technique, this
group determined the effect of tryptophan loading on 5-HT and 5-HIAA
levels in the cisternal CSF.
Whilst the technique has witnout doubt provided some interesting
and informative results, it is rather limited with respect to both
temporal and spatial resolution. This arises from the fact that
the CSF is present in a relatively large volume and is in contact
with many distinct brain areas. Consequently, any compounds of
interest within the CSF are not only diluted, but the source of
these compounds may also be doubtful.
1.3.3 Push-Pull perfusion
The principle and application of the push-pull cannula was
developed at a similar time to the cortical cup. Gaddum (1961)
proposed the use of a push-pull cannula to limit the area of
perfusion. This was based on a system developed by Fox & Hilton in
1958 (see Philippu, 1984) which consisted of two parallel needles
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separated by 1.5-2cm. This arrangement was used for the perfusion
of subcutaneous tissues. Gaddum adapted this for perfusion of
small areas of the brain.
Principles of the technique
The push-pull cannula is based on the principle of a controlled
infusion and simultaneous withdrawal of an artificial physiological
fluid through the nervous tissue. This creates a stream of
perfusing fluid that mixes with the extracel1ular fluid allowing
bidirectional diffusion between the tissue and the exogenous
fluid. Drugs and other chemicals affecting neurotransmission are
added to the perfusing buffer and so are delivered to discrete brain
areas. The reverse is also possible in that endogenous chemicals
present in the extracellular fluid can be removed and assayed.
An advantage that is immediately apparent over the cortical cup
and ventricular perfusion techniques is that very discrete areas
deep within the brain can be perfused using the push-pull perfusion
technique. The experimental scope is consequently greater as shown
by the literature that auotes the use of this technique.
Applications of push-pull perfusion
The types of investigations that have been performed using
push-pull perfusion are listed below with reference to some of the
groups responsible.
1. The perfusion of ventricles of the brain with drugs or
radiolabelled neurotransmitters and the subsequent determination
of the release of endogenous or labelled compounds (Chase &
Kopin, 1968; Sulser et al., 1969; Redgrave, 1978; Korf et
al., 1976).
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2. The perfusion of distinct brain areas with drugs and the study
of their effects upon neurotransmission and behaviour. Tilson
& Sparber (1972) perfused the psychoactive drugs amphetamine and
mescaline and determined their effects upon the release of
[^H]—NA and [^H] 5-HT. Bhargava et al. (1978) determined
the peripheral effects upon cardiovascular control of drugs
perfused into the CNS.
3. The injection of radiolabelled neurotransmitters such as NA, DA,
5-HT, GABA and glycine and the investigation of spontaneous and
stimulated release of these transmitters and their
metabolites. The use of electrical stimulation and drugs with
this technique has been extensive (Chase & Kopin, 1968; Sulser
et al., 1969; Myers & Mora, 1977; Redgrave, 1978; Kondo &
Iwatsubo, 1978). One drawback with this approach is that the
radiolabelled transmitter may be taken up and released from
non-neuronal sites as well as neuronal. This is overcome by
the use of transmitter precursors in most cases.
4. The perfusion of discrete brain areas with transmitter
3 3 3
precursors such as [ H] tyrosine, [ H] tryptophan, or [ H]
glutamine and the determination of the release of the respective
transmitters, DA or NA, 5-HT and GABA. This allows the study
of resting and stimulated release of transmitter although it is
necessary to separate the transmitter from the precursors and
metabolites (Nieoullon et al., 1977; Cheramy et al., 1978,
1979; Hery et al., 1979, 1980). This technique excludes the
possibility of release from non-neuronal sites since the
transmitters are only synthesised intraneuronally.
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5. The perfusion of discrete brain areas of anaethetised and
conscious animals and the determination of the release of
endogenous transmitters. Early experiments were limited due to
the lack of sensitive assays for determination of the
transmitters. Bioassays and fluorometric methods were the best
available (Mckenzie & Szerb, 1968; Phillis et al., 1968).
More recently, radioreceptor assays have been used for the
determination of GABA (Dietl & Philippu, 1979) and with the
advances in HPLC technology and the technique of electrochemical
detection as well as radioenzymatic procedures, the accurate and
sensitive determination of catecholamines has become possible
(Bartholini et al., 1976; Stadler et al., 1975; Philippu et
al., 1979, 1980, 1981; Elghozi et al., 1981). Other
techniques such as radioimmunoassay have been used for
determination of enkephalin (Cesselin et al., 1981) and
substance P (Michelot et al., 1979). Mass fragmentography has
been used for determination of glycine and glutamate
(Wolfsenberger et al., 1981).
It is doubtless that the development of the push-pull perfusion
technique has introduced a very versatile technique. Coupled with
sensitive and accurate neurotransmitter assays, the method opened a
new perspective for the study of the dynamics of neurotransmitter
release in specific brain areas. However, no technique is perfect
and there are drawbacks to the technique. These shall be discussed
1ater.
1.3.4 In vivo voltammetry
The techniaue of in vivo voltammetry is a more recent
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development along with that of brain microdialysis for the study of
the extracellular compartment of the brain.
The appealing aspects of in vivo voltammetry are that endogenous
compounds can be measured in the brain without the necessity of
removing them and that real time measurements of transmitter levels
are possible in response to physiological and pharmacological
stimuli.
Principles of the technique
The technique relies on the placement of electrochemical
detection apparatus within the brain. This is in the form of a
miniature electrode, the size of which may vary between 1 and lOOOuM
in diameter. An oxidative potential is applied between this
electrode and a reference electrode attached to the animal. The
specificity of the technique relies on the fact that oxidisable
species present in the extracel1ular fluid undergo optimal oxidation
at characteristic potentials. The oxidation of the compound
produces a current response, the size of which is proportional to
the concentration of oxidisable material around the electrode.
The technique of j_n vivo voltammetry was pioneered by Adams and
co-workers (1973) and by Lane et al. (1979) and has since been
refined into several different techniques. These include fast
cyclic voltammetry, differential normal pulse voltammetry,
chronoamperometery and linear sweep voltammetry. The literature on
the theory and application of these techniques is extensive and has
recently been reviewed by Marsden et al. (1988).
1.3.5 In vivo brain microdialysis
The principle of brain microdialysis has been appropriately
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described by Ungerstedt (1984) as an artificial blood vessel,
represented by a dialysis membrane, implanted into the brain
parenchyma. Substances present within the extracellular fluid are
able to diffuse across the dialysis membrane into a perfusing medium
and are thereby removed from the extracellular fluid without any
nett transfer of fluid. Once contained within the perfusing
medium, dialysates are collected and appropriately assayed for the
compounds of interest. Chemicals and drugs can also be included in
the perfusing medium and these enter the extracellular fluid by
diffusion down a concentration gradient. Drugs and chemicals can,
therefore, be directed into a specific region of the brain endowing
anatomical specificity upon the technique.
The earliest use of the dialysis principle was by Bito et al.
(1966) who implanted small dialysis sacs filled with saline and
dextran into the cerebral cortex of a dog between the cortical
surface and the lateral ventricle. The sac was left in place for
10 weeks and then removed and analysed for amino acids. The next
step was the development of a dialytrode (Delgado et al., 1972)
which could be perfused thereby allowing continuous analysis of
dialysates. The dialytrode consists of concentric cannulae forming
a probe. The end face is formed from dialysis membrane giving a
2
porous surface area of several mm . Later modifications included
electrodes combined with the dialytrode for the recording of
electrical activity wihtin its vicinity. Further refinements were
made by Ungerstedt & Pycock (1974) who constructed dialysis probes
less than 300um in diameter using thin dialysis tubings. The
technique had, therefore, advanced from the implantation of small
dialysis sacs in non-specific brain areas, into the use of miniature
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dialysis probes which can be accurately positioned within small
brain areas. Brain microdialysis using this dialysis tubing has
now become a widely used technique. The precise methodology
employed varies with different groups. Ungerstedt & Pycock (1974),
Tossman et al. (1983), Hamberger et al. (1985) and more recently
Imperato et al. (1984,1988) used a trans-striatal dialysis device in
which the dialysis fibre was inserted laterally through the brain,
entering on one side of the skull and exiting on the other. The
same groups have also used smaller, more discrete dialysis loops
(see Fig. 1.3.1). The most recently developed technique is that of
the dialysis probe. This is designed as a vertical probe of a
single diameter, the size and design of which allow easy stereotaxic
placement in small experimental animals compared with transverse
probes. Several groups have used this probe design (Hamberger et
al., 1985; Zetterstrom and coworkers, 1983, 1984, 1986; Church et
al., 1987; Hernandez et al., 1986, 1987; Kendrick et al., 1986;
Robinson et al., 1986). The dimensions of dialysis probes and
loops can be varied so increasing or decreasing the
dialysing area according to the size of the brain area of interest.
1.3.6 Critical assessment
Each in vivo sampling technique represents a different approach
to similar problems and it is, therefore, worthwhile comparing and
contrasting the four techniaues described.
Both perfusion and voltammetric techniaues work in a small pool
of extracellular fluid. Both approaches measure neurotransmitter
overflow rather than neurotransmitter release. This is an
important point to remember and arises from the fact that there are
(b) Dialysis loop
Fig.1.3.1 Illustration of the types of microdialysis
devices used.
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differences of several orders of magnitude between both the time
resolution and size of the cannula/probe/electrode, and the
synapse. For example, a synapse is between l-10nm wide,
voltammetric electrodes between 1-lOOOpm in diameter and the
smallest dialysis probe about 200pm in diameter. As a result of
this, it is the collected overflow of transmitters from many
synapses rather than release from individual synapses that is
monitored. Moreover, synaptic events occur in a sub-second
timescale whereas most sampling techniques, with the possible
exception of recent advances in voltammetric probes, cannot sample
on this timescale.
The obvious drawback to the cortical cup techniaue is that it is
only possible to determine transmitter output from relatively large,
non discrete areas of nervous tissue that are close to or at the
cortical surface. The study of deep brain regions is not possible
with this techniaue. However, this is only a drawback if the
researcher wishes to sample from deep brain areas. The technique
is particularly amenable to the study of ACh overflow from the
cortical surface.
Precautions must be taken with this techniaue as with the others
to maintain the animal at the correct constant temperature. A fall
in temperature will also cause a fall in transmitter overflow.
A technical difficulty associated with the cortical cup is the
ease with which the surface of the cortex may be damaged during
placement of the cup. Such damage may destroy cortical cells or
release blood into the cup. This will effectively terminate the
experiment.
A major drawback to both the cortical cup techniaue and the
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push-pull perfusion techniaue is whether or not the overflow of
transmitter, whether it is resting or stimulated overflow, is solely
neuronal or derived from non-neuronal tissue also. This problem
was highlighted by Chase & Kopin (1968). Using push-pull perfusion
of the olfactory bulb, they demonstrated that olfactory stimulation
caused by exposing the animal to an odour, increased the efflux of
[^H]-NA and [^H] 5-HT in the push-pull perfusate. To determine
whether or not this efflux was neuronal, they injected the
14 14
metabolically inert substances C-inulin, C-urea and
14 3 14
C-a-aminoisobutyric acid with the H amines. The C
compounds acted as extracel1ular markers since they are not taken up
by cells. Odour stimulation was reported to increase the efflux of
3 14
both H and C with the same response pattern. Manipulations
3
of the experiment failed to dissociate the co-efflux of H and
14
C. So in this example, it was not possible to determine if the
stimulation induced alterations in NA and 5-HT efflux reflected
physiological release from neuronal stores or just extracellular
shifts of exogenous amine. The authors proposed that the push-pull
perfusion techniaue seriously compromised the intra-extracel1ular
barrier due to traumatised tissue. This complicates the
interpretation of the efflux of exogenously applied transmitters.
Following this, Collier & Murray-Brown (1968) published work
supporting the validity of the cortical cup techniaue for studying
neuronal release of ACh. They perfused the surface of the cortex
whilst stimulating the mesencephalic reticular formation and found
that ACh was released independently of labelled urea.
This problem is overcome to a large degree if the efflux of
endogenous transmitters is measured rather than exogenous. This is
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not universally true though since large amounts of GABA and amino
acids are present in the blood and in glial cells. Moreover, amino
acids are also involved in non-transmitter functions.
Consequently, the results of perfusion experiments measuring these
transmitter substances should be interpreted with care.
When compared with the dialysis technique, the two major
drawbacks of push-pull perfusion are that it is technically
difficult and unreliable and that there may be a nett transport of
perfusate to or from the tissue because the system is not closed.
These technical difficulties arise from trying to balance the
infusion and removal of liquid from the tissue. This is not easily
achieved and any imbalance in flow rates may cause positive or
negative alteration in hydrostatic pressure leading to mechanical
damage to the tissue. Another common problem is the blockage of
the cannula by tissue fragments. This may again cause accumulation
of fluid in the brain leading to unreliable results and/or
experimental failure. The perfusion of fluid through the
extracellular space may lead to a nett transport of water to or from
the tissue unless the osmolarity is carefully controlled and may
also cause mechanical damage. Either of these will result in
local biochemical interference, the effects of which may be long
lasting.
The technique of in vivo microdialysis has several inherent
advantages that overcome some of these problems. These are:
1. It is a closed system, i.e., there is no mixing of perfusing
fluid and extracel1ular fluid.
2. The dialysis probe is made of soft material which reduces
mechanical damage and helps make the probe an integrated part of
the brain (Hamberger et al., 1985).
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3. The dialysis probe can be pre-calibrated in vitro, enabling
absolute concentrations of substances in the brain extracel1ular
fluid to be estimated.
The assay of compounds of interest in the perfusate is
simplified due to the diffusional barrier to large molecules.
Perfusate samples are conseauently 'clean' and may not require any
extraction or purification prior to the assay.
A disadvantage of both the push-pull cannula and the dialysis
probe is the poor resolution in time and space of neurochemical
events. Both methods require sample volumes of several microlitres
collected over a time scale of minutes, resulting in poor resolution
of neurotransmitter dynamics. Advances have been made in this
direction and will be described at the end of this section.
In vivo voltammetry lacks some of the methodological problems
associated with perfusion techniques, but is not without problems of
its own. Voltammetric electrodes range from 1 to lOOOym in
diameter and are prepared as well as used in several different ways
(see Marsden et al., 1988 for review). The technique has been used
to measure DA release and changes in extraneuronal concentrations of
DOPAC reflecting altered striatal dopaminergic activity (Cespuglio
et al., 1981a,b; Conti et al., 1978; Yamamoto et al., 1982;
Wightman et al., 1988). Also, 5-HT release and changes in levels
of 5-HIAA have been measured (Cespuglio et al., 1981a,b; Kennet et
al., 1982). However, drawbacks of the technique are that firstly,
the ability of the electrodes to resolve multicomponent signals into
separate electrochemical peaks is rather limited. Secondly, the
sensitivity of the method is limited and the ability to measure
basal DA levels is question able (see Marsden et al., 1988).
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The poor resolution of single compounds is due to the presence
of other compounds which oxidise at similar potentials in brain
tissue. In an attempt to help overcome this, modified electrodes
have been developed such as stearate modified electrodes used by
Knott et al. (1985) and Lane & Blaha, (1986) or nafion coated
electrodes as used by Gerhardt et al. (1984, 1986). These
modifications have helped to overcome some of the selectivity
problems particularly those associated with interference from
ascorbate and DOPAC.
In vivo microdialysis coupled with HPLC-ECD overcomes the
problems of selectivity since the individual substances are
separated by HPLC before being measured electrochemically. In
addition to this, it is possible to simultaneously measure basal and
stimulated levels of DA, DOPAC, HVA, 3MT and 5-HIAA representing a
great advantage over voltammetric techniaues. This enables
correlations of drug induced changes in transmitter and metabolite
levels.
Having listed the most apparent advantages and disadvantages of
each technique, the intention is not to say that one method is
preferable to another, but rather to recognise the limitations of
each technique and so realise and utilise the potentials of each.
The advantages and potential uses of these techniques in the study
of in vivo neurobiology are numerous. Despite the importance of
chemically mediated neurotransmission and the general acceptance of
it as the means of neuronal communication, there has been a scarcity
of methodologies available for the study of the mechanisms mediating
neurotransmitter release and metabolism. The techniques of in vivo
microdialysis and in vivo voltammetry represent the best hopes for
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future studies of these processes. The study of biochemical
1synaptology1 in response to physiologically relevant as well as
pharmacological stimulations appear to be an attractive use of these
methods. However, the gap in time resolution to the real events is
great, more so for dialysis than for voltammetry. This limits the
role of dialysis techniaues to the study of pharmacologically
induced biochemical changes in defined CNS regions. In vivo
voltammetry probably offers the greatest potential for monitoring
real time (sub second) physiological phenomena. Improvements in
selectivity and sensitivity of eauipment may allow detection of
rapidly changing concentrations of substances (e.g. Kuhr & Wightman,
1985). Both techniaues are increasingly being used for the chronic
measurement of neurotransmitters in awake freely moving animals (see
Church et al., 1987; Hernandez et al., 1987; Westerink et al.,
1982, 1985, 1987; Zetterstrom et al., 1984, 1986; Knott et al.,
1985). This allows pharmacological, physiological and behavioural
correlations of neurotransmitter release and metabolism to be made.
The most exciting prospect for in vivo microdialysis is its use
with smallbore HPLC apparatus (see Carlsson et al., 1986). This
involves using HPLC columns as narrow as 0.5mm internal diameter.
The conseauences of this are that injection volumes as small as lpl
can be used for the determination of catecholamines. This
increases the temporal resolution of the microdialysis technique as
well as enabling very slow perfusion speeds to be used thereby
increasing the relative recovery of compounds from the extracellular
fluid.
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1.4 Analytical techniques for catecholamine and indoleamine analysis
Several techniaues have been developed for the measurement of
small auantities of catecholamines. The application of these to in
vivo release methods has been possible because of their increased
sensitivity compared with techniques used previously, such as
bioassays and fluorometric assays. Examples are: (1)
radioenzymatic procedures (2) gas chromatography alone or with
mass spectrometry (3) HPLC with fluorimetric or electrochemical
detection. The latter technique of HPLC-ECD provides the most
useful method with regard to convenience and sensitivity in the
present application. This approach was first applied by Kissinger
et al. (1973) and rapidly adopted by others for the determination of
catecholamines. The principle of electrochemical detection is
fully discussed in the following section (2.3).
1.4.1 Reverse-phase ion-pair HPLC
For the prelminary separation of the catecholamines,
reverse-phase ion-pair HPLC has become the method of choice.
Reverse phase refers to the aqueous rather than organic mobile phase
and the high organic carbon content of the stationary phase. The
techniaue provides high resolution and rapid analysis times without
the need for prior derivatisation. This is important for the
measurement of catecholamines which are thermally labile and
unstable at high pH. The method is also popular due to the high
column stability and the ability to separate several different
compounds in a single chromatographic run. Recently, a method was
described for the separation of nine catecholamines and metabolites
within a run time of 10 min (Murai et al., 1988).
Ionic strength of mobile phase
Increasing the ionic strength of the mobi le phase using citrate
may cause slightly longer retention times since citrate ions can
function as secondary ion pairing agents interacting with the column
stationary phase and with the amine solutes (Krstulovic et al.,
1981).
Concentration of organic modifier
Organic modifiers, such as methanol and tetrahydrofuran, serve
to shorten the retention times of all the catecholamine solutes.
This effect relies on the polarity and dielectric constant of the
organic modifier along with its interaction with the ion pairing
agent (Horvath et al., 1977).
Ion pairing agent
At the pH values used in reverse phase chromatography, DA, 5-HT,
NA and AD are protonated and this charge diminishes the retention of
these molecules. In order to overcome this problem, an ion pairing
agent, such as sodium octanesulphonate, is included in the mobile
phase. This attaches to the stationary phase and increases the
retention times of these compounds. The precise mechanism by which
the ion pair achieves the longer retention times remains a matter of
controversy (see Krstulovic, 1982), but relies on the reversible
binding of the ion pair to the hydrocarbon surface of the stationary
phase. Dynamic ion exchange between the solute and the ion pairing
agent then occurs and this retards the movement of the solute down
the column. This effect requires that the solute molecule is
charged for the interaction to occur. It is important to avoid
high concentrations and excessively long chain lengths of the ion
pairing agent since this will result in excessively long retention
times and column eaui1ibration times. Octanesulphonate was found
to be ideal, the excessive retention times caused by its inclusion
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being overcome by the inclusion of the organic modifiers mentioned
above.
Effects of pH of the mobile phase
Retention times were most sensitive to the pH of the mobile
phase. At lower pH values, the amino groups of the catecholamines
are fully protonated whilst the carboxyl group of the metabolites is
stabilised. This has the effect of enhancing the interaction
between the solute molecules and the stationary phase due to the
increased solute hydrophobicity. Thus, the acidic metabolites
DOPAC, HVA and 5-HIAA are retained longer at lower pH values whilst
the reverse is true for DA.
In the present study, the only mobile phase manipulation
commonly used to ensure separation was varying the pH of the mobile
phase. Occasional alterations of the ion pair concentration were
used when this proved inadequate. This allowed the easy
differentiation of the DOPAC, DA, HVA, 5-HIAA and 3MT peaks. Thus,
either sodium hydroxide was added to differentially reduce the
retention time of DOPAC when it co-eluted with DA, or perchloric
acid added in order to retard HVA elution when it co-eluted with or
close to DA.
On the whole, the system was very reliable and consistent,
provided the HPLC apparatus was adequately maintained.
1.5 Electrochemical Detection
Electrochemical detection is based upon a process in which
electroactive compounds are either oxidised or reduced. The
resulting loss (oxidation) or addition (reduction) of electrons
causes a change in potential difference between two electrodes.
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This forms the basis for the detection of such compounds.
Electrochemical detection was first applied to catecholamine
detection by Adams and co-workers (Kissinger et al., 1973). Since
then, the technique has been used for the detection of many
different chemicals, pharmaceuticals, dyes and carcinogens. It is
now a popular techniaue for catecholamine detection due to its high
sensitivity, being able to detect picogram auantities, and to its
reliability and ease of use.
Electrochemical activity can be defined as the ability of a
molecule to rearrange itself in such a way as to accommodate the
loss or addition of one or more electrons. This must occur within
certain potential limits which are defined by the electrode material
and the properties of the solvent. The system commonly used for
the detection of catecholamines consists of a carbon electrode and
an aqueous solvent. This sets the potential limits between +1.2
and -0.8v with regard to a Ag-AgCl reference electrode.
Most aromatic amines and phenols are oxidisable between these
potentials. Electrochemical oxidation converts catecholamines to
the corresponding quinone. Serotonin is oxidised to a
quinone-imine. O-methylated metabolites such as HVA and 3MT are
more difficult to oxidise since the methoxy group must be cleaved.
This requires a higher energy of activation and conseauently, a
higher electrochemical potential.
The current derived from the release of these electrons is
proportional to the concentration of the species in solution. This
is shown by the following expression for the current developed by
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Levich (1962) (see Mefford, 1981). This is:
i. = KnFVaC,
L b
i^ is the limiting current obtainable from oxidation or reduction
of a species.
K is the cell constant dependent upon the diffusion coefficient of
the species of interest, the viscosity of the solvent and the
geometry and area of the electrode.
n is the number of electrons involved in the oxidation or reduction
of one molecule of the species.
F is Faradays constant
Va is the velocity of the solution passing over the electrode
surface to some power a.
is the bulk concentration of the electroactive species present
in solution.
For a given species under isocratic chromatographic conditions
at a constant flow rate, n, Va, F and K are all constant. So the
equation simplifies:
1L = BCb
where B is a constant containing all the other constant terms.
The current obtained is, therefore, dependent only on the
concentration of electroactive species in solution.
A greater selectivity is conferred upon the technique of
HPLC-ECD by the fact that different electrochemically active species
have different oxidation potentials. Some of these are listed in
Table 1.5". 1 (from Mefford, 1981).
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TABLE 1.5.1








This fact can be used to validate the identity of a peak of a
suspected compound by determining the relationship between the
applied potential and the current response for that compound. The
resulting curve is uniaue to that compound and is known as a
hydrodynamic voltammogram (see section 2.2. and Fig. 2.2.2).
Electrochemical detector design
The detector used in all experiments presented here was the BAS
LC-17 oxidative transducer. Tnis is a thin layer electrode and is
depicted in Fig. 2.2.1 (upper panel) and complete with the reference
electrode in Fig. 2.2.1 (lower panel). It contains a glassy carbon
electrode which is part of a channel wall formed by a gasket between
a plastic and a metal block.
The primary concern in detector design are the thickness of the
gasket which affects the volume of the electrode chamber and
consequently the sensitivity, and the surface area of the
electrode. The above expression for current produced by oxidation
shows that the larger the electrode surface area, the greater the
current derived from oxidation and the greater is the sensitivity of
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the electrode. The same is true for the flow rate over the
electrode. However, increasing either of these decreases the
signal to noise ratio of the detector which is deleterious to
detector performance since the increased 'noise' may obscure the
peak of interest.
Baseline noise which is caused by the presence of electroactive
species in solution is always present but should be minimised. The
most common causal factors are dissolved oxygen and ferrous ions
from the eauipment. In addition to these, the mobile phase itself
is electroactive so any variation in flow rate will cause baseline
fluctuations.
To help overcome this, the following precautions were routinely
taken:
1. Mobile phase was degassed under vacuum and helium bubbled
through to remove dissolved oxygen.
2. A pulse dampener was included with the pump to reduce pulsations
in the flow rate caused by the reciprocating piston.





2.1 Microdialysis Probe Construction and Characterisation
Microdialysis probes were constructed in the laboratory with the
aid of a low powered binocular microscope.
The probes were made according to the method of Sandberg et al.
(1986). Two lengths of plastic coated vitreous silica tubing
(Scientific Glass Engineering; VS 170/110) were inserted into a 6mm
length of dialysis membrane (Cuprophan B4 AH, Cobo Medical Supplies,
Lafeyette, USA). The dialysis membrane has a molecular weight cut
off of approximately 5,000, which prevents molecules of a greater
molecular weight (e.g. proteins) diffusing across the membrane.
The tips of the tubing were separated by 3mm, one being positioned
1mm from the end of the dialysis tubing and the second 3mm behind
tnis. A length of teflon coated tungsten wire (Clark
Electromedical, WT3) was then inserted alongisde the two pieces of
tubing within the dialysis membrane in order to strengthen the
probe. The tip of the wire was positioned to coincide witn the
open end of the dialysis tubing. Both ends were sealed with
cyanoacrylate adhesive (Loctite Xtra). This assembly was then
inserted into a short length of 21 gauge stainless steel tubing with
the dialysis tubing protruding 10mm from this. This provided an
anchoring point for mounting the dialysis probe in a stereotaxic
probe holder. The structure of the dialysis probe is shown
schematically in Fig. 2.1.1.
The completed dialysis probe has an outer diameter of
approximately 0.3mm. The effective length of the dialysis membrane
is 3mm since any membrane above the outlet capillary was coated in
glue to prevent any diffusion above this point. This length was
chosen to be suitable for placement in the particular area of the







striatum studied, which is greater than 3mm in depth at the point of
insertion.
The use of this vitreous silica inlet and outlet tubes reduced
the dead volume of the dialysis probe to an absolute minimum. This
ensured that the responses measured correlated directly in time with
drug or chemical application.
In vitro characterisation of dialysis probes
Determination of variations in probe efficiency
In order to assess the variation in efficiency between probes,
four newly constructed probes were compared. The probes were
perfused at a rate of 1.25u1/min in a standard solution containing
DOPAC, DA, HVA, 5-HIAA and 3MT. The percentage recovery of each
compound was determined for each probe and the values averaged.
The results are shown in Table 2.1.1
TABLE 2.1.1







It is apparent from the results that variations in efficiency
between probes were small.
-65-
Effect of perfusion speed on in vitro recovery
The effect of perfusion speeds on the recovery of DOPAC, DA,
HVA, 5-HIAA and 3MT is illustrated in Fig. 2.1.2. This was
performed by placing a dialysis probe into artificial CSF containing
known concentrations of the above compounds. The probe was then
perfused at rates of 0.5, 1.0, 1.25, 2.5, 5 and lOyl/min. Three
25y1 samples were collected for each perfusion speed and the
concentrations of DA, DOPAC, HVA, 5-HIAA and 3MT measured by
HPLC-ECD. The results were averaged for each compound. On the
basis of these results, a perfusion speed of 1.25yl/min was chosen
for all experiments. At this speed, the % recovery varies between
7.9£ for DA to 12.4J for HVA (see Table 2.1.1). Fig. 2.1.2 shows
that at higher perfusion speeds than this, recovery rapidly
decreases. Using a slower perfusion speed would necessitate longer
collection times and so reduce the temporal resolution of the
experiments.
2.2 HPLC and Electrochemical Detection
The separation of DA, DOPAC, HVA, 5-HIAA and 3MT was achieved
using a reverse phase liauid chromatography system. An Altex 110A
delivery pump set at a flow rate of l.Oml/min was used. Samples
were injected through a Rheodyne 7125 syringe loading sample
injector fitted with a 20yl loop and an Altex 5ym Ultrasphere ODS
C-18 column (250 x 4.6mm) was used. A thin layer oxidative
transducer (BAS LC17) connected to an amperometric detector (BAS
LC4A) was used for electrochemical detection of catecholamines and
indoleamines. The detector output was recorded on a Bryans BS600
twin channel chart recorder.
40 i
FLOW RATE(ul/min)
Fig.2.1.2 The relationship between perfusion speed and relative




An isocratic mobile phase prepared according to the method of
Sheward & Watts (1985) was used. This consisted of lOOmM sodium
citrate/acetate buffer (pH 5.2) containing 51 methanol, 2t
tetrahydrofuran and lOOyg/ml sodium octanesulphonate as an ion
pairing agent. The mixture was degassed under vacuum prior to the
addition of the tetrahydrofuran in order to remove dissolved gas.
This is necessary to reduce interference from electroactive species
such as dissolved oxygen at the working electrode of the detector.
Experience showed that the mobile phase prepared in this way was
stable and usable for several days.
HPLC/ECD Care and Maintenance
Occasional problems were experienced with the HPLC apparatus
such as excessive pump pressure or leaks. These were all overcome
or prevented by regular maintenance. Care was taken to ensure that
no air bubbles or any other foreign material entered the system.
To aid this, a pre-column was included (Spheri-5RP-18 OD-GU, 30mm x
4.6mm; Brownlee labs) which served as a guard for the main
column. Other preventative maintenance included (i) piston and
piston seal replacement in the liquid head of the pump (ii) frit
renewal at the top of the column (iii) check valve cleansing
Between experiments and whilst not in use, the column was washed
successively with water, methanol-water and finally metnanol. This
removed the ion pairing agent from the column as well as washing the
system.
Electrode care and maintenance
The oxidative transducer electrode consists of a working
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electrode, a reference electrode and an auxiliary electrode (see
Fig. 2.2.1 for a schematic diagram). It is at the surface of the
working electrode that the eluted solutes are oxidised. The
working electrode is made of glassy carbon and has a long working
life. Following prolonged use, this surface becomes contaminated
thereby reducing the efficiency of the electrode. To prevent this,
the electrode was disassembled regularly and polished with alumina
according to the manufacturer's recommendations. Most importantly,
care was taken not to scratch the surface of the electrode. The
electrode was then sonicated and washed in methanol before
reassembly.
The reference electrode is a sealed unit (BAS RE—1) consisting
of a Ag/AgCl electrode containing 3M NaCl. It was important not to
allow the tip of the electrode to dry out. A faulty reference
electrode causes a drifting baseline due to deviations in the set
potential of the electrode. This may be due to a leaking or
cracked electrode. If this was suspected, the electrode was tested
by placing it with a new electrode into a beaker containing 3M
NaCl. The potential difference between the two electrodes was then
measured with a voltmeter. If the meter reading exceeded ± 20mv,
the electrode was faulty and was replaced.
A final precaution was to ensure that no bubbles of air were
present in the reference chamber. This was done by removing the
reference electrode and allowing the chamber to overflow whilst
gently tapping the sides to dislodge any bubbles. The reference
electrode was then re-inserted.
Construction of hydrodynamic voltammogram











Fig.2.2.1 Schematic representation of the oxidative
electrode used for electrochemical detection.
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response was determined for DOPAC, DA, HVA, 5-HIAA and 3MT. The
results are shown in Fig. 2.2.2. These show that at the voltages
used, the detector was most sensitive for DA. The response for any
electroactive species is characterised by a rapid increase in
response as more voltage is applied which levels off to a plateau.
An applied potential of +0.7V was used for all experiments which
ensures optimum sensitivity for DOPAC, DA and 5-HIAA whose oxidation
potentials are +0.56, +0.5 and +0.58V respectively. The
0-methylated metabolites HVA and 3MT have higher oxidation
potentials of +0.76 and 0.74V respectively which is illustrated by
the rapidly rising current response for both compounds between 0.6
and 0.7V with HVA continuing to rise rapidly between 0.7 and 0.8V.
The recommended voltage to use is at the beginning of the plateau
phase within approximately lOOmv of the oxidation potential. This
ensures maximum sensitivity whilst keeping the background current to
a minimum which also reduces the likelihood of interference from
other solutes. Thus an oxidation potential of +0.7V was considered
as suitable since DA and DOPAC were the primary compounds of
interest.
Daily Operation of the HPLC
To allow the column to equilibrate with the mobile phase, and in
particular, with the ion pairing agent, the mobile phase was
prepared 12-18 hours in advance and pumped through the column
overnight at a speed of O.lml/min. On the day of use, the pump
speed was reset at l.Oml/min and the electrochemical detector
switched on. A large current signal due to charging and transient
background current occurs each time the electrode is switched on.
The signal gradually decays to a steady state background current







Fig.2.2.2 A hydrodynamic voltammogram for DA,DOPAC,HVA,5-HIAA
and 3-MT.
-69-
after 5 min. The detector electrode was always switched on at
least one hour prior to use for this reason.
Baseline drift caused by oxidative species present in the mobile
phase was occasionally observed and this was corrected for using the
offset control on the detector. After use, the detector electrode
was always switched to standby to avoid unnecessary use of the
electrode and subseauent deterioration over time. The electrode
was regularly cleaned to ensure consistent performance and results.
Elution and identification of standards and samples
The buffer system used allowed the separation and identification
of DOPAC, DA, HVA, 5-HIAA and 3MT with each injection of
dialysate. Typical retention times for these compounds were as
follows; DOPAC, 5 min; DA, 7 min; HVA, 8.5 min; 5-HIAA, 9.5 min;
3MT 11.5 min. Variations in these values occurred with variations
or changes of mobile phase. In particular, the acid metabolites of
DA, namely DOPAC and HVA as well as the serotonin metabolite 5-HIAA,
are very sensitive to changes in pH of the mobile phase. The
reasons for this are explained in 1.4. Any deviation in the pH of
the mobile phase, therefore, altered the retention times of these
compounds.
Dopamine, being uncharged, is relatively unaffected by
alterations in pH of the mobile phase and the retention time is,
therefore, relatively unaffected by altering buffer pH.
Measurements of 3MT were not routinely performed since basal levels
were usually close to the detection limit. However, measurements
were taken if the applied drugs caused an increase in 3MT.
Dialysate samples were collected for 20 min and since most
experiments involved bilateral implantation of dialysis probes, two
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samples were collected every 20 min. This reduced the storage time
of dialysate samples to a maximum of 10 min.
Standard amounts of DA, DOPAC, HVA, 5-HIAA and 3MT were injected
for calibration of the response to each. Standard solutions of
100ug/ml were prepared monthly in 0.2M perchloric acid and were
stored at 4°C. These were mixed and diluted daily to a
concentration of lOOng/ml and 20yl samples (i.e. 2ng of each
compound) of this solution containing DOPAC, DA, HVA, 5-HIAA and 3MT
were injected routinely before each experiment. The standard
solution was injected until three identical responses were
obtained. The mean of each signal was then used to calibrate the
detector and so determine the concentrations of catecholamines in
the dialysate samples by comparing the sample peak heights with
those of the standards. Fig 2.2.3 shows a typical chromatograph of
a standard solution and a chromotograph of a dialysate sample with
basal levels of DOPAC, DA, HVA, 5-HIAA and 3-MT.
The basal values of the dialysate catecholamines and indoleamine
overflow varied between experiments, but were always within a
certain range. These are shown in Table 2.2.1.
TABLE 2.2.1


































Fig.2.2.3 Elut.i.on profile of DA and monoamine metabolites separated
by HPLC/ECD.a.Separation of a calibrating solution containing
2ng of each compound.b and c: experimental dialysate measured
at two different sensitivities.
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The values in Table 2.2.1 cover the normal range of basal
concentrations of these compounds. Higher and lower values were
occasionally encountered.
The detection limit for DA was approximately .03 pmoles i.e.,
5.5pg for the reliable measurement of the DA peak
(signal:noise ratio > 3). The usual basal value of DA was,
therefore, approximately 2-3 times the detection limit.
DOPAC levels were the most variable between animals as the range
shows in Table 2.2.1. Once again, this range was occasionally
exceeded in either direction. HVA and 5-HIAA levels were more
consistent.
Since there was a 200-fold or greater difference in
concentrations of DOPAC and DA, a dual channel chart recorder was
used. This enabled simultaneous measurement of all compounds over
the entire range of concentrations encountered. DA and 3MT were
measured on one channel with 2nA full scale deflection whilst the
metabolites DOPAC, HVA and 5-HIAA were measured on a second, less
sensitive channel with 20nA full scale deflection. This provided
an ideal method of simultaneously monitoring all the compounds and
also enabled a decrease in peak height to be accurately followed
from the less sensitive to the more sensitive channel.
It was important to establish the identity of the
chromatographic peaks. This was performed in two ways. Firstly,
the retention times of the identifiable standards were compared with
those of the experimental samples. These times could be determined
auite accurately and, therefore, provided a reliable method.
Fig. 2.2.3 shows a chromatograph of the standards compared to a
chromatograph of a sample. The retention times are identical as
shown by those peaks indicated for the compounds of interest.
Secondly, a dialysate sample was collected over a period of 40 min
from a probe inserted into the striatum of an untreated rat. The
sample was divided into two equal parts, one of which was 'spiked'
with a known concentration of either DOPAC, DA, HVA or 5-HIAA.
Each was then injected onto the HPLC system. The spiked samples
have a larger peak which corresponds to the known amount of standard
plus that in the unspiked sample. These methods prove beyond doubt
the identity of the chromatogram peak.
In practice, problems with 'foreign' peaks co-eluting with any
of the catecholamine peaks were not encountered. Noradrenaline and
ascorbic acid both elute close to the solvent front whilst 5-HT
elutes at approximately 20 min and is barely detectable due to peak
broadening. Providing that the five peaks DOPAC, DA, HVA, 5-HIAA
and 3MT were separated by at least one minute, no problems were
encountered with peak resolution or interference by otner peaks.
2.3 Surgical Procedures
Male Han-Wistar rats supplied by the Institute of Occupational
Medicine (Edinburgh) were used throughout the study. These were
housed in a 14 hour 1ight:10 hour dark cycle with free access to
water and lab chow. The weights of animals varied between 180 and
300g, typically being around 250g.
Rats were initially anaesthetised using Brietal (sodium
methohexitone, Eli Lilly & Co., U.K.) at a dose of 75mg/kg i.p..
An incision was made in the neck and the parotid glands deflected to
expose the trachea. A cannula was inserted into the trachea below
the thyroid arch and secured in place. The animal was then mounted
in a David Kopf stereotaxic frame with the tooth bar set at 3.0mm
below the interaural plane (according to Paxinos & Watson, 1982).
Anaesthesia was maintained using halothane (< 1%) in air. Body
temperature was maintained between 36-38°C using an electric blanket
thermostatically controlled by a rectal probe. The surface of the
skull was exposed and burr holes were drilled above both striata.
The dura was carefully cleared to allow the insertion of dialysis
probes. Each dialysis probe was mounted in a purpose built nolder
(supplied by Carnegie Medicine) and this assembly was held in a
micro-manipulator mounted on the stereotaxic frame. Probes were
then positioned above the striatum (AP +0.5, ML ± 2.5mm; relative
to bregma; Paxinos & Watson, 1982) and were inserted to a depth of
7.5mm below the dura. The bottom 1mm of the probe therefore lies
below the striatum but with the actual dialysing area centred in the
striatum.
Each probe was perfused with freshly made oxygenated
Krebs-bicarbonate buffer of the following composition in mM: NaCl,
124; KC1, 3.3; MgS04, 2.4; KH2 P04, 1.25; CaCl2, 2.5;
NaHC03, 25 ; pH 7.4.
Animals were frequently monitored for depth of anaesthesia.
2.4 Drug Delivery and Sample Collection
Following implantation of the dialysis probes, each was
connected via a short length of small bore polythene tubing to a 1ml
syringe mounted in a constant drive microinfusion pump (Carnegie
Medicine, CMA 100). It was important to ensure that no air bubbles
were present within the syringe or within the connecting tubing
since these may become trapped within the probe and so reduce its
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efficiency. Buffer solution was then perfused through the probes
at a rate of 1.25yl/min. The probes were perfused in this fashion
for approximately 60 min prior to the commencement of all
experiments. This was regarded as a necessary eaui1ibration period
to allow recovery from the acute effects of implantation trauma.
Basal levels of the compounds of interest were found to be steady
after this initial washout period. Perfusate samples were
collected by placing a small Eppendorf tube over the outlet
tubing. Each sample was collected for 20 min which gave a volume
of 25p1. At least three 20 min samples were collected before drug
application for determination of basal efflux of catecholamines.
Dopamine is an unstable compound and is easily oxidised under
certain storage and analytical conditions. However, the dopamine
and metabolites of interest, DOPAC, HVA and 5-HIAA, were found to be
stable when collected in air. The inclusion of 0.2M perchloric
acid in the Eppendorf tube was found to be unnecessary since there
were no differences in basal values of DA, DOPAC, HVA or 5-HIAA
dialysate content in successive samples collected with and witnout
the inclusion of perchloric acid in the Eppendorf tube. This was
probably due to the short length of time (maximum 10 min) between
sample collection and subseauent analysis and the minimal deadspace
of the dialysis apparatus.
After collection, 20yl of the dialysate was injected onto the
HPLC for determination of the levels of the compounds of interest.
A 20yl HPLC injection loop was used and the entire 25yl of dialysate
was injected, the excess being lost through the valve overflow.
This ensured minimal sample to sample variation in injection volume.
Drugs and chemicals were given by two routes depending upon the
experimental procedure. These were intraperitoneally (i.p.) or via
the dialysis probe. When given via the probe, account must be
taken of the efficiency of the probe when considering the amount
that actually reaches the extracellular fluid of the rat striatum.
The probes used had a recovery of between 10-15% suggesting that a
similar percentage of the drug/chemical will enter the extracellular
fluid by passive diffusion from the probe. The solution containing
the drug/chemical was simply exchanged with the perfusing buffer
either by disconnecting the connection to the probe or by using a
liquid switch (Carnegie Medicine, CMA 110). The advantage of using
the liquid switch is that the flow of perfusate through the probe is
uninterrupted. Although changing the tubing connected to the probe
involves interrupting the flow, no change-over artefacts were
noticed in the levels of the compounds of interest. Obviously, the
ideal method is to use the liauid switch but this was not always
possible since a liquid switch and pump are reauired for each
probe. Many of the experiments involved bilateral implantation of
dialysis probes so requiring two pumps and two liquid switches which
were not available.
Basic experimental protocol
Details of the combinations and duration of administration of
drugs and chemicals are shown in the results for each experiment.
Table 2.4.1. below indicates the route of administration and the
dose range of all the drugs and chemicals used. All drugs given
intraperitoneally were dissolved in saline {0.9% w/v) except for
reserpine. The procedure for dissolving reserpine was as follows:
citric acid (125mg) and reserpine (125mg) were dissolved in 1ml
benzyl alcohol by warming and stirring. 5ml Tween 80 were added
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with continued stirring. The volume was then made up to 50ml with
0.9% saline. The final concentration of reserpine was 2.5mg/ml.
Nomifensine was found to be virtually insoluble and so was
injected as a fine suspension.
All drugs and chemicals given via the dialysis probe were mixed





Amphetamine IP and Probe 2-16mg/kg and 5pM
Ouabain Probe lOuM-lmM
Veratrine Probe 10pg/ml-lmg/ml
Nomifensine IP and Probe 20mg/kg, 1-lOOyM









2.5 Tissue levels of catecholamines
In order to validate the conclusions based on the dialysate
results concerning drug effects upon DA, DOPAC, HVA, 5-HIAA and 3MT
in the nerve terminal, it was necessary to determine tissue levels
of those same compounds following drug administration. This will
then allow the correlation of the pharmacological effects of these
drugs upon catecholamine efflux with their effects upon
intracellular levels of these compounds. Each drug was
administered to anaesthetised animals for sufficient time to allow
maximal effect and this time was eauivalent to that used in dialysis
experiments. The following drug paradigms were used:
1. Amphetamine
Amphetamine was administered 30 min prior to decapitation. The
maximal effect of amphetamine upon DA efflux occurs during the
second dialysate collection period, that is, between 20 and 40
min. It is at this point that tissue levels of DA and metabolites
are most relevant.
A dose of 4mg/kg i.p. D,L,-amphetamine was chosen for its
relevance to behavioural experiments (see Zetterstrom et al.
1986). This allows behavioural and biochemical correlations of
amphetamine to be drawn.
2. g-Methyl-p-tyrosine
The effects of AMT upon tissue levels of DA and metabolites were
determined at two time points, 20 min and 120 min. At the shorter
time point, DA synthesis has been reported to be decreased by up to
80* (Widerlov & Lewander, 1978), whilst the reserpine sensitive pool
is unaffected. This suggests that DA synthesis is largely
inhibited without depleting tissue stores of DA. The longer time
point was used in order to obtain a 100* inhibition of DA
synthesis. A dose of 250mg/kg over 2h was reported to cause a
complete inhibition of DA synthesis (Scheel-Kruger, 1971).
However, at this time point, tissue levels of DA are reported to be
reduced by more than 50* (Papeschi, 1975; Widerlov & Lewander,
1978). This is borne out by the results in section 3.1.
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3. Reserpine
A dose of 5mg/kg of reserpine over 3h was chosen based on the
histochemical results of Dahlstrom & Fuxe (1964). Using the
Falck-Hi11arp fluorescence technique to study monoamine stores in
various brain regions, they demonstrated that a dose of 5mg/kg of
reserpine strongly reduced or abolished any fluorescence within
2h. In accordance with this, Umezu & Moore (1979) obtained a 95%
decrease in tissue DA levels 2h after the i.p. administration of
reserpine (2mg/kg). DA levels remained decreased by more than 90%
for 24h.
4. Pargyline
Pargyline is widely used and well documented (see Westerink,
1978; Kato et al., 1986; Sharp et al., 1986). Sharp and
co-workers used a dose of lOOmg/kg and demonstrated that DOPAC
levels in tissue decreased to 30£ of control and 5% of control at 20
and 60 min respectively. They also reported > 95% reduction in
DOPAC levels in perfusates collected from rat striatum over 120 min.
In this study, a dose of 75mg/kg was injected 120 min prior to
pharmacological stimulation. This was shown to almost entirely
inhibit DOPAC formation in tissue whilst greatly elevating 3MT
levels indicating a significant inhibition of monoamine oxidase.
5. Selegeline
The MAO-B inhibitor selegeline was administered at a dose that
reportedly almost entirely blocks MAO-B activity (see Demarest et
al., 1980). Demarest and co-workers used a dose of lmg/kg i.v.
which is thought to be equivalent to lOmg/kg i.p. This caused a
90% inhibition of phenylethylamine (PEA) deamination and a 50;S
inhibition of DA deamination. PEA is an MAO-B selective substrate
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whi1st OA is a substrate for both MAO-A and MAO-B (Houslay & Tipton,
1976).
Similar results were obtained by Christmas et al. (1972).
Using benzylamine as an MAO-B selective substrate and 5-HT as a
MAO-A selective substrate, they demonstrated almost 1004 inhibition
of MAO-B using lOmg/kg orally administered selegeline whilst the
same dose caused a 254 inhibition of 5-HT deamination.
So a dose of lOmg/kg i.p. was used in an attempt to completely
inhibit MAO-B with the knowledge that MAO-A would also be inhibited
to some extent at this dose.
6. Nomifensine
A dose of 20mg/kg i.p. nomifensine was used. Nomifensine was
given simultaneously with other drugs since the effects upon uptake
blockade are rapid in onset.
Determination of tissue levels of catecholamines
The following groups of aminals in Table 2.5.1 were treated with
the drugs indicated. Twelve animals were grouped in a large box at
one time where they were held under halothane anaesthesia for the
reauired length of time. The rats were then decapitated and the
brain rapidly removed. The two striata were dissected out and
frozen in liauid nitrogen. After weighing, the tissue samples were
stored at -70°C until they were assayed for catecholamine content.
Each tissue sample was homogenised in 1ml 0.2M perchloric acid
at 4°C. lOOng of n-acetyl dopamine was added in a volume of 20yl
as internal standard. The sample was centrifuged at 2000g for
2min. lOOyl of the supernatant was then filtered through cellulose
filters under centrifugation at 5000g for 5 min. The supernatant
was injected directly onto the HPLC for determination of
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tissue levels of DOPAC, DA, HVA, 5-HIAA and 3MT.
TABLE 2.5.1













amphetamine 4 30 6
a-methyl-p-tyrosine 250 30 6
a-methyl-p-tyrosine 250 120 6
nomifensine 20 20 6
pargyline 75 120 6
selegeline 10 60 6





All drugs were supplied by Sigma Chemical Co. except for
a-methyl-P-tyrosine supplied by Aldrich. The following were
generously donated by the parties mentioned:
1. Nomifensine hydrogen maleate; Hoechst Pharmaceuticals
2. Selegeline hydrochloride; Britannia Pharmaceuticals Ltd.
All chemicals used were analar grade and supplied by British
Drug Houses except for methanol and tetrahydrofuran from Rathburn
Chemicals and octanesulphonic acid from Fisons pic.
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2.6 Data analysis
1. Tissue levels of catecholamines
The calculated tissue content of each catecholamine (nmol/g
tissue) for the individual treatments in individual animals was
grouped and then compared with the eauivalent catecholamine in
control animals. The comparison was done using the Mann Whitney U
test, where n = 11 individual animals for control and n = 6
individual animals in drug treated groups. A probability level of
less than 5% was used to indicate significance.
2. Microdialysis data
(a) Drug controls
Total catecholamine efflux over a period of time was calculated
for each individual animal. This was done by subtracting the mean
basal efflux before the drug from each timepoint following the drug
and then summing these values to give the total increase or decrease
in efflux over the stated period of time. These values are then an
indication of total increase or decrease in efflux compared to the
control where no drug treatment was given. The two sets of data
were compared using the unpaired t-test with a probability limit of
< 5% for significance. The number of individual animals ranged from
6 to 18.
(b) Manipulated animals
These results were statistically assessed by comparing
stimulated efflux over a certain time period in biochemically or
pharmacologically manipulated animals with stimulated efflux over
the equivalent time period in non-manipulated control animals.
Catecholamine efflux in the first 20 min or total efflux in the 60
min following the releasing drug was calculated by subtracting the
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mean efflux value immediately prior to the releasing drug from each
individual timepoint following the releasing drug. These values
were then summed for individual animals to give total efflux over
20 min or 60 min. This allowed for basal efflux under the
conditions of the particular biochemical or pharmacological
manipulation used in that experiment prior to the releasing drug.
The same method was used for determination of control efflux in the
absence of any treatment before the releasing drug.
These data were statistically analysed using either a Wilcoxon
test for the paired data or a Mann Whitney U test for the unpaired
data. A probability of < 5% was taken to indicate a significant
result. The number of individual animals for each experiment is
given in the text. Efflux data are presented as mean ± the




3.1 Effects of pharmacological and biochemical treatments upon
tissue levels of catecholamines
3.1.1 Amphetamine
Amphetamine (4mg/kg i.p.) increased tissue levels of DA to 120%
of control levels 30 min after injection (Fig. 3.1.1, control 19.6 ±
1.15nmole/g tissue [n = 11] AMPH 23.5 ± 1.72 nmoles/g tissue [n =
6], p < 0.05). Tissue levels of DOPAC decreased to 42% of control
over 30 min (Fig. 3.1.1, control 1.97 ± 0.18nmole/g tissue [n = 11],
AMPH 0.82 ± O.llnmoles/g tissue [n = 6], p < 0.001). Tissue levels
of HVA also decreased to 72% of control over 30 min (Fig. 3.1.2,
control 1.37 ± 0.36nmole/g tissue [n = 11], AMPH 0.98 ± O.llnmol/g
tissue [n = 6], p < 0.05). Tissue levels of 5-HIAA were not
affected; (control 1.06 ± 0.09nmole/g tissue [n = 11[, AMPH 1.05 ±
O.lOnmole/g tissue [n = 6]. Tissue levels of 3-MT were also not
affected (control 0.25 ± O.Olnmole/g tissue [n = 11], AMPH 0.24 ±
0.02nmole/g tissue [n = 6].
3.1.2 a-Methyl-p-tyrosine
AMT (250mg/kg i.p.) did not affect tissue levels of DA, DOPAC,
HVA or 5-HIAA up to 20 min after injection (Figs. 3.1.1. and
3.1.2). In contrast to this, over a time period of 120 min AMT
decreased the tissue levels of DA to 61% of control (Fig. 3.1.1,
control 19.6 ± 1.15nmole/g tissue [n = 11], AMT 12.0 ± l.Onmole/g
tissue [n = 6], p < 0.05). Similarly, tissue levels of DOPAC were
decreased to 31% of control over 120 min (Fig. 3.1.1, control 1.97 ±
0.18nmole/g tissue [n = 11], AMT 0.62 ± 0.13nmoles/g tissue [n = 6],
p < 0.001). Tissue levels of HVA were reduced to 18% of control
over 120 min (Fig. 3.1.2, control 1.37 ± 0.36nmole/g tissue [n = 11]
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AMT 0.24 ± 0.02nmole/g tissue [n = 6], p < 0.001). Tissue levels
of 5-HIAA were not affected by AMT (Fig. 3.1.2).
3.1.3 Reserpine
Injection of reserpine vehicle alone had no effect upon tissue
levels of DA or DOPAC (Fig. 3.1.1). However, tissue levels of HVA
increased to 1972 of control over 180 min (Fig. 3.1.2, control 1.37
± 0.36nmole/g tissue [n = 11], reserpine vehicle 2.70 ± 0.12nmoles/g
tissue [n = 6], p < 0.001). Reserpine vehicle also increased
tissue levels of 5-HIAA to 142* of control over 180 min (Fig. 3.1.2,
control 1.06 ± 0.09nmole/g tissue [n = 11] reserpine vehicle 1.50 ±
0.19nmoles/g tissue [n = 6], p < 0.05).
Reserpine (5mg/kg i.p.) decreased tissue levels of DA to 21% of
the reserpine vehicle control over 180 min (Fig. 3.1.1, control 20.1
± 0.67nmole/g tissue [n = 6] reserpine 5.48 ± 2.10nmoles/g tissue [n
= 6], p < 0.01). Tissue levels of DOPAC were increased by
reserpine when compared to the reserpine vehicle control
(Fig. 3.1.1, control 2.33 ± 0.14nmole/g tissue [n = 6[, reserpine
2.67 ± 0.34nmole/g tissue [n = 6[, p < 0.05). Tissue levels of HVA
were increased by reserpine to 123t of vehicle control over 180 min
(Fig. 3.1.2, control 2.20 ± 0.12nmole/g tissue [n = 6] reserpine
3.33 ± 0.61nmoles/g tissue [n = 6], p < 0.05). Reserpine also
increased tissue levels of 5-HIAA to 2032 of vehicle control over
180 min (Fig. 3.1.2, control 1.50 ± 0.19nmole/g tissue [n = 6],
reserpine 3.04 ± 0.53nmoles/g tissue [n = 6], p < 0.01).
3.1.4 Pargyline
Pargyline (75mg/kg i.p.) induced a striking increase in tissue
DA levels to 151% of control over 120 min (Fig. 3.1.1, control 19.6
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± 1.15nmo1e/g tissue [n = 11] pargyline 29.6 ± 2.18nmoles/g tissue
[n = 6], p < 0.001). Equally striking was the decrease in DOPAC
tissue levels to It of control over 120 min. In some individual
animals tissue DOPAC was undetectable (Fig. 3.1.1, control 1.97 ±
0.18nmole/g tissue [n = 11], pargyline 0.02 ± 0.02nmoles/g tissue [n
= 6], p < 0.001). Pargyline also reduced tissue levels of HVA
which decreased to 34J of control over 120 min (Fig. 3.1.2, control
1.37 ± 0.36nmole/g tissue [n = 11], pargyline 0.47 ± 0.36nmoles/g
tissue [n = 6], p < 0.05). Tissue levels of 5-HIAA were reduced to
36% of control over 120 min (Fig. 3.1.2, control 1.06 ± 0.09nmole/g
tissue [n = 11] pargyline 0.38 ± 0.04nmoles/g tissue [n = 6], p <
0.01). A good demonstration of pargyline upon MAO activity is the
large increase in tissue 3MT levels to 876% of control over 120 min
(Fig. 3.1.3, control 0.25 ± O.Olnmole/g tissue [n = 11] pargyline
2.19 ± 0.20nmoles/g tissue [n = 6], p < 0.001).
3.1.5 Selegeline
In selegeline (lOmg/kg i.p.) treated animals, tissue levels of
DA were increased to 123% of control over 60 min (Fig. 3.1.1,
control 19.6 ± 1.15nmole/g tissue [n = 11], selegeline 24.2 ± 1.92
nmoles/g tissue [n = 6], p < 0.05). Tissue levels of DOPAC were
not affected by selegeline (Fig. 3.1.1) whereas HVA increased to
120Z of control over 60 min (Fig. 3.1.2, control 1.37 ± 0.36nmole/g
tissue [n = 11] selegeline 1.65 ± 0.14nmole/g tissue [n = 6], p <
0.05). 5-HIAA tissue levels were also increased to 123% of control
over 60 min (Fig. 3.1.2, control 1.06 ± 0.09nmole/g tissue [n = 11],
selegeline 1.30 ± 0.12nmole/g tissue [n = 6], p < 0.05). Tissue
levels of 3-MT were not affected by selegeline over 60 min when
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compared to control Fig. 3.1.3).
3.1.6 Nomifensine
Nomifensine (20mg/kg i.p.) had no effect on tissue levels of DA,
DOPAC, HVA or 5-HIAA when compared to control over 20 min














CONTROL AMPH AMT20' AMmO' RES VEH
DRUG
Fig. 3.1.1 Effects of drugs on the total striatal tissue
content of DA (upper panel) and DOPAC (lower
panel). Drugs were administered for the
lengths of time indicated in the text. Results
(nmole/g tissue) are the mean ± s.e.m. of eleven
animals for control and six animals for drug
treated.




























CONTROL AMPH AMT20* AMT120' RESVEH RES PARG SELEG NOM
DRUG
Fig. 3.1.2 Effects of drugs on the total striatal tissue
content of HVA (upper panel) and 5-HIAA (lower
panel). Drugs were administered for the
lengths of time indicated in the text. Results
(nmole/g tissue) are the mean ± s.e.m. of eleven
animals for control and six animals for drug
treated.

















Fig. 3.1.3 Effects of pargyline (75mg/kg i.p.) and
selegeline (lOmg/kg i.p.) on the total striatal
tissue content of 3-MT. Pargyline and
selegeline were administered for the lengths of
time indicated in the text. Results (nmole/g
tissue) are the mean ± s.e.m. of eleven animals
for control and six animals for drug treated.
***p < 0.001
-88-
3.2 Effects of pharmacological and biochemical manipulations upon
the efflux of DA and metabolites
3.2.1 Control
Striatal perfusates were collected over a period of 4h without
the addition of any drugs. Dialysate levels of DA remained
constant over the whole time course with no apparent tendency to
decline. Basal DA efflux varied between 0.06 and 0.10pmoles/20 min
(n = 4) (Fig. 3.2.1).
Both DOPAC and the other metabolites, HVA and 5-HIAA maintained
constant basal efflux levels over the time course of 4h (Fig.
3.2.1). DOPAC efflux levels were approximately 200 times greater
than DA averaging between 18.3 and 23.9 pmoles/20 min n = 4. HVA
efflux levels averaged between 7.4 and 9.0pmoles/20 min, n = 4.
5-HIAA efflux levels were the lowest of the metabolites averaging
between 3.3 and 4.0pmoles/20 min, n = 4. Basal 3MT efflux levels
could not be readily measured in all experiments. However, those
peaks that were auantifiable produced mean values between 0.04 and
0.07pmoles/20 min (data not shown).
3.2.2 Amphetamine
DL-Amphetamine (4mg/kg i.p.) induced a rapid rise in DA efflux
levels to 789£ of control 40 min after injection (Fig. 3.2.2). DA
efflux levels rose from a pre-stimulation level of 0.09 ± 0.02 to a
maximal 0.71 ± 0.11pmoles/20 min (n = 6, p < 0.05). DA efflux
subseauently declined over the following 60 min towards
pre-stimulation levels.
The same dose of amphetamine induced a decrease in DOPAC to
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Fig. 3.2.1 The efflux of DA (upper panel), DOPAC, HVA and
5-HIAA (lower panel) in striatal dialysates over
240 min in the absence of any pharmacological or
biochemical intervention. Results (pmoles/20








































Fig. 3.2.2 Effects of AMPH (4mg/kg i.p.) on the efflux of
DA (upper panel), DOPAC, HVA and 5-HIAA (lower
panel). Results (pmoles/20 min) are tne mean ±
s.e.m. of six independent experiments.
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to 3.6 ± 0.6pmoles/20 min (n = 6, p < 0.01) and HVA efflux to
approximately 361 of control 100 min after injection from 8.1 ± 1.3
to 4.2 ± 0.6pmoles/20 min (n = 6, p < 0.05) (Fig. 3.2.2). 5-HIAA
efflux was unaffected by amphetamine.
3.2.3 Potassium chloride
The inclusion of KC1 (90mM) for 20 min in the perfusing buffer,
induced a rapid increase in DA efflux to 12551 of control 20 min
after infusion, from 0.11 ± 0.02 to 1.38 ± 0.32pmoles/20 min (Fig.
3.2.3, n = 14, p < 0.001). This was followed by a rapid return to
pre-stimulation levels when KC1 was removed.
D0PAC efflux declined following KC1 stimulation (Fig. 3.2.3),
from 33.0 ± 3.8 to 24.4 ± 3.1pmoles/20 min to 741 of control 40 min
after infusion (n = 14, p < 0.05). After the removal of the
stimulating dose of KC1, D0PAC efflux levels increased but remained
below control levels. HVA efflux was not significantly affected by
KC1 despite an apparent tendency to decrease.
3.2.4 Tyramine
_5
Administration of tyramine (5 x 10 M) via the dialysis probe
for 20 min increased DA efflux to 18001 of control 20 min after
infusion from a pre-stimulation level of 0.11 ± O.Olpmoles to a
level of 1.80 ± 0.17pmoles/20 min (Fig. 3.2.4, n = 11, p < 0.001).
Following removal of tyramine, DA efflux levels declined to control
levels over the following 60 min.
In sharp contrast to other DA releasers, tyramine had no effect






















Fig. 3.2.3 Effects of KC1 (90mM) perfused intrastriatally
for 20 min from the time indicated on the efflux
of DA (upper panel), DOPAC and HVA (lower
panel). Results (pmoles/20 min) are the mean ±
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Fig. 3.2.4 Effects of tyramine (50yM) perfused
intrastriatally for 20 min from the time
indicated on the efflux of DA (upper panel),
DOPAC and HVA (lower panel). Results
(pmoles/20 min) are the mean ± s.e.m. of eleven
independent experiments.
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Ouabain (lOOyM) perfused intrastriatally, increased DA efflux to
2358% of control 40 min after infusion from 0.12 ± 0.02 to 2.83 ±
0.56 pmoles/20 min (Fig. 3.2.5, n = 15, p < 0.001). As for
amphetamine, maximal efflux occurred between 20 and 40 min following
drug administration and subseauently declined.
DOPAC efflux decreased to 72% of control over 100 min from 24.6
± 5.3 to 17.8 ± 4.2pmoles/20 min (Fig. 3.2.5, n = 15, p < 0.01).
However, HVA efflux levels were not significantly decreased by
ouabain.
3.2.6 Veratrine
Veratrine (100ug/ml) induced an increase in DA efflux to 32221
of control 20 min after infusion from 0.09 ± 0.01 to 2.9 ±
0.56pmoles/20 min (Fig. 3.2.6, n = 13, p < 0.001). DA efflux was
maximal after 20 min.
Both DOPAC and HVA efflux declined following veratrine
stimulation to 43* and 46% of control respectively over 100 min.
DOPAC declined from 22.6 ± 3.1 to 9.7 ± 1.7pmoles/20 min and HVA
from 15.0 ± 2.0 to 6.9 ± 0.9pmoles/20 min (Fig. 3.2.6, n = 13 for
both, p < 0.001, p < 0.05 respectively).
3.2.7 Clorgyline
Clorgyline (lOmg/kg i.p.) induced a gradual rise in DA efflux to
192% of control from 0.12 ± 0.02 to 0.23 ± 0.05pmoles/20 min (Fig.
3.2.7, n = 6, p < 0.05). Similarly, clorgyline induced an increase
in 3MT efflux to 442% of control over 120 min from 0.12 ± 0.06 to
0.53 ± 0.15pmoles/20 min (Fig. 3.2.7, n = 6, p < 0.01). Both DOPAC
















































Fig. 3.2.5 Effects of ouabain (100uM) perfused continuously
intrastriatally from the time indicated on the
efflux of DA (upper panel), DOPAC and HVA (lower
panel). Results (pmoles/20 min) are the mean ±
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Fig. 3.2.6 Effects of veratrine (100yg/ml) perfused
continuously intrastriatally from the time
indicated on the efflux of DA (upper panel),
DOPAC and HVA (lower panel). Results




































Fig. 3.2.7 Effects of clorgyline (lOmg/kg i.p.) on the efflux of
DA (upper panel), DOPAC, HVA and 5-HIAA (middle
panel) and 3-MT (lower panel). Results (pmoles/20
min) are the mean ± s.e.m. of six independent
experiments.
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to 19* and 30* of control respectively. DOPAC decreased from 12.8
± 0.81 to 2.4 ± 0.32pmoles/20 min, (Fig. 3.2.7, n = 6, p < 0.01) and
HVA from 9.3 ± 1.6 to 2.8 ± 0.5pmoles/20 min (Fig. 3.2.7, n = 6, p <
0.05).
5-HIAA efflux was also reduced by clorgyline to 50* of control
from 4.3 ± 0.18 to 2.4 ± 0.18pmoles/20 min (Fig. 3.2.7, n = 6,
p < 0.01).
3.2.8 Pargyline
Pargyline (75mg/kg i.p.) induced a greater increase in DA efflux
than clorgyline to 280* of control over 120 min from 0.10 ± 0.02 to
0.28 ± 0.06pmoles/20 min (Fig. 3.2.8, n = 18, p < 0.05). 3MT
efflux also increased to a greater extent to 813* of control over
120 min from 0.08 ± 0.01 to 0.65 ± 0.17pmoles (Fig. 3.2.8, n = 18, p
< 0.05).
DOPAC and HVA efflux levels were both decreased by pargyline to
10* and 15* of control respectively over 120 min. DOPAC decreased
from 18.6 ± 2.8 to 1.8 ± 0.5pmoles/20 min (Fig. 3.2.8, n = 18, p <
0.01 and HVA from 10.3 ± 1.5 to 1.5 ± 0.45pmoles/20 min (Fig. 3.2.8,
n = 18, p < 0.001).
5-HIAA efflux was also reduced by pargyline to 60* of control
over 120 min from 4.8 ± 0.80 to 2.9 ± 0.36pmoles/20 min (Fig. 3.2.8,
n = 18, p < 0.05).
3.2.9 Selegeline
Selegeline (lOmg/kg i.p.) had no effect upon DA efflux levels
(Fig. 3.2.9) which averaged between 0.14 ± 0.02 to 0.17 ±
0.03pmoles/20 min. DOPAC efflux was reduced to 67* of control over
160 min from 20.1 ± 2.1 to 13.4 ± 3.0pmoles/20 min (Fig. 3.2.9,
Fig. 3.2.8 Effects of pargyline (75mg/kg i.p.) on the efflux of
OA (upper panel), DOPAC, HVA and 5-HIAA (middle
panel), and 3-MT (lower panel). Results (pmoles/20
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Fig. 3.2.9 Effects of selegeline (10mg/kg i.p.) on the
efflux of DA (upper panel), DOPAC, HVA and
5-HIAA (lower panel). Results (pmoles/20 min)
are the mean ± s.e.m. of seven independent
experiments.
-92-
n = 7, p < 0.01).
HVA efflux was also reduced to 742 of control over 160 min from
10.9 ± 0.8 to 8.1 ± 1.5pmoles/20 min (Fig. 3.2.9, n = 7,
p < 0.001). 5-HIAA efflux was consistently reduced in all
experiments to 892 of control over 160 min from 5.5 ± 0.6 to
4.9 ± 0.76pmoles (Fig. 3.2.9, n = 7, p < 0.001).
3.2.10 Reserpine
Reserpine (5mg/kg i.p.) induced a progressive decline in DA
efflux levels to 18% of control over 180 min from an average of 0.17
± 0.04 to 0.03 ± 0.01pmoles/20 min (Fig. 3.2.10, n = 18,
p < 0.01). Reserpine had no significant effect upon D0PAC, HVA or
5-HIAA efflux levels (Fig. 3.2.10).
3.2.11 g-Methyl-P-Tyrosine
AMT (250mg/kg i.p.) administration led to a progressive decline
in DA efflux to 332 of control levels over 120 min from 0.14 ± 0.02
to 0.05 ± 0.01pmoles/20 min (Fig. 3.2.11, n = 6, p < 0.05). Both
D0PAC and HVA efflux declined to 312 and 392 of control respectively
over 120 min from 18.1 ± 3.2 to 5.7 ± l.lpmoles/20 min and 10.3 ±
1.3 to 4.0 ± 0.6pmoles/20 min respectively (Fig. 3.2.11, n = 6, p <
0.01 for both), whereas 5-HIAA efflux was unaffected.
3.2.12 Nomifensine
Nomifensine induced an increase in DA efflux when given
intraperitoneally (20mg/kg) or via the dialysis probe (10yM) to 3082
and 2252 of control respectively over 100 min. In the former case,
efflux levels increased from 0.12 ± 0.05 to 0.37 ± 0.08pmoles/20 min
(Fig. 3.2.12a, n = 6, p < 0.05) and in the latter case, efflux





Fig. 3.2.10 Effects of reserpine (5mg/kg i.p.) on the efflux
of DA (upper panel), DOPAC, HVA and 5-HIAA (lower
panel). Results (pmoles/20 min) are the mean ±





































Fig. 3.2.11 Effects of AMT (250mg/kg i.p.) on the efflux of
DA (upper panel), DOPAC, HVA and 5-HIAA (lower
panel). Results (pmoles/20 min) are the mean ±




































Fig. 3.2.12a Effects of nomifensine (20mg/kg i.p.) on the
efflux of DA (upper panel), DOPAC, HVA and 5-HIAA
(lower panel). Results (pmoles/20 min) are the






































Fig. 3.2.12b Effects of nomifensine (10yM) perfused
intrastriatally through the dialysis probe on the
efflux of DA (upper panel) and D0PAC (lower
panel). Nomifensine was perfused continuously
from the time indicated. Results (pmoles/20
min) are the mean ± s.e.m. of twelve independent
experiments.
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1 eve 1s increased from 0.12 ± 0.04 to 0.27 ± 0.07pmoles/20 min (Fig.
3.2.12b, n = 12, p < 0.01). Neither route of administration
affected D0PAC efflux levels whereas HVA efflux was increased by
i.p. nomifensine to 143jt of control over 100 min, from an average of
7.5 ± 1.3 to a maximal 10.7 ± 1.9pmoles/20 min (Fig. 3.2.12a, n = 5
animals, p < 0.05). 5-HIAA efflux was not affected by i.p.
nomifensine (Fig. 3.2.12a).
3.2.13 Tetrodotoxin
TTX (2yM) induced a steady decline in DA efflux levels to 20% of
control over 180 min from 0.14 ± 0.03 to 0.03 ± 0.02pmoles/20 min
(Fig. 3.2.13, n = 6, p < 0.01). Similarly, DOPAC efflux also
decreased to 46£ of control over 180 min from 24.3 ± 3.4 to 11.2 ±
2.2pmoles/20 min (Fig. 3.2.13, n = 6, p < 0.01). HVA and 5-HIAA
efflux levels were not affected by TTX.
3.2.14 EGTA
EGTA (20mM) caused an overall decline in DA efflux levels to 0%
of control over 160 min. The results were variable due to
sometimes undetectable levels of DA. DA efflux levels decreased
from 0.12 ± 0.03 to 0 ± 0.03pmoles/20 min (Fig. 3.2.14, n = 6, p <
0.01). DOPAC efflux also decreased to 56% of control over 160 min
from a control value of 19.3 ± 4.2 to 10.9 ± 1.5pmoles/20 min (Fig.
3.2.14, n = 6, p < 0.01). HVA and 5-HIAA efflux were not affected
by EGTA.
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Fig. 3.2.13 Effects of TTX (2pM) perfused intrastriatally
through the dialysis probe from the time
indicated, on the efflux of DA (upper panel),
DOPAC, HVA and 5-HIAA (lower panel). Results
(pmoles/20 min) are the mean ± s.e.m. of six
independent experiments.
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. 3.2.14 Effects of calcium removal and EGTA (20mM)
perfused intrastriatally through the dialysis
probe on the efflux of DA (upper panel), DOPAC,
HVA and 5-HIAA (lower panel). Results
(pmoles/20 min) are the mean ± s.e.m. of six
independent experiments.
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3.3 Effects of biochemical and pharmacological manipulations upon
amphetamine induced efflux of DA, DOPAC, HVA, 5-HIAA and 3MT
3.3.1 Dose dependence of the amphetamine response
A dose of 2mg/kg AMPH induced an increase in DA efflux (maximal
response = 3504 of control) and decrease in DOPAC (20-304 of
control) and HVA efflux (40-504 of control) (Fig. 3.3.1a and b).
Increasing the dose of AMPH (4,8 and 16mg/kg), led to a graded
increase in maximal DA efflux (7204, 11004 and 14004 of control
respectively). In contrast, DOPAC and HVA efflux were not reduced
further as the AMPH dose increased. Low doses of AMPH (2 and
4mg/kg) had no effect upon 5-HIAA efflux, whereas higher doses (8
and 15 mg/kg) induced a small dose related decrease (Fig. 3.3.1b).
3MT efflux was also unaffected at the two lower doses, but increased
in a dose related manner at 8 and 16mg/kg AMPH (Fig. 3.3.1b). A
4mg/kg dose of AMPH was chosen for use in further experiments since
this dose permits increases and decreases in AMPH induced DA efflux
following drug pretreatment to be determined. This dose also
allows behavioural correlations to be made with AMPH induced DA
efflux.
3.3.2 g-Methyl-p-tyrosine
In AMT treated animals (250mg/kg simultaneous), AMPH maximally
increased DA efflux to 2564 of basal efflux 40 min after injection
(Fig. 3.3.2a, 0.16 ± 0.03 to 0.41 ± 0.04pmoles/20 min, n = 6).
Total DA efflux over a 60 min period was reduced by 704 when
compared with control animals (Table 3.3.1; control 2.0 ±
0.4pmoles; AMT 0.6 ± 0.2pmoles; p < 0.01). When AMT was given

















. 3.3.1a Effects of increasing doses of AMPH on DA efflux
(upper panel) and DOPAC efflux (lower panel).
Results are expressed as a percentage ± s.e.m. of







Fig. 3.3.1b Effects of increasing doses of AMPH on HVA (upper
panel), 5-HIAA (middle panel) and 3-MT efflux (lower
panel). Results are expressed as a percentage ±
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Fig. 3.3.2a Effects of AMT (250mg/kg i.p.) given
simultaneously with AMPH (4mg/kg i.p.) on the
efflux of DA (upper panel), D0PAC and HVA (lower
panel). Results (pmoles/20 min) are the mean ±









































Fig.3.3.2b Effects of AMT (250mg/kg i.p.) given 120 min
prior to AMPH (4mg/kg i.p.) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).
Results (pmoles/20 min) are the mean ± s.e.m. of
six independent experiments.
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basal efflux 40 min after injection of AMPH (Fig. 3.3.2b, 0.33 ±
0.10 to 1.58 ± 0.11pmoles/20 min, n = 6). Total DA efflux over a
50 min period was reduced by 85% when compared with control animals
(Table 3.3.1, control 2.0 ± 0.4pmoles; AMT 0.3 ± O.lpmoles; p <
0.01).
AMT induced a decline in D0PAC and HVA efflux (Fig. 3.3.2b)
which appeared to be accelerated by AMPH.
3.3.3 Reserpine
In reserpine (5mg/kg i.p.) treated animals, AMPH maximally
increased DA efflux to 545% of basal efflux 40 min after injection
(Fig. 3.3.3, 0.11 ± 0.02 to 0.50 ± 0.08pmoles/20 min, n = 6).
Total DA efflux over a 60 min period was not reduced by a
significant amount (Table 3.3.1; control 1.8 ± 0.2pmoles;
reserpine 1.3 ± 0.2pmoles). Reserpine induced a decline in D0PAC
and HVA efflux which appeared to be accelerated by AMPH (Fig. 3.3.3).
3.3.4 Pargyline
In pargyline (75mg/kg i.p.) treated animals, AMPH maximally
increased DA efflux to 627?i of basal efflux 40 min after injection
(Fig. 3.3.4, 0.33 ± 0.07 to 2.07 ± 0.22pmoles/20 min, n = 6).
Total DA efflux over 60 min was increased by 239?; when compared with
control animals (Table 3.3.1, control 1.8 ± 0.4pmoles; pargyline
4.3 ± 0.6pmoles; p < 0.01). The rapid decline in D0PAC and HVA
efflux following the pargyline injection (Fig. 3.3.4) prevented any
evaluation of the effects of AMPH upon efflux of these metaolites.
Pargyline induced a rapid rise in 3-MT efflux to 722% of basal
efflux over 100 min (Fig. 3.3.4). AMPH induced a further more
rapid rise in 3-MT efflux to 246% of pre-AMPH levels, 1778% of
TIME(min)
TIME(min)
Fig. 3.3.3 Effects of reserpine (5mg/kg i.p.) given 180 min
prior to AMPH (4mg/kg i.p.) on DA efflux (upper
panel), DOPAC and HVA efflux (lower panel).
Results (pmoles/20 min) are the mean ± s.e.m. of
six independent animals.
Fig. 3.3.4 Effects of pargyline (75mg/kg i.p.) given 120 min
prior to AMPH (4mg/kg i.p.) on DA (upper panel),
DOPAC, HVA and 5-HIAA (middle panel) and 3-MT efflux
(lower panel). Results (pmoles/20 min) are the mean




















































l l l 1 1 1 l 1 1 1 1 1 1 1 \
0 100 200 300
TIME(min)
-96-
pre-pargyline levels. 5-HIAA efflux was not affected.
3.3.5 Selegeline
In selegeline (lOmg/kg i.p.) treated animals, AMPH maximally
increased DA efflux to 757% of basal efflux 40 min after injection
(Fig. 3.3.5; 0.07 ± 0.01 to 0.53 ± 0.06pmoles/20 min, n = 6).
Total DA efflux over 60 min was not increased by a significant
amount (Table 3.3.1).
AMPH appeared to accelerate D0PAC and HVA efflux in selegeline
treated animals (Fig. 3.3.5). 5-HIAA efflux was not affected
whilst 3-MT efflux was maximally increased to 2602 of basal efflux
40 min after AMPH injection (Fig. 3.3.5, 0.05 ± 0.01 to 0.13 ±
0.02pmoles/20 min, n = 6). A Quantitative assessment of this was
not possible due to the lack of control values for 3-MT.
3.3.6 Nomifensine
In animals treated with an intraperitoneal dose of nomifensine
(20mg/kg i.p.), AMPH maximally increased DA efflux to 344% of basal
efflux 40 min after injection (Fig. 3.3.6a; 0.16 ± 0.06 to 0.55 ±
0.08pmoles/20 min, n = 6). Total DA efflux over 60 min was reduced
by 78% when compared with control animals (Table 3.3.1; control 1.8
± 0.3pmoles; nomifensine 0.4 ± O.lpmoles; p < 0.01). Similarly,
when nomifensine was perfused intrastriatally (10yM) through the
dialysis probe, AMPH maximally increased DA efflux to 141% of basal
efflux over 60 min (Fig. 3.3.6b; 0.27 ± 0.07 to 0.38 ±
0.16pmoles/20 min, n = 6). Total DA efflux over 60 min was reduced
by 99% when compared with control animals (Table 3.3.1; control 1.9
± 0.3pmoles; nomifensine 0.01 ± O.Olpmoles; p < 0.01). In
animals treated with intraperitoneal nomifensine, AMPH maximally
Fig. 3.3.5 Effects of selegeline (lOmg/kg i.p.) given 50 min
prior to AMPH (4mg/kg i.p.) on DA (upper panel),
DOPAC, HVA and 5-HIAA (middle panel) and 3-MT efflux
(lower panel). Results (pmoles/20 min) are the mean
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Fig. 3.3.6a Effects of nomifensine (20mg/kg i.p.) given
simultaneously with AMPH (4mg/kg i.p.) on DA (upper
panel), D0PAC and HVA efflux (lower panel). Results
(pmoles/20 min) are the mean ± s.e.m. of six
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Fig. 3.3.6b Effects of nomifensine (10pM) perfused
intrastriatally 120 min prior to AMPH (4mg/kg
i.p.) on DA (upper panel) and D0PAC efflux (lower
panel). Results (pmoles/20 min) are the mean ±





reduced DOPAC efflux to 65% of basal efflux over 100 min (Fig.
3.3.6a; 11.6 ± 1.4 to 7.5 ± 0.8pmoles/20 min, n = 6). The decline
in total DOPAC efflux over 60 min was inhibited when compared with
control animals (control 34.8 ± 4.9pmoles below basal efflux,
nomifensine 3.0 ± 2.0pmoles below basal efflux, p < 0.05). When
perfused via the dialysis probe however, nomifensine had no
inhibitory effect upon the AMPH induced decline in DOPAC efflux
(Fig. 3.3.6b). HVA efflux increased maximally to 136% of control
over 80 min when nomifensine was given intraperitoneally with AMPH
(Fig. 3.3.6a, 7.5 ± 0.4 to 10.2 ± 0.7pmoles/20 min, n = 6). The
decline in total HVA efflux over 60 min was inhibited when compared
with control animals (control 11.1 ± 1.3pmoles below basal efflux,
nomifensine 3.7 ± 0.9pmoles above basal efflux, p < 0.05).
3.3.7 Tetrodotoxin
In TTX (2yM) treated animals, AMPH maximally increased DA efflux
to 463% of basal levels 40 min after injection (Fig. 3.3.7, 0.08 ±
0.02 to 0.37 ± 0.12pmoles/20 min, n = 6). Total DA efflux over 60
min was not reduced by TTX (Table 3.3.1, control 0.9 ± 0.3pmoles,
TTX 0.8 ± 0.4pmoles). TTX had no effect upon AMPH induced efflux
of DOPAC or HVA (Fig. 3.3.7).
3.3.8 EGTA
When EGTA (20mM) was perfused through the dialysis probe in a
2+
Ca free buffer, AMPH maximally increased DA efflux to 1288% of
basal efflux 20 min after injection (Fig. 3.3.8, 0.09 ± 0.02 to 1.16
± 0.52pmoles/20 min, n = 6). Total DA efflux over 60 min was not
reduced by EGTA (Table 3.3.1, control 2.7 ± 0.4pmoles, EGTA 2.4 ±
0.3pmoles). AMPH induced an almost identical decline in DOPAC and
HVA efflux in the presence or- absence of EGTA (Fig. 3.3.8).
Fig. 3.3.7 Effects of TTX (2pM) perfused intrastriatally for 60
min prior to AMPH (4mg/kg i.p.) on DA (upper panel),
DOPAC (middle panel) and HVA efflux (lower panel).
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Fig. 3.3.8 Effects of EGTA (20mM) and Ca^"1" removal from the
perfusing medium for 60 min prior to AMPH (4mg/kg
i.p.) on DA (upper panel), DOPAC (middle panel) and
HVA efflux (lower panel). Results (pmoles/20 min)
are the mean ± s.e.m. of six paired experiments.
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EFFECTS OF BIOCHEMICAL AND PHARMACOLOGICAL MANIPULATIONS
ON AMPH (4mg/kg i.p.) INDUCED DA EFFLUX
DA EFFLUX
n (pmol/60 min)
Control 6 2.0 ± 0.4
AMT (simultaneous) 6 0.6 ± 0.2**
Control 6 2.0 ± 0.4
AMT (120 min pretreatment) 6 0.3 ± 0.1**
Control 6 1.8 ± 0.2
Reserpine 6 1.3 ± 0.2
Control 6 1.8 ± 0.4
Pargyline 6 4.3 ± 0.6**
Control 6 0.9 ± 0.3
Selegeline 6 1.1 ± 0.2
Control 6 1.8 ± 0.3
Nomifensine (i.p.) 6 0.4 ± 0.1**
Control 6 1.9 ± 0.3
Nomifensine (perfused) 6 0.01 ^t 0.01**
Control 6 0.9 ± 0.3




EGTA 6 2.4 ± 0.3
* p < 0.05, ** p < 0.01
Mean and standard errors are given for guidance only. Statistical
differences in amount released were assessed using the non-parametric
Mann-Whitney 'U' test. The data were corrected for basal release prior to
comparison.
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3.4 Effects of biochemical and pharmacological manipulations upon
KC1 induced efflux of DA, DOPAC, HVA, 5-HIAA and 3MT
3.4.1 Dose dependence of the KC1 response
A dose of 30mM KC1 had little effect upon DA efflux, maximal
efflux was 1374 of control (Fig. 3.4.1a, n = 4). Increasing the
dose of KC1 (60, 90 and 120mM) led to a graded increase in maximal
DA efflux (242, 1017 and 15214 of control respectively). The same
was true for the metabolites DOPAC (Fig. 3.4.1a), HVA and 5-HIAA
(Fig. 3.4.1b) which exhibited a dose dependent decrease in efflux
levels. Following the removal of the stimulating dose of KC1, DA,
DOPAC, HVA and 5-HIAA efflux levels returned towards control
levels. A dose of 90mM KC1 was chosen for future experiments since
these results demonstrate that this dose is neither maximal or
minimal for an elicited response.
3.4.2 a-Methyl-p-tyrosine
In AMT (250mg/kg i.p., 20 min pretreatment) treated animals, KC1
maximally increased DA efflux to 4204 of basal efflux over 20 min
(Fig. 3.4.2a, 0.25 ± 0.08 to 1.05 ± 0.17pmoles/20 min, n = 6).
Total DA efflux over 60 min was reduced by 424 when compared with
control animals (Table 3.4.1, control 1.91 ± 0.26pmoles, AMT 1.10 ±
O.27pmoles, p < 0.05). When the same dose of AMT was given 120 min
prior to KC1, DA efflux was maximally increased to 4334 of basal
efflux 20 min after KC1 infusion (Fig. 3.4.2b, 0.12 ± 0.04 to 0.52 ±
0.11pmoles/20 min, n = 6). Total DA efflux over 60 min was reduced
to a much greater extent by 744 when compared with control animals
(Table 3.4.1, control 1.91 ± 0.26pmoles, AMT 0.50 ± 0.14pmoles, p <
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Fig. 3.4.1a Effects of increasing doses of KC1 included in
the perfusing medium on DA (upper panel) and
DOPAC efflux (lower panel). Results are
expressed as a percentage ± s.e.m. of basal
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Fig. 3.4.1b Effects of increasing doses of KC1 included in
the perfusing medium on HVA (upper panel) and
5-HIAA efflux (lower panel). Results are
expressed as a percentage ± s.e.m. of basal


































Fig. 3.4.2a Effects of AMT (250mg/kg i.p.) given 20 min prior
to KC1 (90mM) on the efflux of DA (upper panel),
DOPAC and HVA (lower panel). Results (pmoles/20
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Fig. 3.4.2b Effects of AMT (250mg/kg i.p.) given 120 min
prior to KC1 (90mM) on the efflux of DA (upper
panel), DOPAC and HVA (lower panel). Results
(pmoles/20 min) are the mean ± s.e.m. of six
independent experiments.
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seem to be accelerated by KC1 (Fig. 3.4.2b).
3.4.3 Reserpine
In reserpine (5mg/kg i.p.) pretreated animals, KC1 maximally
increased DA efflux to 44002 of basal efflux over 20 min (Fig.
3.4.3, 0.02 ± 0.02 to 0.88 ± 0.3pmoles/20 min, n = 6). Total DA
efflux over 60 min was not reduced by reserpine (Table 3.4.1,
control 1.91 ± 0.26pmoles, reserpine 1.16 ± 0.35pmoles) despite an
apparent reduction. This was probably due to the high variation of
the results.
Reserpine induced a rising followed by a decreasing efflux for
both D0PAC and HVA (Fig. 3.4.3). KC 1 infusion seemed to accelerate
the decline in both D0PAC and HVA.
3.4.4 Pargyline
In pargyline (75mg/kg i.p.) treated animals, KC1 maximally
increased DA efflux to 12412 of basal efflux over 20 min (Fig.
3.4.4, 0.29 ± 0.05 to 3.60 ± 0.82pmoles/20 min, n = 6). Total KC1
induced DA efflux over 60 min was increased by pargyline (Table
3.4.1, control 1.91 ± 0.26pmoles, pargyline 4.45 ± 1.19pmoles, p <
0.05).
Pargyline caused a rapid decline in D0PAC and HVA efflux over
120 min to low levels (Fig. 3.4.4., 23.9 ± 3.5 to 2.8 ± 0.7pmoles/20
min, 12.8 ± 1.1 to 1.6 ± 0.7pmoles/20 min respectively).
Conseauently, no additional effect of KC1 was apparent following
this decline.
3.4.5 Selegeline
In selegeline (lOmg/kg i.p.) treated animals, KC1 maximally
Fig. 3.4.3 Effects of reserpine (5mg/kg i.p.) given 180 min
prior to KC1 (90mM) on the efflux of DA (upper
panel), DOPAC and HVA (lower panel). Results
(pmoles/20 min) are the mean ± s.e.m. of six
independent experiments.
Fig. 3.4.4 Effects of pargyline (75mg/kg i.p.) given 120 min
prior to KC1 (90mM) on the efflux of DA (upper panel),
DOPAC and HVA (middle panel) and 3-MT (lower panel).
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Fig. 3.4.5 Effects of selegeline (lOmg/kg i.p.) given 60 min
prior to KC1 (90mM) on the efflux of DA (upper panel),
DOPAC and HVA (middle panel) and 3-MT (lower panel).










































increased DA efflux to 1644S of basal efflux over 20 min (Fig.
3.4.5, 0.09 ± 0.02 to 1.48 ± 0.55pmoles/20 min, n = 6). Total KC1
induced DA efflux over 60 min was not affected by selegeline (Table
3.4.1, control 1.91 ± 0.26pmoles, selegeline 1.72 ± 0.69pmoles).
The declining efflux of D0PAC and HVA induced by selegeline
appeared to be accelerated by KC1 (Fig. 3.4.5).
3.4.6 Nomifensine
In nomifensine (20mg/kg i.p.) treated animals, KC1 maximally
increased DA efflux to 850% of basal efflux over 20 min (Fig.
3.4.6, 0.24 ± 0.05 to 2.04 ± 0.2pmoles/20 min, n = 6). Total DA
efflux over 60 min was increased by 34S when compared with control
animals (Table 3.4.1, control 1.91 ± 0.26pmoles, nomifensine 2.57 ±
0.34pmoles, p < 0.05). Nomifensine had no effect on DOPAC and HVA
efflux (Fig. 3.4.6).
3.4.7 Tetrodotoxin
In TTX (2yM) treated animals, KC1 maximally increased DA efflux
to 1417J of basal efflux over 20 min (Fig. 3.4.7, 0.12 ± 0.03 to 1.7
± 0.53pmoles/20 min, n = 6). Total DA efflux over 60 min was not
affected by TTX (Table 3.4.1, control 2.19 ± 0.65pmoles, TTX 1.19
0.50pmoles).
TTX caused a decline in DOPAC and HVA efflux which continued at
the same rate for DOPAC and at a slightly faster rate for HVA when
KC1 was infused (Fig. 3.4.7).
3.4.8 EGTA
p+
In animals perfused with EGTA (20mM) in a Ca free buffer,








































Fig. 3.4.6 Effects of nomifensine (lOmg/kg i.p.) given 20
min prior to KC1 (90mM) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).
Results (pmoles/20 min) are the mean ± s.e.m. of
six independent experiments.
Fig. 3.4.7 Effects of TTX (2yM) perfused intrastriatally for 60
min prior to KC1 (90mM) on the efflux of DA (upper
panel), DOPAC (middle panel) and HVA (lower panel).








0.0 i i i i | i I i—i | i i i i |
- TTX
+TTX












i * * t
K
~l 1 1 1 1 1 1 1 1 1 1 I 1 1 J 1 1 1 1 1 1











TTX \ i ^ i
K
I I I I | l -T 1 1 I I 1 p
0 50 100 150
TIME(min)
200




















Fig. 3.4 8 Effects of calcium removal and EGTA (20mM) perfused
intrastriatally for 60 min prior to KC1 (90mM) on the
efflux of DA (upper panel), DOPAC and HVA (lower
panel). Results (pmoles/20 min) are the mean ±
s.e.m. of six paired experiments.
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min (Fig. 3.4.8, 0.09 ± 0.01 to 1.47 ± 0.29pmoles/20 min, n = 6).
Total DA efflux over 60 min was reduced by 61* when compared with
control animals (Table 3.4.1, control 2.09 ± 0.52pmoles, EGTA 0.82 ±
0.33pmoles, p < 0.05).
EGTA caused a decline in DOPAC and HVA efflux, but no additional
effect upon KC1 induced DOPAC and HVA efflux was apparent
(Fig. 3.4.8).
TABLE 3.4.1
EFFECTS OF BIOCHEMICAL AND PHARMACOLOGICAL MANIPULATIONS
ON KC1 (90mM) INDUCED DA EFFLUX
DA EFFLUX
n (pmol/60 min)
Control 16 1.91 ± 0.26
AMT (20 min pretreatment) 6 1.10 ± 0.27*
Control 16 1.91 ± 0.26
AMT (120 min pretreatment) 6 0.50 ± 0.14***
Control 16 1.91 ± 0.26
Reserpine 6 1.16 ± 0.35
Control 16 1.91 ± 0.26
Pargyline 6 4.45 ± 1.19*
Control 16 1.91 ± 0.26
Selegeline 6 1.72 ± 0.69
Control 16 1.91 ± 0.26
Nomifensine 6 2.57 ± 0.34*
Control 6 2.19 ± 0.65
TTX 6 1.19 ± 0.50
Control 6 2.09 ± 0.52
EGTA 6 0.82 ± 0.33*
* p < 0.05, *** p < 0.001
Mean and standard errors are given for guidance only. Statistical
differences in amount released were assessed using the non-parametric
Mann-Whitney 'U' test. The data were corrected for basal release prior to
comparison.
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3.5 Effects of biochemical and pharmacological manipulations upon
tyramine induced efflux of DA, DQPAC, HVA, 5-HIAA and 3MT
3.5.1 Dose dependence of the tyramine response
A concentration of lpM tyramine perfused through the dialysis
probe had no effect upon DA efflux levels (Fig. 3.5.1a).
Increasing the dose of tyramine (10, 50 and lOOuM) led to a graded
increase in maximal DA efflux (360, 1780 and 2270% of control
respectively). The maximal DA response occurred during the 20 min
perfusion of tyramine and subseauently declined to control levels
40 min after the removal of tyramine. A dose of 50pM tyramine was
chosen for future experiments since these results indicate this to
be neither a saturating dose or a minimal dose for stimulating DA
eff1ux.
In striking contrast to other DA releasers, tyramine had no
effect upon DOPAC, HVA or 5-HIAA efflux levels at any of the doses
used (Figs. 3.5.1a and 3.5.1b).
3.5.2 a-Methy1-p-tyrosine
In animals with a 20 min pretreatment of AMT (250mg/kg i.p.),
tyramine maximally increased DA efflux to 1342% of basal efflux
(Fig. 3.5.2a, 0.12 ± 0.02 to 1.61 ± 0.34pmoles/20 min, n = 6).
Total tyramine induced DA efflux over 60 min was not affected by AMT
(Table 3.5.1, control 2.4 ± 0.28pmoles, AMT 2.01 ± 0.39pmoles).
When AMT was injected 120 min prior to tyramine infusion, DA efflux
was maximally increased to 930% of basal efflux over 20 min (Fig.
3.5.2b, 0.10 ± 0.03 to 0.93 ± 0.09pmoles/20 min, n = 6). Total
tyramine induced DA efflux over 60 min was reduced by 54% when
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Fig. 3.5.1a Effects of increasing closes of tyramine (perfused
intrastriataIly) on the efflux of DA (upper
panel) and DOPAC (lower panel). Results are
expressed as a percentage ± s.e.m. of basal
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Fig. 3.5.1b Effects of increasing doses of tyramine (perfused
intrastriatally) on the efflux of HVA (upper
panel) and 5-HIAA (lower panel). Results are
expressed as a percentage ± s.e.m. of basal












































Fig. 3.5.2a Effects of AMT (250mg/kg i.p.) given 20 min prior
to tyramine (50yM) on the efflux of DA (upper
panel), DOPAC and HVA (lower panel). Results



























Fig. 3.5.2b Effects of AMT (250mg/kg i.p.) given 120 min
prior to tyramine (50pM) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).
Results (pmoles/20 min) are the mean ± s.e.m. of
six independent experiments.
-103-
0.28pmoles, AMT 1.11 ± 0.16pmoles, p < 0.001). This is in striking
contrast to the other result for AMT.
AMT caused a decline in DOPAC and HVA efflux which became
apparent 60 min after injection (Figs. 3.5.2a, 3.5.2b). Tyramine
did not appear to alter the pattern of this decline.
3.5.3 Reserpine
In reserpine (5mg/kg i.p.) pretreated animals, tyramine
maximally increased DA efflux to 3500;6 of basal efflux over 20 min
(Fig. 3.5.3, 0.02 ± 0.01 to 0.70 ± 0.27pmoles/20 min, n = 6).
Total DA efflux over 60 min was reduced by 60% wnen compared with
control animals (Table 3.5.1, control 2.4 ± 0.28pmoles, reserpine
0.97 ± 0.22pmoles, p < 0.001).
Tyramine did not appear to have any effect on DOPAC and HVA
efflux in reserpinised animals (Fig. 3.5.3).
3.5.4 Pargyline
In pargyline (75mg/kg i.p.) treated animals, tyramine maximally
increased DA efflux to 689% of basal efflux over 20 min (Fig. 3.5.4,
0.35 ± 0.13 to 2.41 ± 0.22pmoles/20min, n = 6). Total DA efflux
over 60 min was increased by 20% when compared to control animals
(Table 3.5.1, control 2.4 ± 0.28pmoles, pargyline 3.0 ± 0.29pmoles,
p < 0.05).
Pargyline induced a rapid decline in DOPAC and HVA efflux which
did not appear to alter after tyramine (Fig. 3.5.4). The pargyline
induced rise in 3-MT efflux appeared to be accelerated and prolonged
by tyramine (Fig. 3.5.4).
Fig. 3.5.3 Effects of reserpine (5mg/kg i.p.) given 180 min
prior to tyramine (50nM) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).
Results (pmoles/20 min) are the mean ± s.e.m. of
six independent experiments.
Fig. 3.5.4 Effects of pargyline (75mg/kg i.p.) given 120 min
prior to tyramine (50pM) on the efflux of DA (upper
panel), DOPAC, HVA and 5-HIAA (middle panel) and 3-MT
(lower panel). Results (pmoles/20 min) are the mean
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In selegeline (lOmg/kg i.p.) treated animals, tyramine maximally
increased DA efflux to 1922of basal efflux over 20 min (Fig.
3.5.5, 0.10 ± 0.01 to 1.73 ± 0.3pmoles/20 min, n = 6). Total DA
efflux over 60 min was not affected by selegeline (Table 3.5.1,
control 2.4 ± 0.28pmoles, selegeline 2.1 ± 0.34pmoles).
DOPAC and HVA efflux appeared to be unaffected whereas 3-MT
efflux was maximally increased to 5004 of basal efflux over 20 min
(Fig. 3.5.5, 0.05 to 0.25pmoles/20 min, n = 3). A auantitative
assessment of this was not possible due to the small value for n and
the lack of a 3-MT control.
3.5.6 Nomifensine
In nomifensine (20mg/kg i.p.) treated animals, tyramine
maximally increased DA efflux to 6294 of basal efflux over 20 min
(Fig. 3.5.6, 0.14 ± 0.04 to 0.88 ± 0.18pmoles/20 min, n = 6).
Total DA efflux over 60 min was markedly reduced by 734 when
compared to control animals (Table 3.5.1, control 2.4 ± 0.28pmoles,
nomifensine 0.89 ± 0.19pmoles, p < 0.001).
DOPAC and HVA efflux levels remained constant (Fig. 3.5.6).
3.5.7 Tetrodotoxin
In TTX (2yM) treated animals, tyramine maximally increased DA
efflux to 59004 of basal efflux over 20 min (Fig. 3.5.7, 0.02 ± 0.02
to 1.18 ± 0.12pmoles/20 min, n = 6). Total tyramine induced DA
efflux over 60 min was not affected when compared to control animals
(Table 3.5.1, control 1.89 ± 0.48pmoles, TTX 1.50 ± 0.9pmoles).
TTX caused a rapid decline in DOPAC efflux and a less rapid
decline in HVA efflux which did not appear to be affected by
Fig. 3.5.5 Effects of selegeline (lOmg/kg i.p.) given 60 min
prior to tyramine (50uM) on the efflux of DA (upper
panel), DOPAC and HVA (middle panel) and 3-MT (lower
panel). Results (pmoles/20 min) are the mean ±





















































f—i « ♦ *
t t
NOM TYR
-i 1 1 1 1 1—i 1 1 1 1 1 1 1
50 100 150
TIME(min)
Fig. 3.5.6 Effects of nomifensine (20mg/kg i.p.) given 20
min prior to tyramine (50uM) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).
Results (pmoles/20 min) are the mean ± s.e.m. of
six independent experiments.
Fig. 3.5.7 Effects of TTX (2uM) perfused intrastriatally for 60
min prior to tyramine (50uM) on the efflux of DA
(upper panel), DOPAC (middle panel) and HVA (lower
panel). Results (pmoles/20 min) are the mean ±













In animals perfused with EGTA (20mM) in a Ca free buffer,
tyramine maximally increased DA efflux to 211* of basal efflux over
20 min (Fig. 3.5.8, 0.09 ± 0.01 to 1.90 ± 0.22pmoles/20 min,
n = 6). Total tyramine induced DA efflux over 60 min was not
affected when compared to control animals, indeed the patterns of
release were about identical for control and EGTA treated animals
(Table 3.5.1, control 2.48 ± 0.22pmoles, EGTA 2.32 ± 0.33pmoles).
EGTA caused a lesser rate of efflux of DOPAC and HVA which did
not appear to alter following tyramine infusion (Fig. 3.5.8).
Fig. 3.5.8 Effects of calcium removal and EGTA (20mM) perfused
intrastriatally for 60 min prior to tyramine (50yM) on
the efflux of DA (upper panel), DOPAC (middle panel)
and HVA (lower panel). Results (pmoles/20 min) are


























































EFFECTS OF BIOCHEMICAL AND PHARMACOLOGICAL MANIPULATIONS
ON TYRAMINE (5 x 10~5M) INDUCED DA EFFLUX
DA EFFLUX
n (pmol/60 min)
Control 12 2.4 ± 0.28
AMT (20 min pretreatment) 6 2.01 ± 0.39
Control 12 2.4 ± 0.28
AMT (120 min pretreatment) 6 1.11 ± 0.16***
Control 12 2.4 ± 0.28
Reserpine 6 0.97 ± 0.22***
Control 12 2.4 ± 0.28
Pargyline 6 3.0 ± 0.29*
Control 12 2.4 ± 0.28
Selegeline 6 2.1 ± 0.34
Control 12 2.4 ± 0.28
Nomifensine 6 0.89 ± 0.19***
Control 6 1.89 ± 0.48
TTX 6 1.50 ± 0.9
Control 6 2.48 ± 0.22
EGTA 6 2.32 ± 0.33
* p < 0.05, *** p < 0.001
Mean and standard errors are given for guidance only. Statistical
differences in amount released were assessed using the non-parametric
Mann-Whitney 'U1 test. The data were corrected for basal release prior to
comparison.
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3.6 Effects of biochemical and pharmacological manipulations upon
ouabain induced efflux of DA, DOPAC, HVA, 5-HIAA and 3MT.
3.6.1 Dose dependence of the ouabain response
Ouabain was perfused through the dialysis probes at
concentrations of 10,100 and lOOOyM. The lowest concentration of
10yM had no effect upon DA, DOPAC, HVA or 5-HIAA efflux levels.
However, increasing the concentration to 100 and lOOOyM caused a
graded increase in DA efflux levels (Fig. 3.6.1a, maximal DA efflux
= 22414 and 66044 of control respectively) and a graded decrease in
DOPAC, HVA and 5-HIAA efflux levels (Figs. 3.6.1a and 3.6.1b). A
dose of lOOyM ouabain was chosen for all further experiments as it
was apparent from these results that this dose was neither minimal
or maximal for stimulating DA efflux.
3.6.2 g-Methyl-p-tyrosine
In animals given a 20 min pretreatment of AMT (250mg/kg i.p.)
ouabain maximally increased DA efflux to 1113?! of basal efflux over
40 min (Fig. 3.6.2a, 0.15 ± 0.02 to 1.67 ± 0.44pmoles/20 min,
n = 6). Ouabain induced DA efflux over 20 min was not affected
when compared with control values (Table 3.6.1, control 2.0 ±
0.49pmoles, AMT 1.0 ± 0.36pmole) whereas DA efflux over 60 min was
reduced by 434 when compared with control animals (Table 3.6.1,
control 5.87 ± 0.80pmoles, AMT 3.37 ± 0.86pmoles, p < 0.05).
When AMT was injected 120 min prior to ouabain, maximal DA
efflux was 11504 of basal efflux over 40 min (Fig. 3.6.2b, 0.02 ±
0.01 to 0.23 ± 0.05pmoles/20 min, n = 6). Ouabain induced DA
efflux over 20 min was reduced by 904 when compared with control






















































Fig. 3.6.1a Effects of increasing doses of ouabain (perfused
intrastriatally) on the efflux of DA (upper
panel) and DOPAC (lower panel). Results are
expressed as a percentage ± s.e.m. of basal















































—i > 1 » 1 ' 1—
20 40 60 80
TIME(min)
100 120
Fig. 3.6.1b Effects of increasing doses of ouabain (perfused
intrastriatal ly) on the efflux of HVA (upper
panel) and 5-HIAA (lower panel). Results are
expressed as a percentage ± s.e.m. of basal















































Fig. 3.6.2a Effects of AMT (250mg/kg i.p.) given 20 min prior
to ouabain (100uM) on the efflux of DA (upper
panel), DOPAC and HVA (lower panel). Results



































Fig. 3.6.2b Effects of AMT (250mg/kg i.p.) given 120 min
prior to ouabain (100uM) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).






0.16pmoles, p < 0.01) and also by 904 over a 60 min period (Table
3.6.1, control 5.87 ± 0.80pmoles, AMT 0.58 ± 0.08pmoles, p < 0.001).
Qualitatively, ouabain appeared to accelerate the decline in
D0PAC and HVA efflux caused by AMT (Fig. 3.6.2b).
3.6.3 Reserpine
In reserpine (5mg/kg i.p.) treated animals, ouabain maximally
increased DA efflux to 23504 of basal efflux over 40 min (Fig.
3.6.3, 0.08 ± 0.02 to 1.88 ± 0.56pmoles/20 min, n = 6). Ouabain
induced DA efflux over 20 min and over 60 min was not affected by
reserpine (Table 3.6.1).
In qualitative terms, ouabain appeared to accelerate the decline
in D0PAC and HVA efflux caused by reserpine (Fig. 3.6.3).
3.6.4 Pargyline
In pargyline (75mg/kg i.p.) treated animals, ouabain maximally
increased DA efflux to 21364 of basal efflux over 20 min (Fig.
3.6.4, 0.22 ± 0.05 to 4.7 ± 2.0pmoles/20 min, n = 6). Ouabain
induced DA efflux over 20 min was not affected by pargyline despite
the higher value (Table 3.6.1, control 2.0 ± 0.49pmoles, pargyline
4.5 ± 2.1pmoles) whereas over a 60 min period, DA efflux was
increased by 2274 when compared to control animals (Table 3.6.1,
control 5.87 ± 0.80pmoles, pargyline 13.3 4.53pmoles, p < 0.05).
Pargyline induced a rapid decline in DOPAC and HVA efflux and a
less rapid decline in 5-HIAA efflux (Fig. 3.6.4). Ouabain did not
seem to have any additional effect on the efflux of any of these
metabolites.
Ouabain appeared to substantially increase the rate of 3-MT





























Fig. 3.6.3 Effects of reserpine (5mg/kg i.p.) given 180 min
prior to ouabain (100uM) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).
Results (pmoles/20 min) are the mean ± s.e.m. of
six independent experiments.
Fig. 3.6.4 Effects of pargyline (75mg/kg i.p.) given 120 min
prior to ouabain (lOOyM) on the efflux of DA (upper
panel), DOPAC, HVA and 5-HIAA (middle panel) and 3-MT
(lower panel). Results (pmoles/20 min) are the mean
± s.e.m. of six independent experiments.
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In selegeline (lOmg/kg i.p.) treated animals, ouabain maximally
increased DA efflux to 2692% of basal efflux over 40 min (Fig.
3.6.5. 0.13 ± 0.02 to 3.5 ± 1.3pmoles/20 min, n = 4). the efflux
of DA over 20 and 60 min was not affected when compared to control
animals (Table 3.6.1).
The efflux of D0PAC, HVA and 5-HIAA did not appear to be
affected by selegeline whereas 3-MT efflux on the other hand was
maximally increased by ouabain to 222% of basal efflux over 40 min
(Fig. 3.6.5, 0.09 ± 0.02 to 0.20 ± 0.12pmoles/20 min, n = 4). The
significance of this was not determined due to the lack of a 3-MT
control.
3.6.6 Nomifensine
In nomifensine (20mg/kg i.p.) treated animals, ouabain maximally
increased DA efflux to 1167% of basal efflux over 60 min (Fig 3.6.6,
0.12 ± 0.02 to 1.4 ± 0.50 pmoles/20 min, n = 6). Interestingly, DA
efflux over a 20 min period was reduced by 86% when compared with
control animals (Table 3.6.1, control 2.0 ± 0.49pmoles, nomifensine
0.28 ± 0.06pmoles, p < 0.001), whereas over a 60 min period, DA
efflux was reduced to a lesser extent by 56% when compared with
control animals (Table 3.6.1; control 5.87 ± 0.80pmoles,
nomifensine 2.6 ± 0.83pmoles, p < 0.01).
Ouabain induced efflux of DOPAC and HVA did not appear to be
affected by nomifensine (Fig. 3.6.6).
3.6.7 Tetrodotoxin
In TTX (2yM) treated animals, ouabain maximally increased DA
efflux to 3333% of basal efflux over 40 min (Fig. 3.6.7, 0.06 ± 0.02
Fig. 3.6.5 Effects of selegeline (10mg/kg i.p.) given 60 min
prior to ouabain (IOOmM) on the efflux of DA (upper
panel), DOPAC, HVA and 5-HIAA (middle panel) and 3-MT
(lower panel). Results (pmoles/20 min) are the mean
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Fig. 3.6.6 Effects of nomifensine (20mg/kg i.p.) given 20
min prior to ouabain (lOOpM) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).
Results (pmoles/20 min) are the mean ± s.e.m. of
six independent experiments.
Fig. 3.6.7 Effects of TTX (2yM) perfused intrastriatally for 60
min prior to ouabain (lOOuM) on the efflux of DA
(upper panel), DOPAC (middle panel) and HVA (lower
panel). Results (pmoles/20 min) are the mean ±
s.e.m. of six paired experiments.
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to 2.0 ± 0.26pmo1es/20 min, n = 6). Total DA efflux over a 20 min
period was reduced by 50% when compared with control animals (Table
3.5.1, control 1.02 ± 0.17pmoles, TTX 0.51 ± 0.18pmoles, p < 0.05)
and by 74% over 50 min when compared with control animals (Table
3.6.1, control 4.30 ± 0.63pmoles, TTX 1.55 ± 0.42pmoles, p < 0.05).
TTX caused a decline in the efflux of D0PAC and HVA which did
not appear to be affected by ouabain (Fig. 3.6.7).
3.6.8 EGTA
2+
In animals perfused with EGTA (2QnM) in a Ca free Puffer,
ouabain maximally increased DA efflux to 3917% of basal efflux over
20 min (Fig. 3.6.8, 0.06 ± 0.02 to 2.35 ± 1.3pmoles/20 min, n =
6). Ouabain induced DA efflux over 20 min was not affected (Table
3.6.1) whereas over 60 min DA efflux was decreased by 26% when
compared to control animals (Table 3.6.1, control 6.2 ± 1.75pmoles,
EGTA 4.6 ± 1.49pmoles, p < 0.05). EGTA caused a declining efflux
of DOPAC and HVA which appeared to be prolonged by ouabain.
Fig. 3.6.8 Effects of calcium removal and EGTA (20mM) perfused
intrastriatally for 60 min prior to ouabain (lOOyM) on
the efflux of DA (upper panel), DOPAC (middle panel)
and HVA (lower panel). Results (pmoles/20 min) are
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TABLE 3.6.1
EFFECTS OF BIOCHEMICAL AND PHARMACOLOGICAL MANIPULATIONS
ON OUABAIN (lOOpM) INDUCED DA EFFLUX
DA EFFLUX DA EFFLUX
n (pmole/20 min) (pmole/60 min)
Control 14 2.0 ± 0.49 5.87 ± 0.80
AMT (20 min pretreatment) 6 1.0 ± 0.36 3.37 ± 0.86*
Control 14 2.0 ± 0.49 5.87 ± 0.80
AMT (120 min pretreatment) 6 0.19 ± 0.16** 0.58 ± 0.08***
Control 14 2.0 ± 0.49 5.87 ± 0.80
Reserpine 6 1.52 ± 0.29 4.20 ± 0.80
Control 14 2.0 ± 0.49 5.87 ± 0.80
Pargyline 6 4.5 ± 2.1 13.3 ± 4.53*
Control 14 2.0 ± 0.49 5.87 ± 0-.80
Selegeline 4 2.38 ± 0.31 7.18 ± 0.61
Control 14 2.0 ± 0.49 5.87 ± 0.80
Nomifensine 6 0.28 ± 0.06*** 2.60 ± 0.83**
Control 6 1.02 ± 0.17 4.30 ± 0.63
TTX 6 0.51 ± 0.18* 1.55 ± 0.42*
Control 6 2.55 ± 1.31 6.2 ± 1.75
EGTA 6 2.30 ± 0.93 4.6 ± 1.49*
* p < 0.05, ** p < 0.01, *** p < 0.001
Mean and standard errors are given for guidance only. Statistical
differences in amount released were assessed using the non-parametric
Mann-Whitney 1U1 test. The data were corrected for basal release prior to
comparison.
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3.7 Effects of biochemical and pharmacological manipulations upon
veratrine induced efflux of DA, DOPAC, HVA, 5-HIAA and 3MT
3.7.1 Dose dependence of the veratrine response
Increasing doses of veratrine were given (10,100 and lOOOpg/ml)
via the dialysis probe. DA efflux was unaffected by the lowest
dose of 10ug/ml but exhibited a graded response to the two higher
doses (Fig. 3.7.1a) reaching 28134 (100yg/ml) and 65004
(1000ug/ml). DOPAC, HVA and 5-HIAA efflux levels decreased in a
graded fashion in response to the two higher doses of veratrine
(Figs. 3.7.1a and 3.7.1b). A dose of 100yg/ml veratrine was used
for all further experiments due to its submaximal effects upon DA
efflux.
3.7.2 g-Methyl-p-tyrosine
In animals injected with AMT (250mg/kg i.p.) 20 min prior to the
infusion of veratrine, DA efflux was maximally increased to 17604 of
basal efflux over 20 min (Fig. 3.7.2a, 0.10 ± 0.02 to 1.76 ±
0.47pmoles/20 min, n = 6). DA efflux over 20 min was not reduced
when compared to control animals (Table 3.7.1, control 2.65 ±
0.26pmoles, AMT 1.71 ± 0.30pmoles) whereas over 60 min DA efflux was
reduced by 394 when compared to control animals (Table 3.7.1,
control 4.48 ± 0.46pmoles, AMT 2.75 ± 0.43pmoles, p < 0.05). When
AMT was injected 120 min prior to veratrine infusion, DA efflux was
maximally increased to 18504 of basal efflux over 20 min (Fig.
3.7.2b, 0.02 ± 0.01 to 0.37 ± 0.09pmoles/20 min, n = 6). In
contrast to the above result, the efflux of DA over 20 min was
reduced by 864 when compared with control animals (Table 3.7.1,
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Fig. 3.7.1a Effects of increasing doses of veratrine,
perfused intrastriatally for 20 min from the time
indicated, on the efflux of DA (upper panel) and
DOPAC (lower panel). Results are expressed as a














































• i i i i t—■—■—r t—1—■—r
0 20 40 60 80 100 120
TIME(min)
Fig. 3.7.1b Effects of increasing doses of veratrine,
perfused intrastriatally for 20 min from the time
indicated, on the efflux of HVA (upper panel) and
5-HIAA (lower panel). Results are expressed as













































Fig. 3.7.2a Effects of AMT (250mg/kg i.p.) given 20 min prior
to veratrine (100ug/ml) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).











































Fig. 3.7.2b Effects of AMT (250mg/kg i.p.) given 120 min
prior to veratrine (100yg/ml) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).
Results (pmoles/20 min) are the mean ± s.e.m. of
six independent experiments.
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DA efflux over 60 min was reduced by 88%, a statistically
significantly decrease when compared to control animals (Table
3.7.1, Control 4.48 ± 0.46pmoles, AMT 0.55 ± 0.08pmole, p < 0.01).
No aualitative effect of the 20 min pretreatment of AMT on
veratrine induced efflux of DOPAC and HVA was apparent (Fig.
3.7.2a). When AMT was injected 120 min before veratrine infusion,
veratrine appeared to accelerate the efflux of DOPAC and HVA the
decrease of which was tailing off before veratrine (Fig. 3.7.2b).
3.7.3 Reserpine
In reserpine (5mg/kg i.p.) treated animals, veratrine maximally
increased DA efflux to 2714% of basal efflux over 20 min (Fig.
3.7.3, 0.07 ± 0.02 to 1.9 ± 0.37pmoles/20 min, n = 6). DA efflux
over 20 min was reduced by 31% when compared to control animals
(Table 3.7.1, control 2.65 ± 0.26pmoles, reserpine 1.83 ±
0.24pmoles, p < 0.05). However, surprisingly, DA efflux over 60
min was not reduced by reserpine (Table 3.7.1, control 4.48 ±
0.46pmoles, reserpine 3.23 ± 0.38pmoles).
No aualitative differences in veratrine induced DOPAC and HVA
efflux were apparent in reserpine treated animals.
3.7.4 Pargyline
In pargyline (75mg/kg i.p.) treated animals, veratrine maximally
increased DA efflux to 2033% of basal efflux over 20 min (Fig.
3.7.4, 0.30 ± 0.05 to 6.1 ± 1.2pmoles/20 min, n = 6). DA efflux
over 20 min was increased by 234% when compared to control animals
(Table 3.7.1, control 2.65 ± 0.26pmoles, pargyline 6.2 ± 1.3pmoles,
p < 0.01) and by 248% over a 60 min period (Table 3.7.1, control










Fig. 3.7.3 Effects of reserpine (5mg/kg i.p.) given 180 min
prior to veratrine (100yg/ml) on the efflux of DA
(upper panel), DOPAC and HVA (lower panel).
Results (pmoles/20 min) are the mean ± s.e.m. of
six independent experiments.
Fig. 3.7.4 Effects of pargyline (75mg/kg i.p.) given 120 min
prior to veratrine (lOOyg/ml) on the efflux of DA
(upper panel), DOPAC and HVA (middle panel) and 3-MT
(lower panel). Results (pmoles/20 min) are the mean






Pargyline induced a rapid decline in DOPAC and HVA efflux which
appeared to be unaffected by the subsequent infusion of veratrine
(Fig. 3.7.4).
Pargyline induced a rise in 3-MT efflux to 7502 of basal efflux
over 120 min (Fig. 3.7.4). The infusion of veratrine accelerated
this rise to 3842 of pre-veratrine efflux and 28832 of pre-pargyline
efflux.
3.7.5 Selegeline
In selegeline (lOmg/kg i.p.) treated animals, veratrine
maximally increased DA efflux to 23572 of basal efflux over 20 min
(Fig. 3.7.5, 0.14 ± 0.02 to 3.3 ± 0.6pmoles/20 min, n = 4). DA
efflux over 20 min and 60 min was not different to that for control
animals (Table 3.7.1).
In aualitative terms, veratrine appeared to prolong the decrease
in DOPAC and HVA efflux in selegeline treated animals but had no
effect on 5-HIAA efflux (Fig. 3.7.5).
A rise in 3-MT efflux was detected after veratrine infusion
(Fig. 3.7.5), however, the effect was not statistically tested due
to the lack of adeauate control values.
3.7.6 Nomifensine
In nomifensine (20mg/kg i.p.) treated animals, veratrine
maximally increased DA efflux to 14762 of basal efflux over 20 min
(Fig. 3.7.6, 0.21 ± 0.08 to 3.1 ± l.lpmoles/20 min, n = 6). DA
efflux over 20 min and 60 min was not affected by nomifensine (Table
3.7.1).
No aualitative differences in veratrine induced DOPAC and HVA
efflux were apparent in nomifensine treated animals (Fig. 3.7.6).
Fig. 3.7.5 Effects of selegeline (lOmg/kg i.p.) given 60 min
prior to veratrine (100ng/ml) on the efflux of DA
(upper panel), DOPAC, HVA and 5-HIAA (middle panel)
and 3-MT (lower panel). Results (pmoles/20 min) are



























Fig. 3.7.6 Effects of nomifensine (20mg/kg i.p.) given 20
min prior to veratrine (100yg/ml) on the efflux
of DA (upper panel), DOPAC and HVA (lower
panel). Results (pmoles/20 min) are the mean ±
s.e.m. of six independent experiments.







In TTX (2pM) treated animals, veratrine maximally increased DA
efflux to 250£ of basal efflux over 20 min (Fig. 3.7.7, 0.08 ± 0.01
to 0.20 ± 0.04pmoles/20 min, n = 4). DA efflux over 20 min was
dramatically reduced by 02% when compared with control animals
(Table 3.7.1, control 2.08 ± 0.37pmoles, TTX 0.16 ± 0.06pmoles, p <
0.01) and similarly over 60 min, DA efflux was reduced by 90;S when
compared with control animals (Table 3.7.1, control 3.6 ±
0.51pmoles, TTX 0.35 ± 0.06pmoles, p < 0.01).
No Qualitatively different effects of veratrine upon D0PAC and
HVA efflux were apparent.
3.7.8 EGTA
2+
In animals perfused with EGTA (20mM) in a Ca free buffer,
veratrine maximally increased DA efflux to 2270% of basal efflux
over 20 min (Fig. 3.7.8, 0.10 ± 0.02 to 2.27 ± 1.28pmoles/20 min,
n = 6). DA efflux over a 20 min period was decreased by 55% when
compared with control animals (Table 3.7.1, control 2.17 ±
1.2pmoles, EGTA 0.98 ± 0.43pmoles, p < 0.05) and by 49# over a 60
min period (Table 3.7.1, control 3.9 ± 1.3pmoles, EGTA 2.0 ±
0.61pmoles, p < 0.05).
In Qualitative terms, EGTA appeared to inhibit the veratrine
induced decrease in D0PAC and HVA efflux (Fig. 3.7.8).
Fig. 3.7.7 Effects of TTX (2yM) perfused intrastriatally
simultaneously with veratrine (lOOpg/m1) on the efflux
of DA (upper panel), DOPAC (middle panel) and HVA
(lower panel). Results (pmoles/20 min) are the mean








































Fig. 3.7.8 Effects of calcium removal and EGTA (20mM) perfused
intrastriatally for 60 min prior to veratrine
(lOOug/ml) on the efflux of DA (upper panel) DOPAC
(middle panel) and HVA (lower panel). Results











































3 8" HE . .
3 6" . .
<
> i i *
x 4- Kk
2- EGTA








EFFECTS OF BIOCHEMICAL AND PHARMACOLOGICAL MANIPULATIONS






Control 14 2.65 ± 0.26 4.48 ± 0.46
AMT (20 min pretreatment) 6 1.71 ± 0.30 2.75 ± 0.43*
Control 14 2.65 ± 0.26 4.48 ± 0.46
AMT (120 min pretreatment) 6 0.37 ± 0.06*** 0.55 ± 0.08**
Control 14 2.65 ± 0.26 4.48 ± 0.46
Reserpine 6 1.83 ± 0.24* 3.23 ± 0.38
Control 14 2.65 ± 0.26 4.48 ± 0.46
Pargyline 6 6.2 ± 1.3** 11.10 ± 2.40**
Control 14 2.65 ± 0.26 4.48 ± 0.46
Selegeline 4 2.89 ± 0.72 4.61 ± 1.1
Control 14 2.65 ± 0.26 4.48 ± 0.46
Nomifensine 6 2.82 ± 1.1 4.51 ± 1.51
Control 4 2.08 ± 0.37 3.60 ± 0.51
TTX 4 0.16 ± 0.06** 0.35 ± 0.06**
Control 6 2.17 ± 1.2 3.9 ± 1.30
EGTA 6 0.98 ± 0.43* 2.0 ± 0.61*
* p < 0.05, ** p < 0.01, *** p < 0.001
Mean and standard errors are given for guidance only. Statistical
differences in amount released were assessed using the non-parametric





4.1 In vivo microdialysis
In vivo brain microdialysis is a techniaue which has progressed
considerably since its inception in the early 1970s. The present
work demonstrates that this techniaue is suitable for the
simultaneous in vivo measurement of catecholamines and their
metabolites in brain tissue. Moreover, pharmacologically and
biochemically induced changes in DA efflux and metabolism have been
studied. The techniaue has allowed correlations to be made between
DA efflux and the efflux of DA metabolites thereby increasing the
amount of information conveyed by the results.
The limitations of in vivo microdialysis must be borne in mind
when interpreting the results. Synaptic release of DA occurs on a
sub-second timescale into a space of only several nanometres in
width. The dialysis probes used in this work measured
approximately 300yM in diameter. It is immediately apparent that
any alteration in the level of synaptic DA release will only be
apparent if it is measured collectively. No existing techniaue is
able to measure the release of a transmitter at a single synapse.
Conseauently, the stimulation or inhibition of DA release measured
in these experiments is the collective release from many nerve
terminals. Moreover, the DA that is collected into the perfusate
reflects the DA that escapes reuptake back into the nerve
terminal. For this reason, the release of DA into the
extracel1ular space has been referred to as DA efflux since it
represents the net release of DA and not the absolute release.
It may be argued that the DA efflux measured in these
experiments is derived from non-synaptic sources on the basis that
the majority of DA released into a synapse is probably captured on
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the DA uptake carrier. Therefore, little if any DA will reach the
extrasynaptic space. This may be so during normal nerve cell
activity when the auantitites of DA released are much less than
those stimulated biochemically or pharmacologically. However,
lesions of the nigro-striatal pathway have been reported to reduce
basal DA efflux by > 95£ (Zetterstrom et al., 1986). This suggests
that the basal extracellular level of DA is derived from synaptic
sources released by normal physiological nerve activity. Under
artificial stimulating conditions, it seems likely that the synaptic
DA uptake carrier will rapidly be saturated especially if it is
remembered that some of the stimulating conditions used here
apparently depleted the vesicular or cytosolic pools of DA quite
rapidly. This situation probably does not normally occur during
normal physiological activity. The results illustrate the fact
that a majority of the DA efflux measured is synaptically derived,
since any interference with the DA uptake carrier affected the
efflux of DA. Thus nomifensine, by inhibiting the action of the DA
uptake carrier, increased the extracellular level of DA (Fig.
3.2.6). This discounts the argument that the DA efflux measured in
these experiments was non-synaptic. Raiteri et al. (1979)
demonstrated that the action of nomifensine is solely that of uptake
inhibition when nomifensine failed to release [ H] DA in their
superfused striatal slice preparation. Thus, nomifensine does not
increase the extracellular level of DA by stimulating release.
The previously mentioned limitations of in vivo microdialysis
relating to spatial and temporal resolution, prevent its use for
following electrically induced changes in DA release that occur over
a millisecond timescale. This is not surprising if it is
-116-
remembered that stimulation of the medial forebrain bundle (MFB) for
example, releases DA from dopaminergic nerve endings in the striatum
in a fashion analogous to the physiological norm. Thus, the
released DA will rapidly be taken back up into the nerve terminal
and the nett DA efflux into the extracellular space over a sampling
period of minutes will be minimal. This is illustrated by Kuhr &
Wightman (1986) and Wightman et al. (1988) who used fast scan cyclic
voltammetry to measure DA release in the striatum following
stimulation of the MFB at various stimulation parameters. Their
results demonstrated raised levels of DA in the extracel1ular fluid
for periods up to 3 or 4 seconds. Such short lasting increases
will not be detected by microdialysis which samples over a period of
several minutes, unless electrically stimulated release can be
maintained for the duration of the sampling time, which is not
likely.
In vivo microdialysis has been used to follow behaviourally
induced changes in extracellular DA. Thus, Church et al. (1987)
used a sampling time of 5 min to measure feeding induced changes in
DA levels in rats. The sensitivity of their technique was enhanced
by the use of an automated smallbore chromatography system. This
can handle small sample volumes without a loss in sensitivity and so
allows for short sampling times, enhancing the temporal resolution
of the techniaue.
4.2 The DA releasing effect of amphetamine
The results demonstrate that AMPH increases the efflux of
endogenous DA into the extracel1ular space of the striatum
(Fig. 3.2.2). The effect on DA efflux is maximal 40 min after the
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injection of AMPH. DA efflux subseauently declines over the
following 60 min. As well as increasing DA efflux, AMPH also
increased the tissue content of DA to 1202 of control (Fig.
3.1.1). This result may at first seem to be paradoxical since it
seems logical that a releasing agent should deplete the tissue
stores of DA. AMPH has been reported to decrease impulse flow in
neurones (Roth et al., 1976). If impulse flow is reduced using
y-butyrolactone (GBL) or by electrolytic lesion of the dopaminergic
pathway, tissue levels of DOPAC decrease (Roth et al., 1976).
Amphetamine was found to produce a much greater decrease in DOPAC
than either GBL or lesioning. Roth interpreted this as indicating
that the DOPAC lowering effect of AMPH was not due solely to its
impulse blocking properties but could also be attributed to its
uptake blocking properties. In the present experiments, AMPH
caused a 602 reduction in tissue DOPAC levels (Fig. 3.1.1) and an
802 reduction in DOPAC efflux levels (Fig. 3.2.2). AMPH is known
to inhibit the neuronal uptake of DA (Green, 1971; Mantle et al.,
1976; Green & El Hait, 1978). It is thus possible that AMPH could
indirectly increase DA efflux by blocking the re-uptake of
transmitter that is spontaneously released from the neurone.
However, in reserpinised striatal slices, the DA uptake inhibitor
nomifensine produced only a slight acceleration of DA efflux (Parker
& Cubeddu, 1986). Moreover, under the conditions of blockade of DA
reuptake by nomifensine in the present experiments, there was only a
slight increase in DA efflux. Additionally, unlike AMPH
nomifensine did not cause tissue levels of DOPAC (Fig. 3.1.1) or
DOPAC efflux (Fig. 3.2.12) to decrease. This is in agreement with
Westerink et al. (1987) who reported that the DA re-uptake inhibitor
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6BR 12909 had no effect on the efflux level of DOPAC when measured
by intracerebral dialysis. Conseauently, it is unlikely that the
sole action of AMPH is to inhibit the reuptake of DA. The auestion
still remains as to why AMPH should increase tissue levels of DA if
its action is to release DA. The possibility exists that AMPH is
inhibiting MAO so reducing the intraneuronal metabolism of DA to
DOPAC. This action of AMPH has been reported by several groups
(Green, 1971; Mantle et al., 1976; Green St Elhait, 1978) and would
explain both the AMPH induced decrease in DOPAC concentration in
tissue and perfusates as well as the increase in DA levels in tissue
and perfusates. However, there are several results that refute
this possibility. Firstly, the MAO inhibitor pargyline was much
more effective than AMPH at increasing tissue DA and decreasing
tissue DOPAC levels (Fig. 3.1.1). Secondly, pargyline induced only
a slow rise in DA efflux levels to a maximal 280X of control over
120 min (Fig. 3.2.8) in contrast to the more rapid and greater
effect of AMPH. Thirdly, pargyline induced an increase in 3-MT
efflux to 813S of control over 120 min (Fig. 3.2.8), an effect that
was not seen after the dose of AMPH used in these experiments.
Finally, and most convincingly, in pargyline pretreated animals
i.e., in animals where MAO activity was already inhibited, AMPH
further increased the efflux of DA by 239% above control animals
(Table 3.3.1). A similar effect was reported in vitro by Miller St
3
Shore (1982) who observed an elevation of [ H]-DA accumulation on
top of that caused by pargyline. So whilst the inhibition of MAO
by AMPH may partially explain tne reduction in DOPAC efflux, such an
action of AMPH does not completely account for the results. The
present results suggest that AMPH has little, if any, MAO inhibitory
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activity at doses below 8mg/kg. At 8mg/kg or higher, 3-MT efflux
is increased which does suggest an inhibition of MAO (Fig.
3.3.1b). Similar results were reported for AMPH stimulated DA
efflux from striatal slices (Parker & Cubeddu, 1986). Moreover,
Parker & Cubeddu perfused the slices with both nomifensine and
pargyline together. However, this combination still failed to
elicit the same magnitude of DA efflux as that elicited by AMPH.
Thus, in the light of these results that do not support the
hypothesis that the releasing action of AMPH is a result of an
inhibition of DA reuptake and of MAO activity, AMPH must, therefore,
have a direct DA releasing action as well as stimulating the
accumulation of DA in tissue. The possibility exists that AMPH, as
well as causing the release of DA into the synaptic cleft (Azzaro &
Rutledge, 1973; Arnold et al., 1977; Kamal et al., 1981), makes
available more DA for seauestration into storage sites. This could
be achieved if AMPH were to stimulate DA synthesis. Such an effect
of AMPH was demonstrated in vitro by Uretsky & Snodgrass (1977). A
concentration of lyM AMPH in the perfusing medium maximally
3 3
stimulated the synthesis of [ H]-DA from [ H]-tyrosine. Such
an effect could explain the accumulation of DA in tissue exposed to
AMPH.
Reserpine, which depletes vesicular stores of DA (Carlsson,
1958), reduced striatal tissue content of DA by 73i (Fig. 3.1.1).
Other workers have reported more than a 95i reduction in tissue
levels of DA by reserpine (Umezu & Moore, 1979). Under these
conditions, AMPH induced efflux of DA was not affected (Fig. 3.3.3)
which indicates that the pool of DA that is sensitive to the
releasing action of AMPH is not the vesicular storage pool. This
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is in harmony with in vitro results obtained by other workers (e.g.
Scheel-Kruger, 1971; Chiueh & Moore, 1975; see McMillen, 1983) and
behavioural results (Scheel-Kruger, 1971). This is substantiated
by the effects of the DA synthesis inhibitor AMT which led to a
dramatic inhibition of the AMPH induced DA efflux (Table 3.3.1).
When AMT was given 120 min before AMPH, DA efflux was reduced by
854. However, at this timepoint, tissue levels of DA were reduced
by 394 (Table 3.1.1) which suggests a concurrent depletion of both
newly synthesised and vesicular stores of DA. This difficulty was
overcome by administering AMT simultaneously with AMPH. AMT had no
effect on tissue levels of DA after 20 min (Table 3.1.1), the time
at which the effect of AMPH becomes maximal. However, the effect
of AMPH on DA efflux was still reduced by 704 (Table 3.1.1). This
suggests that the newly synthesised pool of DA is released by AMPH
which explains the exauisite sensitivity of this release to AMT.
Moreover, the location of the newly synthesised pool of DA could be
in the cytosol of the neurone since this pool is not affected by
reserpine which depletes vesicular pools. This is in agreement
with results obtained by other groups (Moore, 1977, 1978; McMillen,
1983) who also proposed that AMPH releases newly synthesised DA.
Moreover, this pool of DA has been reported to be responsible for
AMPH stimulated behaviours which are blocked by AMT (Weissman et
al., 1965; Rech & Stolk, 1970; Scheel-Kruger, 1971). In keeping
with this suggestion, the effects of AMPH on DA efflux were
facilitated in pargyline treated animals (Table 3.3.1). Pargyline
inhibits the metabolism of free cytosolic DA that would normally be
vulnerable to MAO. This is borne out by the pargyline induced
increase in tissue levels of DA to 1514 of control (Table 3.1.1).
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The increase in cytosolic DA levels are reflected in an increased
efflux of DA by AMPH. On the other hand, selegeline, an inhibitor
of MAO B (see Houslay & Tipton, 1976) was without effect on AMPH
stimulated DA efflux. MAO B has been reported to occur
predominantly postsynaptically and extraneuronally in glial cells
with only a small amount of activity in presynaptic terminals
(Levitt et al., 1982; Francis et al., 1985). This is further
evidence for the origin of the DA efflux stimulated by AMPH.
Moreover, it implies that little if any DA is metabolised by MAO B
in the striatum.
Nomifensine was very effective at inhibiting AMPH induced DA
efflux (Fig. 3.3.6a,b, Table 3.3.1). This is in harmony with
results obtained by Parker & Cubeddu (1986) in striatal slices and
also with Liang & Rutledge (1982a) who used the DA uptake inhibitor
benztropine in striatal slices. Both groups demonstrated that
uptake inhibition virtually abolished AMPH elicited DA efflux.
This was also demonstrated for a variety of other phenylethylamines
as well as AMPH by Raiteri et al. (1979). Nomifensine blocked
their ability to increase the efflux of [ H]-DA from striatal
synaptosomes. AMPH stimulated behavioural effects were also
inhibited by a variety of uptake inhibitors (Ross, 1979). This
suggests that the uptake carrier is essential for the action of AMPH.
Correlations appear to exist between these pharmacological
effects on AMPH induced DA efflux and the effects of similar
treatments on AMPH induced behavioural responses. Such direct
correlations should be treated with caution but do suggest a
consistency of events. Thus, reserpine pretreatment fails to
affect AMPH stimulated DA efflux as well as AMPH stimulated
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behaviours (Scheel-Kruger, 1971; McMillen, 1983). In contrast,
AMT when administered 30 min or 120 min before AMPH causes either a
partial or complete blockade of behavioural responses (Weissman et
al., 1966; Scheel-Kruger, 1971; Papeschi, 1975; Widerlov &
Lewander, 1978; see McMillen, 1983).
The effects of AMPH on DA metabolites also convey much
information concerning the nature of DA release. What is
immediately apparent is that although increasing doses of AMPH led
to a graded response in DA efflux, the same was not true for DOPAC
and HVA efflux (Figs. 3.3.1a, b). Such a result has been
interpreted previously as evidence that the AMPH stimulated decline
in DOPAC and HVA efflux is closely related to the depletion of the
newly synthesised pool of DA (Zetterstrom et al., 1986). The
possibility that uptake blockade of DA by AMPH is responsible for
the decrease in DOPAC efflux is unlikely since nomifensine had no
effect on DOPAC efflux (Fig. 3.2.12a,b) (See Westerink et al.,
1987). The suggestion is that the pool supplying MAO is rapidly
exhausted and at higher doses of AMPH (8 and 16mg/kg) DA is released
from vesicular pools as well (Zetterstrom et al., 1986). The
results presented here are in agreement with this. This is
strengthened by the results obtained with nomifensine since this
inhibited the AMPH stimulated decline in DOPAC and HVA efflux as
well as the AMPH stimulated increase in DA efflux (Fig. 3.3.6a).
Thus, protection of the newly synthesised pool by nomifensine,
prevents the depletion of DA and so maintains a pool of substrate
for MAO.
At this point, it seems pertinent to highlight the contrasting
results obtained when nomifensine was administered via two different
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routes. When administered intraperitoneally, it inhibited the
effect of AMPH on DA, DOPAC and HVA (Fig. 3.3.6a). However, when
nomifensine was infused through the dialysis probe, there was a lack
of effect on the AMPH induced alterations in DOPAC and HVA efflux
but not on DA efflux (Fig. 3.3.6b). The latter route was still
effective for the inhibition of DA uptake in the immediate vicinity
of the probe, as shown by the inhibition of AMPH stimulated DA
efflux, but was not effective over a sufficient distance from the
probe from where DOPAC was able to diffuse to the probe and enter
the perfusate. The possible reason for this discrepancy between
efficacy against DA and DOPAC may be that DOPAC has been reported to
diffuse more readily through extracellular fluid than DA (Rice et
al., 1985), thereby extending the distance over which DOPAC is
collected by the dialysis probe. Intraperitoneally administered
nomifensine overcomes this problem by universally affecting the
whole striatum.
Nomifensine was ineffective against basal DOPAC efflux (Fig.
3.2.12) which suggests that the basal overflow of DOPAC is not
derived from DA taken up into nerve terminals but rather solely from
cytosolic DA within the terminals. This is in agreement with the
results of Zetterstrom et al. (1988).
The effects of AMT and reserpine on DOPAC and HVA efflux
substantiate their effects on DA efflux. Reserpine was without
effect on DOPAC and HVA (Fig. 3.2.10) whereas AMT caused a decline
in both DOPAC and HVA efflux (Fig. 3.2.11). This suggests that the
extracel1ular pool of these compounds is formed by the metabolism of
newly synthesised DA.
The increase in HVA efflux following nomifensine (Fig. 3.2.12a)
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may reflect a shift towards a postsynaptic and/or glial metabolism
of DA. This result is to be expected since the inhibition of DA
reuptake by nomifensine is likely to increase the flux of
extracel1ular DA into postsynaptic and glial cells.
The precise mechanism by which AMPH releases DA from the nerve
terminal remains unclear. These results demonstrate that AMPH
releases newly synthesised DA by a carrier dependent mechanism.
The involvement of the carrier is beyond doubt since any
interference with it resulted in a decreased efflux of DA. AMPH is
a highly lipophilic compound and readily accumulates within the
nerve terminal by diffusion (Fischer & Cho, 1979). Conseauently, a
functioning membrane carrier is not reauired for AMPH to enter the
terminal, but it is required for the AMPH stimulated efflux of DA.
This suggests that DA may exit the nerve terminal in a carrier
dependent fashion. Such a mechanism has been proposed previously
and has been called exchange diffusion (Levine et al., 1965; Paton,
1973; Fischer & Cho, 1979; Raiteri et al., 1979; Liang &
Rutledge, 1982b; McMillen, 1983; Parker & Cubeddu, 1986). This
process was originally described for glucose transport into
erythrocytes (Levine et al., 1965) and later for NA release from
nerve terminals (Paton, 1973). The data presented here are
compatible with an exchange-diffusion model of AMPH-induced DA
release for the reasons outlined below. For the process of
exchange diffusion to be viable, the membrane uptake carrier is
envisaged as a protein located within the neurolemma that is able to
shuttle from one side of the neurolemma to the other. In the
+
_
presence of high [Na J, the carrier has a high affinity for DA.
_ +
In conditions of low [Na ], the carrier nas a lower affinity for
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DA. Conseauently, DA present on the outside of a polarised cell
membrane i.e., where [Na+] is high, is bound by the carrier to
form a DA-Na+-carrier complex. This complex is then transported
to the cytoplasmic side of the neurolemma where [Na+] is low and
the DA and Na+ dissociate from the carrier which then recycles.
It has been hypothesised that AMPH binds to the DA uptake carrier
and is transported across the neurolemma in the same way as DA.
The increased shuttling of the carrier as well as the increase in
+
intraneuronal Na brought about by the transport of the
+
AMPH-Na -carrier complex might favour the outward transport of
DA. In support of this, the reduction of extracellular [Na+] has
been used to stimulate DA release in a carrier dependent fashion
+
(see Raiteri et al., 1978). In these conditions, the Na
gradient is reversed which causes the uptake carrier to operate in
+
the reverse direction. Furthermore, if Na is allowed to
accumulate intracel1ularly by the ouabain induced inhibition of
4- +
Na -K -ATPase, DA efflux is also stimulated in a carrier
dependent fashion (Raiteri et al., 1978).
Under normal physiological conditions, if carrier mediated
efflux of DA occurred, the process would not be saturated since
intraneuronal metabolism probably holds DA at a low concentration.
The Km of the carrier for DA is likely to be high on the cytoplasmic
+
surface of the neurone due to the relatively low levels of Na .
+ +
It appears that Na and more particularly the Na gradient
across the neurolemma determines the action of the DA uptake
carrier. The hypothesis that this carrier is reversed by AMPH
explains the results obtained in the present experiments.
1. Exchange diffusion provides a mechanism whereby the diffusional
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barrier to DA is circumvented. Despite the fact that AMPH is able
to accumulate intracellularly by diffusion across the neurolemma
(Fischer & Cho, 1979), DA efflux is only stimulated if the membrane
carrier is operative. The hypothesis predicts that inhibitors of
the carrier mechanism should block the efflux of DA produced by
AMPH. This explains the ability of nomifensine to inhibit the
efflux of DA elicited by AMPH.
2. If DA is transported out on the uptake carrier, then only the
cytosolic pool of DA should have access to the carrier. This is
supported by the results for AMT and pargyline which decrease and
increase the size of the cytosolic pool respectively and
concurrently decrease and increase the AMPH stimulated efflux of DA.
3. The AMPH stimulated decline in DOPAC efflux may be partially
explained by exchange diffusion. By facilitating the efflux of DA,
AMPH would indirectly lower the amount of cytoplasmic DA available
for deamination by MAO. This is supported by the effect of
nomifensine which protected against the AMPH induced decline in
DOPAC efflux.
To summarise, the results support the hypothesis that AMPH
stimulates DA efflux by a process of exchange diffusion. The
+
mechanism probably relies on alterations of the Na gradient that
act to reverse the direction of action of the DA uptake carrier.
It is probable that other drugs that interfere with the Na
gradient have a similar action on the uptake carrier. This will be
discussed with relation to ouabain, veratrine and increased K
levels in the following sections.
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4.3 The DA releasing effect of raised extracelluar K
Calcium ions play a central role in the release of
neurotransmitter substances from a nerve ending. Calcium entry
into the nerve terminal is the trigger for the exocytotic release of
neurotransmitter (Augustine, 1987; Nachshen & Sanchez-Armass,
1987). Potassium evoked release of neurotransmitter is closely
2+
allied to the influx of Ca ions (Nachshen & Sanchez-Armass,
1987). This method of depolarisation induced release is widely
used and has been demonstrated recently for NA release from
peripheral tissue (El-Din & Malik, 1982) and from synaptosomes
(Raiteri et al., 1977), for amino acids from the intact striatum
(Tossman & Ungerstedt, 1984), and for DA from superfused striatal
synaptosomes (Raiteri et al., 1979) and from the isolated rat
striatum (Harsing & Vizi, 1984). When KCl was perfused
intrastriatally through the dialysis probe, there was a large and
rapid increase in DA efflux (Fig. 3.2.3). The DA response was
maximal during the 20 min perfusion of KCl, subsequent to which it
rapidly declined to pre-stimulation levels over 40 min. However,
the origin of this DA in the presynaptic terminal is not exclusively
vesicular as would be expected when stimulating release with a
depolarising agent. This is evident from the sensitivity of KCl
stimulated DA efflux to AMT (Fig. 3.4.2a,b). If the KCl sensitive
pool of DA was exclusively vesicular, then inhibition of synthesis
of extravesicular DA would not be expected to affect this pool.
However, AMT administered 20 min and 120 min prior to KCl infusion
was effective at reducing KCl stimulated DA efflux (Table 3.4.1).
Moreover, KCl infusion also reduced the efflux of DOPAC (Fig. 3.2.3)
which is evidence of an effect on the non-vesicular pool of DA.
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This effect is in contrast to results obtained by other groups who
reported that KC1 released unmetabolised NA in an exocytotic
2+Ca -dependent fashion without affecting deaminated metabolites
(Baldessarini & Kopin, 1967; Raiteri et al., 1975; Mulder et al.,
1975; Holz, 1975). Another surprising result was that despite an
apparently strong tendency of reserpine to inhibit KC1 stimulated DA
efflux (Fig. 3.4.3), the result was not statistically significant
(Table 3.4.1). However, this may be attributed to the high
variation of the results since reserpine, which is a potent depletor
of the vesicular stores of DA, would be expected to affect the
depolarisation induced efflux elicited by KC1. Overall, these
results would seem to suggest that depolarisation induced by high
extracel1ular [K ], does not exclusively release vesicular stores
of DA. This is probably the case and can be explained as
follows. Depolarisation by constant perfusion of 90mM KC1 through
the dialysis probe was found to sub-maximally stimulate DA efflux in
the striatum (Fig. 3.4.1). However, constant exposure of the
+
tissue to elevated extracelluar [K ] for 20 min grossly departs
from the physiological norm where depolarisation over a timescale of
milliseconds stimulates exocytotic release of DA. It seems likely
and indeed probable from these results that a prolonged exposure of
the striatal tissue to KC1 rapidly depletes the small releaseable
vesicular pool of DA, probably within seconds. Following this, the
vesicles are replenished from the newly synthesised (cytosolic?)
pool of DA which thereby contributes to the pool of DA sensitive to
KC1 stimulation. This would explain the sensitivity to synthesis
inhibition by AMT. This would also explain the apparent lack of
sensitivity to reserpine since the reserpine sensitive pool of DA
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would contribute only a small proportion of the DA released during
20 min by KC1. The KC1 induced decline in DOPAC efflux supports
the involvement of a cytosolic component.
If it is to be accepted that depolarisation induced release
occurs directly from synaptic vesicles through an exocytotic like
process, then inhibition of the DA uptake carrier with nomifensine
should have no effect. This was reported to be so by Raiteri et
al. (1979) in superfused synaptosomes. Thus, co-perfusion of
nomifensine with 56mM KC1 had no inhibitory effect on the
KCl-induced efflux of DA. In the present experiments, the
injection of nomifensine 20 min before KC1 infusion, facilitated
KCl-stimulated DA efflux (Table 3.4.1). This is probaoly as a
result of the inhibition of re-uptake of the DA released by KC1.
This result was not obtained by Raiteri and co-workers because of
the superfusion conditions used which effectively nullifies the
effect of DA re-uptake. If part or all of the KC1 stimulated DA
efflux was via the membrane carrier in a fashion analogous to that
of AMPH (i.e. by reversal of the carrier to transport DA outwards)
then nomifensine would be expected to inhibit and not facilitate the
effect. Therefore, this result substantiates the evidence that KC1
stimulates DA efflux via exocytosis from a vesicular pool. Further
credence is given to this mechanism by the inhibition of KC1
2+
stimulated DA efflux by EGTA in a Ca free buffer (Table
3.4.1). The exocytotic release of DA is triggered by the influx of
2+ . 2+ 2+
Ca into the cell. Ca influx is largely prevented in Ca
free EGTA containing buffer which would explain this inhibition.
2
The operation of the plasma membrane reuptake carrier is Ca
independent and consequently insensitive to conditions of low
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2+
extracel1ular [Ca ]. Similar results were obtained by Raiteri
et al. (1979), by Harsing & Vizi (1984) and by El-Din & Malik
2+
(1982). Raiteri and co-workers demonstrated the Ca dependency
2+
by progressively reducing the concentration of Ca perfused over
striatal synaptosomes. Even in conditions of no extracel1ular
2+
Ca , KC1 was still able to stimulate some DA efflux albeit
substantially reduced. This was in contrast to KCl-stimulated NA
2+
and 5-HT efflux which was totally dependent on extracellular Ca
in these superfusion conditions (Raiteri et al., 1979).
+
Tetrodotoxin blocks Na channels in the plasma membrane and
conseauently inhibits depolarisation induced DA release by such
depolarising agents as veratrine and electrical stimulation.
However, it is not effective against KC1 stimulated DA efflux (Table
3.4.1). This is because it is the high extracel1ular [K+] that
2+
facilitates the influx of Ca necessary for depolarisation
+
induced DA release. Na entry into the cell is not an absolute
+
pre-reauisite in these conditions although some Na dependency is
suggested by the apparent tendency of TTX to inhibit KC1 stimulated
DA efflux (Fig. 3.4.7). Statistical significance was probably not
obtained due to the large standard error of the results.
4.4 The DA releasing effect of tyramine
Tyramine is classed as an indirectly acting sympathomimetic
amine. Indirect because the effects of tyramine are brought about
by the released amine transmitter and not by tyramine itself. The
mechanism by which tyramine achieves this is a matter of speculation
although it has been studied in depth in noradrenergic nerve endings
(see Trendelenburg, 1987). The results of the present experiments
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on dopaminergic neurones as well as those of Zetterstrom et al.
(1988) and those of others on noradrenergic neurones (Langeloh &
Trendelenburg, 1987; Trendelenburg et al., 1987), suggests that
tyramine releases DA or NA from vesicular stores of the
transmitter. Thus, in the present experiments, tyramine stimulated
the efflux of DA in a dose dependent fashion but had no effect
whatsoever on the efflux of DOPAC or HVA (Figs. 3.5.1a,b). This is
in agreement with similar in vivo results obtained by Zetterstrom et
al. (1988). It has already been suggested for AMPH that a decline
in DOPAC efflux is indicative of effects on a newly synthesised
possibly cytosolic pool of DA. The lack of such an effect in the
presence of stimulated DA efflux is indicative of the release of
solely non-cytosolic i.e., vesicular pools of DA.
AMT administered 20 min before tyramine, a timepoint at which
tissue levels of DA are not affected (Fig. 3.1.1), had no effect on
tyramine stimulated DA efflux (Table 3.5.1). However, when
administered 120 min previously, a timepoint at which tissue levels
and consequently vesicular stores of DA are depleted, tyramine
stimulated DA efflux was substantially reduced (Table 3.5.1).
Moreover, reserpine pretreatment dramatically reduced the effect of
tyramine (Table 3.5.1). These results combine to suggest that the
releasing effect of tyramine is on vesicular stores of DA in the
absence of the release of cytosolic DA.
As an amine, tyramine is a substrate for MAO which has been
reported to have a Km for tyramine around 600 to 800pM (Caramona,
1982). When MAO activity was inhibited by pargyline, the DA
releasing effect of tyramine was facilitated by 25% (Table 3.5.1).
It might be argued that the raising of cytosolic concentrations of
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DA by pargyline should have no effect on the size of the tyramine
releasable pool of DA which is distinct from the cytosolic pool.
However, it may be that the inhibition of MAO by pargyline protects
tyramine from the enzyme. This action would effectively raise the
intracel 1 ular level of tyramine resulting in the increased releasing
effect. In addition, the protection of DA degradation by pargyline
will effectively protect the DA that is displaced from the vesicles
into the cytoplasm by tyramine so increasing the size of the DA pool
released by tyramine.
The mechansim by which tyramine enters the nerve terminal is
probably via the membrane carrier as a substrate of high affinity DA
uptake. Tyramine has a Km for this uptake process of 1.4pM which
is lower than that auoted for DA of 2.0yM (Langeloh et al., 1987).
The present experiments support this since nomifensine was very
effective at inhibiting tyramine stimulated DA efflux (Table 3.5.1,
Fig. 3.5.6). Once inside the terminal, tyramine displaces DA from
the vesicles. This may be achieved in a combination of two ways.
Firstly, tyramine has a high affinity for the vesicular uptake
carrier (< 15yM, Langeloh & Trendelenburg, 1987) and so by
saturating the carrier competes with DA for reuptake. In this way,
DA re-uptake into the vesicles is inhibited with a consequent
increase in the rate of net leakage from the vesicles. Secondly,
the presence of high levels of tyramine in the nerve terminal
cytoplasm raises the intravesicular pH. This has been reported to
stimulate release of vesicular NA into the cytoplasm (Langeloh &
Trendelenburg, 1987). The same may be true for DA although the
authors express some doubt that this is a significant mechanism for
the effect of tyramine on transmitter mobilisation from vesicles.
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Whatever the precise mechanism, tyramine displaces DA from
vesicles. This may explain the small but consistent apparent rise
in DOPAC efflux in tyramine stimulated animals pretreated with AMT
(Fig. 3.5.2b), reserpine (Fig. 3.5.3), selegeline (Fig. 3.5.5),
nomifensine (Fig. 3.5.6) and TTX (Fig. 3.5.7). This was a small
but consistent tendency and may reflect an increased metabolism of
DA due to the influx of vesicular DA into the cytoplasm.
Subsequent to release from the vesicles, DA probably exits the
nerve terminal via the reversed action of the membrane reuptake
carrier. The mechanism by which this is achieved i.e., exchange
diffusion, has already been discussed for AMPH. A similar process
has been proposed for tyramine stimulated release of NA (see
Langeloh & Trendelenburg, 1987). These workers reported that the
increased operation of the uptake carrier in transporting tyramine,
+
co-transports Na and CI inside the cell. This is proposed to
lower the Km for the outward transport of NA as well as stimulating
the reverse operation of the carrier. This mechanism would also
explain the nomifensine sensitivity of the tyramine stimulated
2
release process as well as the lack of sensitivity to TTX and Ca
2+
free medium (Table 3.5.1). A lack of Ca dependency for the
tyramine releasing process has been described previously for NA
(Starke & Montel, 1974) and for DA efflux from rabbit caudate slices
(Kamal et al., 1981). Tyramine can be distinguished from reserpine
since despite the fact that both agents displace DA from the
vesicles, tyramine is a substrate for uptake on the membrane uptake
carrier (Steinberg & Smith, 1970) whereas reserpine is not.
Consequently, reserpine is unable to promote the release of DA by
accelerated exchange-diffusion.
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4.5 The DA releasing effect of ouabain
Depolarisation induced release of a transmitter from a nerve
2+
ending depends upon the opening of Ca channels followed by the
2+
Ca dependent efflux of transmitter (Katz, 1969). A role for
4* 4-
Na -K -ATPase in depolarisation induced transmitter release has
been proposed (Vizi, 1978). This enzyme derives energy from the
splitting of ATP to drive the membrane Na+ pump and reauires
4* 4*
internal Na and external K for activation (Skou, 1965).
Thus, depolarisation, which causes an influx of Na+ by opening
.4* 4-4-
Na channels, activates Na -K -ATPase which then restores the
4-
ionic gradient by pumping Na out of the cell.
Ouabain is an inhibitor of Na+-K+-ATPase (see Vizi, 1978)
and in common with other inhibitors of this enzyme, has been shown
to stimulate the efflux of transmitters (see Paris, 1983 for
review). The mechanism by which this is achieved is quite
controversial and there is much literature devoted to this.
Inhibition of the Na+-K+-ATPase could lead to depolarisation of
the neurone by causing the intracellular accumulation of Na+.
24-
This has been proposed to stimulate the influx of Ca and
transmitter release by exocytosis (Banks, 1976). Alternatively, it
2+
could lead indirectly to a rise in intracellular Ca through
2+
mobilisation of intracellular Ca stores (Baker & Crawford,
24- 4-
1975), through Ca exchange for intracellular Na (Nakazato et
al., 1978) or through inhibition of Ca^ efflux (Pocock, 1983),
all of which would permit transmitter release by exocytosis.
When perfused intrastriatally, ouabain stimulated an increase in
DA efflux and a concurrent decrease in DOPAC efflux (Fig. 3.2.5).
The maximal response was slower in onset than that for tyramine, KC1
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and veratrine and occurred 40 min after administration. The DA
releasing effect of ouabain over 60 min was inhibited when AMT was
injected 20 min prior to ouabain (Table 3.6.1). This indicates
that the newly synthesised pool of DA is sensitive to the effect of
ouabain. However, it would appear that ouabain also released
vesicular DA since AMT administration 120 min prior to ouabain,
virtually abolished DA efflux (Table 3.6.1, Fig. 3.6.2b). This
result agrees with those of others mentioned above in that ouabain
appeared to release vesicular DA but contrasts in that newly
synthesised possibly cytosolic DA was also released. Surprisingly,
a vesicular releasing effect was not substantiated by reserpine.
In reserpinised animals, ouabain stimulated DA efflux was not
reduced although the tendency appeared to be a reduced efflux (Table
3.6.1). This may be explained by the evidence that ouabain appears
to release DA not only by exocytosis from vesicles but also possibly
by a carrier dependent mechanism. Such a mechanism will continue
to release DA in the absence of vesicular pools of DA in
reserpinised animals. The evidence for this mechanism is discussed
below.
The effects of nomifensine on ouabain stimulated DA efflux are
also of interest. Nomifensine inhibited the effect of ouabain more
potently over the initial 20 min of ouabain stimulated DA efflux
than over 60 min (Table 3.6.1). However, both timepoints were
highly significant. Therefore, the results indicate that ouabain
releases vesicular and newly synthesised DA via a mechanism that
involves the DA uptake carrier. It would appear that DA is also
2+
released by exocytosis since both TTX and Ca free buffer with
EGTA, two conditions that block depolarisation induced release,
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inhibit ouabain stimulated DA efflux (Table 3.6.1). This indicates
that the effect of ouabain is a complex one that appears to release
DA by two mechanisms, exocytosis and carrier dependent release.
The inhibition of Na K ATPase by ouabain blocks the activity
of the Na+ pump. This leads to the accumulation of Na+ inside
the cell and the loss of K from inside the cell. Furthermore,
9+
these conditions stimulate the influx of Ca and cause a fall in
the resting membrane potential (Vizi, 1979). Conditions such as
these mimic those occurring during depolarisation and may release
transmitter in this fashion. However, in addition to this, the
accumulation of intracellular sodium may cause a reversal of the
membrane uptake carrier by a mechanism analogous to that for AMPH
and tyramine. This was also proposed by Raiteri & Levi (1978)
where an increase in intracellular Na+ permits the nonvesicular
efflux of transmitters by reversal of the uptake carrier in a
fashion similar to that of exchange diffusion. A dual action such
as this appears quite attractive since it is possible to conclude
from these results that ouabain releases DA in an exocytotic, Na+
2+
induced, Ca dependent fashion as well as a carrier dependent
fashion. Much of the literature to date appears to have
4* 4*
concentrated on the effect of Na -K -ATPase inhibition on
depolarisation induced exocytotic transmitter release (see Vizi,
1978, 1979; Brosemer, 1985). Indeed, Brosemer (1985) discounted a
4- 4*
carrier mediated efflux of transmitter during Na -K -ATPase
inhibition mainly because of the lack of evidence in the
literature. Other groups, however, have favoured a
carrier-reversal mechanism caused by Na+-K+-ATPase inhibition
for the release of NA (Sweadner, 1985; Artalejo & Garcia, 1986;
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Raiteri & Levi, 1978) and for amino acids (Jacobson et al., 1986).
The present results also support such a mechanism for the release of
DA. It is possible that the initial effect of ouabain is to
reverse the uptake carrier and release DA in this fashion. This
would explain the early exquisite sensitivity to nomifensine as well
4* +
as AMT. As the effect of ouabain upon the Na , K gradients
progresses, the release of DA may be from vesicular pools via an
exocytotic process as well as via tne carrier. This would explain
the decreasing sensitivity to nomifensine and the increasing
2+
sensitivity to Ca free conditions (which were ineffective on the
initial efflux of DA over 20 min but effective over 60 min). In
support of this, a delay in sensitivity of transmitter release by
ouabain was reported by Sweadner (1985) and by Vizi & Vyskocil
(1979). Moreover, Vizi & Vyskocil (1979) reported that ouabain
stimulated both auantal and non-quantal release of ACh from the
mouse diaphragm. Quantal release was sensitive to calcium whilst
non-auantal release was insensitive. This was proposed to
represent exocytotic vesicular release of ACh (auantal) and also
non-vesicular release of ACh stimulated by ouabain.
4.6 The DA releasing effect of veratrine
Veratrine is a mixture of five alkaloids including veratridine
and cevadine whose action is to depolarise nerve terminals (Minchin,
1980). This action has been demonstrated in a variety of excitable
tissues including sauid and crayfish axons, single frog node of
Ranvier and amphibian muscle (see Minchin, 1980 for review). The
mechanism of action of veratrine involves an increase of membrane
permeability to Na+. This effect was demonstrated in
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synaptosomes by Li & White (1977). Veratridine increased the
24 + +
influx of Na into synaptosomes, increased the total Ma
+
content and decreased K content within 10 seconds of exposure.
This effect was prevented by TTX and by a reduction of external
+
[Na ] in the superfusing medium. The present results support
this mechanism of action for veratrine but also suggest that
veratrine has additional effects on DA release from the nerve
terminals that are not consistent with a sole depolarising action of
the drug.
As for ouabain, veratrine stimulated DA efflux was determined
over 20 min as well as over 60 min. This is because there are
certain anomalies in the efflux data that depart from a sole
releasing action of veratrine on vesicular pools. As might be
expected, AMT administered 120 min before veratrine infusion
(conditions that deplete vesicular pools) dramatically inhibited
veratrine stimulated DA efflux (Table 3.7.1). DA efflux over 20
min was more significantly reduced than over 60 min although it is
doubtful that any mechanistic significance can be attached to this
result since the extent of inhibition was about identical over the
two time periods (14S and 12% of control respectively). AMT
administered 20 min before veratrine was also effective at
inhibiting DA efflux but only over 60 min (Table 3.7.1). Under
these conditions tissue levels and consequently vesicular pools of
DA are not depleted. On the other hand, reserpine was only
effective against veratrine over 20 min (Table 3.7.1) despite an
apparent inhibition over 60 min. Thus, the results have departed
from a pure release of DA from vesicular pools as would be expected
with a depolarising agent. This would also explain the reduction
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in DOPAC and HVA efflux following veratrine (Fig. 3.2.6) and the
sensitivity of the veratrine response to pargyline (Table 3.7.1)
both of which are indicators of DA efflux from the cytosolic pool of
DA.
If the mechanism of action of veratrine is to release vesicular
pools of DA by depolarisation-induced exocytosis, then the process
should be sensitive to inhibition by TTX and by Ca removal.
Calcium dependency was demonstrated for veratridine stimulated
efflux of endogenous and exogenous DA by Mulder et al. (1975) and by
Patrick & Barchas (1976). The TTX sensitivity of the process has
been demonstrated for veratrine stimulated efflux of GABA (Bowery et
al., 1979) amino acids (De Belleroche & Bradford, 1977) and for NA
and DA efflux from synaptosomes (Blaustein, 1975; Mulder et al.,
1975; Patrick & Barchas, 1976). Conversely, veratrine-stimulated
DA efflux should be unaffected by nomifensine if the drug is
releasing DA solely by exocytosis. The present results support
this since nomifensine had no effect whatsover on veratrine
stimulated DA efflux (Table 3.7.1). Moreover, in contrast to KC1
induced DA efflux, nomifensine did not enhance veratrine induced DA
efflux. This may be due to the action of veratrine on the Na+
gradient across the neurolemma which would disrupt the activity of
+ *4"
the Na , K -ATPase thereby blocking DA uptake. The addition of
nomifensine in these conditions would not be expected to have any
further effect. However, veratrine does appear to have
similarities to K stimulated DA efflux in that both cytosolic and
vesicular DA is released probably by exocytosis and not involving
carrier mediated efflux. In agreement with this are the results
for TTX and EGTA. TTX virtually abolished veratrine stimulated DA
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efflux (Table 3.7.1 and Fig. 3.7.7) as might be expected if the
action of veratrine is solely to open Na channels. The Ca
dependency of veratrine stimulated DA efflux is demonstrated in Fig.
3.7.8. The results suggest that veratrine releases vesicular DA
via exocytosis. The prolonged exposure of the tissue to veratrine
rapidly depletes the vesicular pool of DA. This pool which is in a
dynamic equilibrium with the cytosolic pool, is replenished
constantly. Both this result and that for KC1 stimulated DA efflux
illustrate a limitation of the present in vivo dialysis technique in
that the temporal resolution is poor when attempting to follow
physiological events.
4.7 General discussion
The results presented here are an attempt to further elucidate
the nature of the DA pools in striatal dopaminergic nerve endings.
In addition, information has been obtained concerning the mechanisms
underlying DA release from these nerve endings. The results will
be collectively discussed in relation to DA pools and DA release.
These results support the hypothesis that DA can be released by
two different mechanisms. The first is by exocytosis which is
thought to be the mechanism of depolarisation induced release (Holz,
1975; Mulder & Snyder, 1976; Raiteri et al., 1978). The second
is by a reversal of the membrane uptake carrier, the so called
chemical release of DA (Raiteri et al., 1978; McMillen, 1983;
Parker & Cubeddu, 1986; Butcher et al., 1988). Drugs known to be
chemical releasers (AMPH), or known to affect the action of the
membrane uptake carrier (ouabain) or to mimic depolarisation induced
DA release (high [K+], veratrine and tyramine to some extent) have
-141-
been used to distinguish between these two mechanisms. Thus,
amphetamine is a chemical releaser of DA that probably causes
release by a reversal of the membrane uptake carrier. The results
are summarised in Fig. 4.1. This figure enables a 'profile' to be
constructed of each releasing agent. These can then be compared
and characterised for chemical release and/or depolarisation induced
release. Thus, it would be expected that only cytosolic DA would
be a substrate for carrier mediated release. So an agent that
stimulates release via the carrier should be very sensitive to
alterations in the size of the cytosolic pool of DA. AMT given 20
min before AMPH greatly reduced the efflux of DA. On the other
hand, the efflux of DA stimulated by tyramine or veratrine was
inhibited to a much lesser degree by AMT given over the short
term. This is the expected result if tyramine and veratrine
release DA from a vesicular pool. Furthermore, AMPH stimulated DA
efflux was insensitive to reserpine as would be expected. The most
distinguishing feature of the AMPH profile is the exquisite
sensitivity to inhibition by nomifensine which was ineffective
against the depolarising agents KC1 and veratrine. Tyramine
stimulated efflux was inhibited for reasons already described.
+ 2"^"
Moreover, the Na and Ca independency of the AMPH effect are
2+
demonstrated by the lack of effect of TTX and Ca removal plus
EGTA respectively. The depolarising agents KC1 and veratrine were
exauisitely sensitive to both TTX and EGTA. Thus, these profiles
suggest the nature of DA release stimulated by these agents and
allow the categorisation of depolarising agents such as veratrine
and KC1, which release DA from vesicular stores by a process of
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releases DA exclusively via a carrier dependent mechanism with
cytosolic DA as the substrate. Tyramine releases vesicular DA not
by exocytosis but most probably by a carrier dependent mechanism.
Thus, after displacing DA from the vesicles into the cytosol, this
pool of DA becomes a substrate for carrier mediated efflux. Such a
mechanism would be facilitated by the sudden increase in
concentration of DA in the cytosol induced by tyramine. This would
have the effect of raising the concentration of DA above the Km for
the carrier and so facilitate the reversal of the carrier. If this
is the actual mechanism by which tyramine releases DA, then it could
be construed that tyramine is releasing from a vesicular pool
indirectly via the cytosolic pool. Other cytosolic releasing
agents such as AMPH and ouabain decrease the efflux of DOPAC whilst
tyramine does not. This is illustrated in Fig. 4.2 which shows the
effects of the releasing agents on DOPAC efflux. AMPH, by
releasing DA from a cytosolic pool, rapidly and significantly
reduces DOPAC efflux probably by depriving MAO of substrate.
Tyramine, on the other hand, does not affect DOPAC efflux. This
may be due to the fact that in displacing DA into the cytosol, the
pool of DA substrate for MAO is maintained. Indeed, it is probably
increased and this may be reflected in the slight rise in DOPAC
efflux immediately after tyramine. AMPH and ouabain are not known
to displace DA from vesicular storage pools and so deplete the
cytosolic pool and conseauently the pool of DA exposed to MAO.
The results do not demonstrate a 100* response one way or the
other i.e., an exclusively chemical releaser that only releases
cytosolic DA or an exclusively vesicular releaser that only releases
vesicular DA. The reasons for this are two fold; firstly, the
AMPH OUAB TYR KCI VER
Fig.4.2 Summary of the effects of the releasing agents
on DOPAC efflux. Results are the % maximal decrease
in DOPAC efflux seen following the releasing agent.
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cytosolic and vesicular pools are in a rapidly exchanging dynamic
equilibrium with each other (Parker & Cubeddu, 1986).
Conseauently, if one pool is depleted, it is rapidly replenished by
the other. Secondly, the methodology demands that events are
measured over a time period of 20 min in these experiments which
reduces the power of resolution between measuring exclusively
cytosolic releasing events or exclusively vesicular releasing
events. This is not to say that these results suggest that AMPH
and depolarising agents all release DA by two mechanisms, but rather
that it is not possible to resolve a 'clean' response.
It is apparent from Fig. 4.1 that ouabain does not appear to fit
a profile for a chemical or a vesicular releaser. The same is also
true to some extent for KC1. Thus ouabain was affected by both TTX
and EGTA. As mentioned already, it seems reasonable to infer that
ouabain acts both as a chemical releaser and as a depolarising agent
under these conditions. Ouabain has been demonstrated previously
to not only inhibit Na-K+-ATPase and so induce a chemical release
of transmitter (Raiteri & Levi, 1978) but also to depolarise
neurones and conseauently stimulate the exocytotic release of
transmitter (Banks, 1967). This is borne out by Fig. 4.1.
What is also apparent is that different releasing agents
stimulate DA release by different effects upon the same two
mechanisms. Thus, carrier mediated release of DA is directly
stimulated by AMPH which is a substrate for the carrier and
indirectly by ouabain and probably by veratrine which reverse the
action of the carrier by affecting the ionic gradient that controls
the carrier. On the other hand, tyramine releases vesicular DA by
displacing it from vesicles into the cytoplasm. Veratrine and KC1
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release vesicular DA by depolarisation induced exocytotic release.
These results support the existence of two mechanisms of DA release
and convey novel information on the mechanism of action of the
releasing drugs in vivo.
In addition to conveying information on the mechanism of action
of the releasing drugs and chemicals used in this study, there is
much that may be inferred from the results concerning the
heterogeneity of DA pools in nerve terminals. The existence of
multiple pools of DA within the nerve terminal as described in the
introduction seems to be beyond doubt. The present results support
such a heterogeneity of intraterminal pools of DA. The evidence
for this is derived from the differing sensitivites of the releasing
drugs/chemicals to pharmacological or biochemical interventions.
Numerous groups have proposed the existence of multiple pools of
DA within nerve terminals (Glowinski, 1975; Groppetti et al.,
1977; Schoemaker & Nickolson, 1983; Leviel & Guibert, 1987;
Justice et al., 1987). From these studies has emerged various
models of the distribution of DA within the terminal. Radioactive
3
tracer studies using [ H]-tyrosine were able to distinguish two
pools of DA according to the rate at which they became labelled
(Schoemaker & Nickolson, 1983; Leviel & Guibert, 1987). These
workers concluded that DA was contained in a cytosolic pool that
contained newly synthesised DA and a storage pool contained within
vesicles. An alternative model was proposed by Justice et al.
(1987). This group proposed that DA was contained in three
intraterminal pools, a cytosolic pool, a releasable bound pool and
an inactive bound pool. Moreover, Justice and co-workers proposed
that the newly synthesised pool of DA is represented by the
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releasable bound pool rather than the free cytosolic pool. In
other words, DA synthesis directly replenishes the releasable
vesicular pool of DA as well as the cytosolic pool which would then
route DA into the vesicles. This proposal was made for their model
to avoid competition between DA uptake into vesicles and DA
metabolism. It was also based on results obtained by this group
when DA release induced by electrical stimulation was followed.
The level of DA release measured could not be accounted for by the
kinetic parameters used in the model if DA synthesis contributed
directly to the cytosolic pool and not the vesicular pool.
However, this model does not agree with the results of others
(Raiteri et al., 1979; Fischer & Cho, 1979; Parker & Cubeddu,
1985a,b), which demonstrate that the newly synthesised pool of DA
and the cytosolic pool of DA may be the same pool. Thus, if DA
synthesis is acutely inhibited with AMT simultaneous to giving AMPH
which releases newly synthesised (cytosolic?) DA, then DA efflux is
markedly reduced (Fig. 3.3.2). The contrasting results may be due
to the very different methdologies between these jn. vivo
microdialysis data and the mathematical model used by Justice and
co-workers. However, Glowinski et al. (1975) reported the newly
synthesised pool to be contained within vesicles. This conclusion
was based on the fact that both electrical stimulation and AMPH
3
stimulated the release of [ H]-DA synthesised from
3
[ H]-tyrosine. So the situation remains unresolved since the
evidence suggests that the pool of newly synthesised DA can be
released by exocytosis or by chemical release.
The present results also convey other evidence for multiple
pools of DA. Thus, AMT and reserpine have contrasting effects in
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that they appear to deplete two different pools of DA. AMT reduced
the effects of AMPH, ouabain and KC1 all of which appear to release
cytosolic DA whereas the effect of tyramine, a vesicular releaser,
was not inhibited. Reserpine reduced the effects of the vesicular
releasers tyramine and veratrine but not of AMPH.
The effects on the efflux of DA metabolites also differentiate
between different pools of DA. Pargyline protects cytosolic DA
from metabolism by MAO. The fact that pargyline failed to enhance
tyramine stimulated DA efflux to the same extent as the
non-vesicular releasers is evidence for an exclusive action of
tyramine on vesicular pools of DA. In agreement with this any drug
or chemical manipulation that releases cytosolic DA would be
expected to reduce the size of the substrate pool of DA for MAO and
consequently reduce DOPAC efflux. This was the case for DA efflux
stimulated by AMPH, ouabain, veratrine and KC1 but not by
tyramine. This suggests the existence of at least two pools of DA,
one cytosolic and one vesicular.
Justice et al. (1987) went further than this and proposed a
third pool of DA, namely an inactive bound pool which represents an
inactive vesicular pool. The basis for this was formed on their
kinetic data which best fitted a model with this third pool. The
present results do not contain any kinetic evaluation of DA release
and consequently no definitive evidence for a third pool. However,
it is tempting to postulate the presence of such a storage pool
based on the fact that both the cytosolic and the releasable
vesicular pool appear to be rapidly depleted. Thus, the
depolarising agents KC1 and veratrine were sensitive to synthesis
inhibition by short-term AMT suggesting that the releasable
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vesicular pool is quickly depleted and then replenished from the
cytosolic pool. However, AMT over the short term did not deplete
total tissue levels of DA (Fig. 3.1.1a) suggestsing that a larger
inactive storage pool is present that is not susceptible to
depolarisation induced release. Similarly, the fact that AMPH
maximally decreased DOPAC efflux at a dose of 4mg/kg whilst DA
efflux was further increased at higher doses suggests that the
cytosolic pool is also small and that at higher doses AMPH also
releases vesicular DA.
These results have demonstrated a heterogeneity of intraterminal
DA pools. By using various combinations of biochemical and
pharmacological agents, different pools of DA have been selectively
affected. This has been reflected in the stimulated efflux of DA
and its metabolites which have allowed inferences to be made
concerning the nature of the DA pools. Furthermore, the results
support the contention that DA release may occur by two mechanisms,
exocytotic and carrier mediated release. The actions of the
releasing agents are not 'clean'. They appear to release DA either
via exocytosis of vesicular pools or via carrier mediated release of
cytosolic pools. However, the prolonged depletion of either of
these pools appears to 'pull' DA from the remaining pools possibly
in an attempt to maintain the equilibrium between the pools. This
is reflected in a sensitivity of either release mechanism to drugs
not directly affecting that mechanism.
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IN VIVO MICRODIALYSIS STUDIES ON DOPAMINE RELEASE FROM THE
STRIATUM EVOKED BY NIGROSTRI ATAL STIMULATION
G.W. Arbuthnott, S.P. Butcher1, I.S. Fairbrother and J.S. Kelly1, MRC Brain
Metabolism Unit, University Department of Pharmacology, 1 George Square,
Edinburgh and Department of Pharmacology, University of Edinburgh, 1 George
Square, Edinburgh.
A considerable body of evidence supports the candidacy of dopamine as the
neurotransmitter utilised by a majority of neurones in the nigrostriatal pathwa;
(Graybiel and Ragsdale, 1983). For example, researchers using both push-pull
cannulae and voltametric methods have demonstrated that stimulation of this
pathway in vivo increases dopamine release from the striatum (Glowinski et al.,
1978; Ewing et al, 1983). In the present study we have further examined the
in vivo release of endogenous dopamine in response to nigrostriatal stimulation
using brain microdialysis.
Wistar rats (260-300 g; either sex) were anaesthetised and tracheotomised.
Anaesthesia was then maintained using halothane (< 1J). Burr holes were
drilled in the skull directly above the striatum (AP + 0.5; ML ± 2.5) and the
medial forebrain bundle (AP - 3.8, ML ± 1.0). A cannula type dialysis probe
was positioned into the striatum, and a steel concentric electrode placed in thi
medial forebrain bundle. The nigrostriatal pathway was stimulated at 0.5 mA
intensity at 100 for 0.5 msec at 1 second intervals for 10 mins. The
dialysis probe was perfused continuously (2.5 pl/min) with oxygenated Krebs
bicarbonate buffer and dialysate samples (25 pi) were collected at 10 min.
intervals. Dopamine (DA), 3.1 dihydroxyphenylacetate (D0PAC) and homovanillic
acid (HVA) were measured by high performance liquid chromatography and
electrochemical detection.
The basal dialysate concentration of each compound was: DA 6.5 ± 0.7 nM;
D0PAC, 0.5 ± 0.1 pM; HVA 0.2 ± 0.1 pM). Electrical stimulation did not
affect the release of these compounds. Inclusion of the dopamine uptake
inhibitor, nomifensine (1 pM) in the perfusion medium did not affect either
basal or stimulated levels of DA, DOPAC and HVA. These parameters were also
unaffected when 1-aminopyridine (1 mM; a dose which facilitates Ca2 + entry int
nerve terminals) was added to the perfusion medium. In a final series of
experiments, ouabain (an inhibitor of Na+/K+ ATPase) was perfused at a dose
which did not influence basal DA or metabolite levels. In the presence of
10 pM ouabain electrical stimulation induced a rapid and reliable increase
(180 % of control) in DA release, without affecting metabolite levels.
These data demonstrate that the microdialysis technique can be used to evaluate
DA efflux in response to afferent stimulation under appropriate conditions.
S.P.B. is supported by an M.R.C. Training Fellowship and I.S.F. by an M.R.C.
Scholarship.
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ON THE MECHANISMS UNDERLYING AMPHETAMINE INDUCED DOPAMINE RELEASE I
IN VIVO MICRODIALYSIS STUDIES.
G.W. Arbuthnott, S.P. Butcher , I.S. Fairbrother and J.S. Kelly , MRC Brain
Metabolism Uni^, University Department of Pharmacology, 1 George Square,
Edinburgh and Department of Pharmacology, University of Edinburgh, 1 George
Square, Edinburgh.
The psychostimulant, amphetamine (AMPH) is believed to interact with
dopaminergic neurones in the brain. AMPH facilitates dopaminergic responses via
a number of mechanisms, including a stimulation of dopamine (DA) efflux (see
Zetterstrom et al., 1983; Parker and Cubeddu, 1986). Although the precise
mechanism by which AMPH influences DA release is unclear, the finding that this
response is inhibited by the dopamine uptake inhibitor, nomifensine, is clearly
of great importance (Arbuthnott et al., 1985; Parker and Cubeddu, 1986). In the
present study we examined the effects of other agents which influence DA uptake
and release on basal and AMPH stimulated DA efflux using the in vivo brain
microdialysis method.
Wistar rats (250-280g; either sex) were anaesthetised, tracheotomised and
placed in the stereotaxic frame. Anaesthesia was then maintained using halothane
(< 1.5?). Cannula type dialysis probes were positioned into both striata (AP +
0.5; ML + 2.5) and perfused with oxygenated Krebs bicarbonate buffer at 1.25
ul/min. Dialysis samples were analysed for DA and related metabolites (3,1
dihydroxyphenylacetate; DOPAC and homovanillic acid; HVA) by high performance
liquid chromatography and electrochemical detection. Ouabain (10-1000 yM) or
veratridine (10-500 uM) were included in the perfusion buffer as indicated. AMPH
Img/kg) was administered by a single intraperitoneal injection.
The basal dialysis concentrations of DA and related compounds were: DA, 18.3
± 0.5 nM; DOPAC, 1.3 ± 0.2 yM; HVA, 0.6 ± 0.2 yM). AMPH induced rapid increase
(150 %) in DA, and a parallel drop in DOPAC and HVA. Although ouabain (10 yM)
did not influence basal levels of any compound, a striking facilitation of the
AMPH response was noted. Moreover, increasing concentrations of ouabain induced
a massive increase in dialysis DA concentration (20-10 fold), which was not
affected when nomifensine (1yM) was coperfused. Veratridine also provoked a dose
related increase in the extracellular concentration of DA, and a decrease in
DOPAC and HVA.
These data demonstrate that AMPH, ouabain and veratridine all increase DA
efflux from the striatum. However, it is unlikely that these actions are
mediated by a common mechanism.
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IN VIVO COMPARTMENTATION STUDIES USING BRAIN MICRODIALYSIS : FOCUS ON
DOPAMINE
S.P. BUTCHER, I.S. FAIRBROTHER », J.S. KELLY and G.W. ARBUTHNOTT *.
Department of Pharmacology, University of Edinburgh, U.K. and * MRC Brain
Metabolism Unit, University Department of Pharmacology, Edinburgh, U.K.
Experimental data obtained using a variety of experimental approaches
suggest that brain dopamine is compartmentalised in a number of discrete
pools within nerve terminals (see McMillan, 1983). In vitro release studies
have been used previously to distinguish the various pools and to assess
their physiological significance.
In the present study, we have utilised the brain microdialysis method,
to study the relevance of these pools in vivo. A number of widely used
chemical releasing agents were used to stimulate the efflux of dopamine into
the synaptic cleft.
For example, amphetamine was found to elevate dialysate dopamine levels,
and depress levels of its metabolites. The releasing action was blocked by
aMPT pretreatment, but not by reserpine, suggesting a preferential release of
a newly syntheslsed (cytosolic ?) pool of dopamine. The mechanism of
amphetamine action was also examined using a number of agents which interfere
with the operation of the membrane dopamine carrier. Our data suggests that
active accumulation of amphetamine is a prerequisite for dopamine release.
These studies demonstrate the potential of the microdialysis method for
studying the compartmentillsation of dopamine in vivo.
McMillan, B.A. (1983). Trends Pharmacol.Scl. 1, 429-132.
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A PHYSIOLOGICAL ROLE FOR MONOAMINE OXIDASE-B IN BRAIN DOPAMINE
METABOLISM?
I.S. Fairbrother, S.P. Butcher*, J.S. Kelly and G.W. Arbuthnott. MRC Brain
Metabolism Unit, University Department of Pharmacology, University of Edinburgh,
U.K. and *Department of Pharmacology, University of Edinburgh, U.K.
The catecholamine degrading enzyme, monoamine oxidase (MAO) exists as two
distinct isoenzymes within the brain. These are differentially localised within
neurones and glia, with MAO-A being found predominantly within neurones, and MAO-
B mainly in glia (see Francis et al, 1985). The major route of dopamine (DA)
inactivation in the brain is believed to involve high affinity uptake followed by
enzymatic breakdown by MAO-A. However, recent microdialysis data have
questioned this assumption (Fairbrother et al, 1987), since DA uptake inhibitors
do not influence extracellular levels of the primary DA metabolite 3,1-
dihydroxyphenylacetic acid (DOPAC). The mode of DA inactivation is therefore
unclear, and the present study is designed to examine whether MAO-B plays a
physiological role in this process.
Cannula design dialysis probes (Sandberg et al, 1986) were implanted into rat
striata (AP ± 0.5, ML ± 2; from Paxinos and Watson, 1982) under halothane
anaesthesia. These were perfused with oxygenated Krebs bicarbonate buffer at
1.25pl/min. After a 60 min washout period, 20 min fractions were collected
throughout the experiment and DA and related metabolites were detected by high
performance liquid chromatography with electrochemical detection. Selegiline
(lOmg/kg), an inhibitor of MAO-B (Housley et al, 1976) was administered as an
intraperitoneal injection 60 min later. Amphetamine (1mg/kg; i.p. injection),
veratrine (lOOpg/ml; via dialysis probe) and ouabain (100pM; via dialysis
probe) were administered 60 min after selegiline injection.
Basal dialysate concentrations of DA and related metabolites were: DA, 7nM;
DOPAC, 0.8pM; homovanillic acid (HVA), O.lpM; 3-methoxytyramine (3"MT), 2nM.
Selegiline did not influence basal efflux of DA, HVA or 3"MT. However, basal
DOPAC efflux was consistently decreased by selegiline (80-85$ of control).
Amphetamine induced an identical increase in DA efflux (700-800? of control) and
decline in DOPAC (20-30$ of control) and HVA (35-10$ of control) in the presence
and absence of selegiline. 3"MT efflux was consistently increased by
amphetamine (150$ of control) only in the presence of selegiline. Veratrine and
ouabain also evoked similar patterns of DA overflow in the presence and absence
of selegiline. 3-MT efflux induced by veratrine and ouabain was slightly
greater in selegiline treated animals (250-300$ of control) than in control
animals (200-250$ of control).
These data suggest that MAO-B plays a minor role in dopamine degradation both in
unstimulated and chemically stimulated striata. The reduction in basal DOPAC
efflux induced by selegiline may reflect a MAO-B mediated breakdown of
extracellular DA to DOPAC in glia. However, a partial inhibition of MAO-A could
also be responsible for these effects. The chemically induced stimulation of 3"
MT efflux noted in the presence of selegiline most probably results from a MAO-B
mediated degradation of released dopamine in glia. However, this relatively
small response suggests that MAO-B does not play a major role in the degradation
of extracellular DA.
Selegiline was a gift from Britannia Pharmaceuticals, Ltd.
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IN VIVO ASSESSMENT OF THE COMPARTMENTALIZATION OF
DOPAMINE IN STRIATAL NERVE TERMINALS G.W. Arbuthnott,
I.S. Fairbrother, S. Butcher. (Spon: European
Neurosciences Association) MRC Brain Metabolism Unit and
Department of Pharmacology 1 George Square, Edinburgh EH8
9JZ, UK.
In rats anaesthetised with Halothane we have examined
the release of dopamine (DA) into the perfusate passing
through a dialysis fibre implanted into the neostriatum.
The actions of various releasing agents including K+,
amphetamine, veratrine, ouabain and tyramine have been
studied. The amount of DA release is altered to
different extents by pretreatment of the animals with
reserpine, or a-methyl-p-tyrosine (ampt), according to
the releaser administered. Similarly the drugs show
markedly different sensitivities to EGTA or to TTX
applied through the probe. Veratrine and K+ cause
release from a pool which is exquisitely sensitive to
TTX, EGTA and ampt. Tyramine results in release which is
little affected by TTX, or by EGTA. Amphetamine and
ouabain share an intermediate position.
The amount of DOPAC in the dialysate is also
differently altered by the various releasing agents. At
doses that cause the release of DA, K+ causes a marked
reduction of DOPAC, whilst tyramine does not.
Thus release in vivo seems to derive from different
nerve terminal pools with differing sensitivities to
pharmacological manipulations.
